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Recombinant human erythropoietin as well as the other synthetic analogs 
darbepoetin alpha and methoxy-polyethyleneglycol-epoetin-β, are protein-based 
drugs which have the ability to stimulate erythrocyte production that leads to their 
abuse as blood doping agents in both human and equine sports. These epoetins 
may produce anti-rhEPO antibodies that can cause severe inhibition of 
erythropoiesis, leading to anemia and even death. Thus, it is essential to develop an 
efficient screening method to detect these doping agents in equine plasma at low 
concentration. 
 
A fast and sensitive method was explored in this project to differentiate and identify 
recombinant human erythropoietin and darbepoetin in equine plasma by LC- MSMS 
for doping control. Various approaches were investigated to improve the sensitivity, 
differentiating the unique peptide fragments of the synthetic analogs, and by creating 
more on-line techniques to reduce the sample handling time and avoid 
contamination.  
 
Capillary flow and nano flow chromatography were study and compared with 
conventional high flow LC. Results of this study showed that capillary flow is capable 
of detecting immunoaffinity-extracted plasma at 0.2 ng. Nano flow has also been 
shown to give better sensitivity when compared with capillary flow. I had also 
explored the fabrication of an internal tapered capillary tip packed with commercial 
 3	  
	  
C18 silica to use as a nano-electrospray tip. This application was shown to improve 
the sensitivity for detecting the peptides.  
 
To differentiate the synthetic analogs, requires the identifying of the unique peptide 
fragments, which involves enzyme digestion and deamination. Immobilised enzyme 
reactors were fabricated to reduce the handling time, avoiding autolysis and sample 
contamination. The on-line enzyme reactors for both the trypsin digestion and 
deglycosylation were shown to be as effective as the off-line in-solution digestion. It 
also showed better sensitivity for some peptides.  
 
A novel organo cross-linker was synthesised and polymerised with a polar 
zwitterionic monomer to form a HILIC monolith. The morphology of fabricating the 
HILIC monolith was studied. Different polymerisation times were studied, with a 
shorter polymerisation time resulting in a monolith that had a significant proportion of 
both mesopores and macropores and this allowed rapid and high resolution 
separation of large biomolecules.  
 
Finally, with the configuring of the orthogonal set-up, solved the incompatibility of the 
loading buffer, which is highly aqueous, and the high organic buffer used for HILIC 
phase. This configuration enables an on-line concentration and desalting, which 
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HILIC   Hydrophilic interaction liquid chromatography 
 
HPLC   High performance liquid chromatography 
 
IAP   Immunoaffinity purification 
 
I.D.   Internal diameter 
 
IEF-PAGE  Isoelectric focusing polyacrylamide gel electrophoresis 
 
IMERs  Immobilised enzyme reactors 
 
ISTD   Internal standard 
 
LC-MS  Liquid chromatography mass spectrometry 
 
MAIIA   Membrane-assisted isoform immunoassay 
 
MDLC   Multi-dimensional Liquid Chromatography 
 
MICERA  Methoxy polyethylene glycol-epoetin beta 
 
mM   Millimole 
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MudPIT  Multidimensional protein identification technology 
 
nM   Nanomole 
 
NP   Normal-phase 
 
PNGase F  Peptide-N-glycosidase F 
 
PPT   Parts per trillion 
 
PTMs   Post-translational modifications 
 
PWHH  Peak width at half-height 
 
RF   Radio frequency 
 
rhEPO  Recombinant human erythropoietin  
 
RP   Reversed-phase 
 
RPM   Revolutions per minute 
 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 
SEM   Scanning electron microscopy 
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SRM   Selected reaction monitoring  
 
THR   Threonine 
 
TIS   Turbo ionspray 
 
TOF   Time of flight 
 
UPLC   Ultra performance liquid chromatography 
 
WCX   Weak cation exchange 
 
WGA   Wheat germ agglutinin  
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1.1 Erythropoietin  
Erythropoietin (EPO) is an endogenous glycoprotein hormone produced primarily in 
the kidney. EPO is a glycosylated protein hormone which maintains erythropoiesis 
homeostasis [1]. It is a key component in the formation of red blood cells and the 
consequent improvement of blood oxygen-carrying capacity [2]. Endogenous human 
EPO (hEPO) has a mass of about 30.4 kDa, and consists of 165 amino acids, 
aligned in a single polypeptide chain, with two intramolecular disulphide bonds (Cys-
7 – Cys161 and Cys-29 – Cys33), three N-linked sites of glycosylation (at 
asparagines residues 24, 38 and 83) and one O-linked site of glycosylation (at serine 
residue 126) [3, 4]. The resulting carbohydrate content accounts for roughly 40 % of 
the total molecular mass of the glycoprotein; Figure 1.1 shows the model of the three 
dimensional structure of erythropoietin and Figure 1.2 shows the two-dimensional 














Figure 1.1 Model of the three dimensional structure of erythropoietin. The four α-
helices are in orange, loops between helices are depicted in green. The 3 N- and 1 





















Figure 1.2 The two dimensional structure of erythropoietin [6]. Human EPO consists 
of 165 amino acids, aligned in a single polypeptide chain, with two intramolecular 
disulphide bonds and four independent polysaccharide chains bound to Asn24, Asn38, 
Asn83 and Ser126. 
 
Genetically engineered recombinant human EPO (rhEPO), darbepoetin alfa (DPO) 
and methoxy polyethylene glycol-epoetin beta (PEG-epoetin β, MICERA) or 
continuous erythropoietin receptor activator (CERA) are synthetic analogues of the 
endogenous hormone erythropoietin (EPO). These erythropoietin-stimulating agents 
have the ability to stimulate the production of red blood cells and are commercially 
available for the treatment of anaemia in humans [7]. These are erythropoiesis-
stimulating agents which are prohibited in racehorses and humans because they are 
known to have performance-enhancing effects due to their stimulation of red blood 
cell production, thereby improving delivery of oxygen to the muscle tissues [8]. 
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Recombinant human EPO (rhEPO) has the same polypeptide backbone as hEPO 
but differs in its glycosylation pattern. Darbepoietin α (DPO) (NESP or Aranesp) is a 
second-generation rhEPO, which has a similar polypeptide backbone as rhEPO but 
with five different amino acids. It has been intentionally modified to increase the 
duration of action while retaining the pharmacological effect of rhEPO [9]. It contains 
two additional sites of N-linked glycosylation (at Asn-30 and Asn-88) and five amino 
acid substitutions relative to rhEPO [9]. Consequently, DPO has an increased 
molecular mass (37.1 KDa) and an increased proportion of carbohydrates, 51 % as 
compared to the Epoetins 41 %. Due to the additional sialic acid content, DPO has a 
slower serum clearance and, therefore, a longer half-life than the epoetins [10]. The 
terminal half-life of intravenous (i.v.) administered Darbepoetin-alpha is three- to four 
fold longer than Epoetin-alpha and beta (24 h vs 8 h), thus affecting biochemical and 
biological properties of NESP. Figure 1.3 shows the comparison of the structure of 




Figure 1.3 Comparison of the structure of rhEPO and darbepoetin alfa. The ‘’X’’s in 
darbepoetin alfa represent the five amino acid exchange sites that were required to 
allow the attachment of two extra N-linked carbohydrate chains [11]. 
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The amino acid compositions of endogenous horse EPO (eEPO), rhEPO or DPO are 
approximately 80-90 % similar (Figure 1.4).  
 
 
Figure 1.4 Sequence alignment of rhEPO, DPO and eEPO 
 
In 2007, methoxy polyethylene glycol-epoetin beta (PEG-EPO) or CERA, better 
known as Mircera®, a third-generation erythropoiesis-stimulating agent (ESA) was 
released by Roche Pharma AG, Reinach, Switzerland. This is synthesised by 
pegylating rhEPO β. This increases its molecular weight by ~ 30 KDa, with the 
resulting molecular mass being about 60 KDa, twice the size of epoetin, which 
increases its half-life, and decreases its urinary excretion [12]. Figure 1.5 shows a 
comparison of epoetin and Micera structures. This is a long-acting erythropoietin 
derivative with methoxy polyethylene glycol butanoic acid linked to the N-terminal 
amino group or the ε-amino group of any lysine, predominantly Lys45 and Lys52, in 
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the protein molecule. Micera has an even longer half-life than Epoetins and 







Figure 1.5 Comparison of epoetin (left) and Micera structures (right) From 
Macdougall, 2006 [11].  
 
DPO, rhEPO, and PEG-EPO are genetically engineered substitutes for treatment of 
anaemia in patients with chronic renal failure or kidney diseases [14-15]. Since they 
can stimulate red blood cell production and lead to increased oxygen delivery to the 
muscle tissues, these protein-based drugs have become one of the most frequently 
used doping agents in endurance sport and horse racing. It has been demonstrated 
in humans that rhEPO provides a significant erythropoietic benefit in trained 
individuals as evidenced by increases in haemoglobin, haematocrit concentrations, 
maximal oxygen uptake, and exercise endurance time [16-19]. Deaths in endurance 
athletes were attributed to rhEPO-induced erythrocytosis [20]. The use of all rhEPO 
analogues is banned by the majority of human and animal sports regulatory 
authorities [21-24]. Like many other banned substances, the use of these protein-
Epoetin  
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based drugs in racehorses during competition violates the rule of fair competition. A 
second reason to ban the use of rhEPO and DPO is the potentially harmful effects 
on the health of the horse. Recombinant human EPO and DPO are foreign proteins 
and when injected into a horse, produce anti-rhEPO antibody that may cross-react 
with endogenous EPO causing inhibition of erythropoiesis and death of some horses 
[25-26]. Therefore, these drugs are banned in equine sports as implied in Article 6 of 
the International Agreement on Breeding, Racing and Wagering (Published by the 
International Federation of Horseracing Authorities (IFHA)) and as stated in the 
Equine Anti-Doping Rules published by the Federation Equestre Internationale.  
 
Therefore, for ethical reasons and for the animal’s safety, it is important to develop 
reliable analytical methods for direct detection of rhEPO and DPO in plasma. Since 
rhEPO became available in the market in the mid-1980s and DPO in the early 2000s, 
various methods using techniques such as enzyme-linked immunosorbent assay 
(ELISA), radioimmunoassay and isoelectric-focusing followed by double blotting 
were developed for the detection of these drugs [27-34]. However, a shortcoming of 
these methods is the lack of definitive mass spectral data to provide unambiguous 
proof for the presence of the prohibited substance in a sample. Liquid 
chromatography-mass spectrometry (LC-MS) has become more mature and widely 
employed in many analytical laboratories in the past decade and as a result, 
definitive confirmation of macromolecules, such as proteins and peptides, in complex 
biological samples has become a reality [35]. LC-MS is an effective method for 
analyses of both polypeptide chains and sugar chains in glycoproteins [36-37]. 
Glycoproteins are digested into peptides and glycopeptides bearing one sugar chain 
by proteases such as trypsin, endoproteinase Lys-C, Glu-C, and Asp-N, and the 
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digests are then subjected to LC-MS equipped with reversed-phase (RP) or 
hydrophilic interaction liquid chromatography (HILIC). Nevertheless, none of the 
reported LC-MS or CE-MS methods have been shown to be adequately sensitive for 
detection or confirmation of the presence of rhEPO or DPO in ‘’real world’’ racehorse 
samples [3]. The difficulty with LC-MS detection and confirmation of rhEPO and DPO 
in plasma samples arises from the fact that they are hormone protein-based drugs, 
and thus, their effective dose and plasma concentration are very low, e.g., ~1 ng/ml 
or 29 fmol/ml in plasma [38]. Unlike small molecule drugs, protein-based drugs such 
as rhEPO and DPO are difficult to separate from plasma due to the presence of 
abundant proteins. The extremely low concentration of rhEPO or DPO in plasma 
makes confirmation very difficult. However, plasma was still the preferred test 
sample because the concentration of rhEPO or DPO in plasma was higher than that 
in urine. Despite the inherent difficulties, the aim of the present study was to develop 
a sensitive and reliable LC-MSMS method for unequivocal confirmation of the 
presence of rhEPO and DPO at very low concentrations in equine plasma.  
 
The detection of rhEPO and DPO using various mass spectrometric instruments has 
been reported since 2000 [3, 38-43]. Guan et al. (2007) [38] claimed that they were 
the first to develop a sensitive LC-MS method for confirmation of the presence of 
rhEPO and DPO in ‘’real-world’’ equine samples, resulting in the first confirmation 
reports for rhEPO/ DPO in the racehorse anywhere in the world. In their paper, they 
have confirmed the presence of rhEPO and DPO in equine plasma by electrospray 
mass spectrometry (linear Ion trap, LTQ) in combination with upstream liquid 
chromatography (LC) separation. Guan et al. has reported the confirmation of rhEPO 
and/ or DPO in equine plasma using immunoaffinity purification with polyclonal anti-
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rhEPO antibodies immobilised on magnetic beads in order to isolate rhEPO/ DPO 
from equine plasma followed by buffer exchange and trypsin digestion to obtain the 
targeted peptides for LC-MSMS full scan analysis. Yu et al. has also reported a 
modified immunoaffinity extraction and trypsin digestion steps in combination with a 
multidimensional nano-LC system to further cleanup the sample extract by trap 
column loading and detection using nano-electrospray using selected reaction 
monitoring (SRM) mode. Both the groups are using buffers to link the anti-rhEPO 
antibody to the magnetic beads and subsequently followed by immunoaffinity 
purification of rhEPO and then tryptic digestion of the purification of the protein. Yu et 
al. reported only on EPO peptide T6, VNFYAWK from immunoaffinity purification 
(with anti-rhEPO antibodies) and trypsin digestion of rhEPO/DPO/PEG-EPO. Guan 
et al. showed that an immunoaffinity extraction procedure followed by trypsin 
digestion isolated a T6 peptide, VNFYAWK and a T17 peptide (VYSNFLR). The 
reported detection limits for rhEPO and DPO were 0.1 ng/ml [38], however Yu et al. 
[8] using a similar method, were not able to reproduce these detection levels. They 
have modified the immunoaffinity extraction and trypsin digestion steps in 
combination with a multi-dimensional nano-LC system to further cleanup the sample 
extract by trap column loading and detection using nano-electrospray in the selected 
reaction monitoring (SRM) mode. They could confirm rhEPO, DPO and PEG-EPO in 
equine plasma at 0.1, 0.2 and 1.0 ng/ml respectively. 
 
As shown in Figure 1.4, eEPO and rhEPO have an 84 % identical amino acids 
composition which is extremely similar, consequently it provides the opportunity to 
use such substances for horse doping. There have been reports showing that the 
use of these erythropoiesis-stimulating agents on horses may not enhance 
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performance and have even caused serious health problems [29-30, 38, 41]. Covert 
administration of these drugs to horses does occur, which compromises not only 
horse welfare but also the integrity of equine sports.  
 
In equine sports, screening for the rhEPO analogues in urine/ plasma is based on 
the use of commercially available rhEPO ELISAs [19, 41, and 44]. However, they are 
good only for detection, not for confirming the presence of rhEPO or DPO in a test 
sample, due to possible cross-reactivity with other proteins [38]. The International 
Olympic Committee (IOC) has adopted an electrophoretic method combining 
Western blotting for the detection of rhEPO and DPO in human urine. The same 
method was also used for the detection of rhEPO and DPO in equine urine samples. 
However, the method occasionally produced false positive results [45]. Its major 
drawback is the lack of mass spectral data or ‘’fingerprints’’ that are required for 
confirmation of a positive finding. The highly complex glycosylation pattern of rhEPO 
makes the application of more sophisticated analytical instrumentation necessary 
[35]. Liquid chromatography-mass spectrometry (LC-MS) methods were reported for 
the characterization of tryptic digests of rhEPO and DPO standards [3, 39-40] and 
the intact proteins [24]. 
 
1.2 Erythropoietin purification 
Erythropoietin purification is required for two different reasons: the first one is that 
pure EPO is required for its characterisation. The second reason, and the most 
important one for this work, is that all direct methods explained before need a prior 
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immunopurification step for EPO analysis. Identification of post-translational 
modifications (PTMs) of proteins in biological samples often requires access to pre-
analytical purification and concentration methods. In the purification step high or low 
molecular weight substances can be removed by size exclusion filters, and high 
abundant proteins can be removed, or low abundant proteins can be enriched, by 
specific capturing tools [46]. A proper pre-treatment and purification of biological 
samples, in order to isolate low-abundance proteins, prior to analytical techniques 
such as IEF-PAGE, SDS-PAGE, 2D-electrophoresis, capillary electrophoresis and 
LC-MSMS is essential in proteomics [47]. This interference can be reduced by using 
EPO affinity purification as sample pre-treatment instead of ultrafiltration. A column 
with anti-EPO bound to porous beads has been utilised for the purification of serum 
samples and ultrafiltration retention from urine samples [48]. For identification of 
human EPO in equine plasma samples, affinity purification with anti-hEPO bound to 
magnetic particles has been used in a lengthy procedure, as a pre-step for LC-
MSMS doping control [38].  These magnetic beads are often re-used however 
potential carryover cannot be ignored. Traditional affinity columns, using anti-EPO 
immobilised on porous particles will be too expensive to be used as disposable items. 
 
Immunoaffinity purification is a valuable and particularly powerful tool to improve the 
signal-to-noise ratio of immune-based methods [49]. It has the advantage of 
specifically purifying urine samples by isolating the various isoforms of EPO thanks 
to a specific antibody targeting both endogenous and exogenous forms of the 
hormone. This results in a lower background noise, and better resolution of the 
different isoforms. The immunoaffinity purification (IAP) strategies include 
immunoaffinity depletion that can be used to remove abundant proteins from 
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biological matrixes [50-51] and immunoaffinity capture that utilises a single antibody 
to isolate and enrich the target peptides or proteins from biological samples. Offline 
affinity purification using different carriers, such as macroporous polymeric beads, 
agarose or sepharose beads [52-53] and magnetic beads [54-56], etc., for 
immobilisation of a variety of enzyme and / or to capture antibodies, enables more 
flexibility in terms of selection of carriers, antibodies, assay formats, and 
experimental conditions as compared to the online approach.  
 
Affinity chromatography separation using the lectin wheat germ agglutinin (WGA) 
has also been used to distinguish hEPO forms [57] by their varying content of 
polylactosamine structures [58]. An on-line combination of lectin affinity 
chromatography with lateral flow immunoassay (strip) for differentiation of 
recombinant and endogenous erythropoietin was developed by Lönnberg et al. [59-
62]. The technology was named ‘’membrane-assisted isoform immunoassay’’ (MAIIA) 
[63]. The so-called ‘’EPO WGA MAIIA’’ test uses wheat germ agglutinin (WGA) in the 
‘’separation zone’’ of the strip- a lectin with specificity for N-acetylglucosamine and 
N-acetylneruaminic acid-containing glycans and which was already known for its 
non-selectivity regarding the capture of EPO isoforms [64].  
 
In the field of human doping control, a novel kit for rhEPO affinity purification has 
been tested for enrichment and purification of EPO from human urine and plasma 
samples. The kit can be used as a pre-step in the EPO doping control procedure, as 
an alternative to the commonly used ultrafiltration, for detecting aberrantly 
glycosylated isoforms. This kit showed a high recovery of rhEPO. The kit is useful for 
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applications in which it is essential to avoid carry-over effects, a problem commonly 
encountered with conventional particle-based affinity columns.  
 
EPO detection using membrane-assisted isoform immunoassay (MAIIA) technology 
is a combination of two techniques, namely a membrane-based chromatographic 
technique for the separation of isoforms of a protein together with an immunoassay 
technique for the detection of the separated isoforms [65-68]. Both steps are 
performed on one single usage device. The sample preparation modifications of the 
kit reagents allow us to work with an anti-EPO monolith membrane contained in a 
disposable column (anti-EPO monolith column) in order to couple to a mass 
spectrometer. This was evaluated to extract efficiently recombinant human EPO 
(rhEPO) from horse plasma and urine samples. The sample preparation was 
improved to allow the detection of rhEPO target peptides by mass spectrometry. This 
technology is flexible, and several types of ligands can be applied to distinguish 
subpopulations through affinity chromatography interaction [63 and 65]. The 
detection sensitivity and specificity have been shown to be high [66-67]. It seems 
possible to adapt the technology to high-throughput testing [68]. 
 
 
Figure 1.6 The EPO affinity purification set-up [46] 
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1.3 Tryptic digestion 
Protein digestion is an indispensable step in contemporary proteomics, followed by 
liquid chromatography coupled to mass spectrometry (MS). Trypsin is the most 
popular enzyme to fragment proteins (tryptic digestion) for their identification/ 
characterization in proteomic studies due to its high cleavage specificity. Trypsin is a 
serine protease that specifically cleaves at the carboxylic side of lysine and arginine 
residues and typically provides peptides in a mass range suitable for high-resolution/ 
high sensitivity mass mapping through mass spectrometry (MS). Trypsin is thus well 
suited for protein identification through database searching [69]. Tryptic digestion 
can be performed in-solution. However, the traditional in-solution based protein 
digestion has several drawbacks, such as a long digestion time (up to 24 h), 
unavoidable enzyme autodigestion, limited enzyme-to-substrate ratio and off-line 
operation [70]. The use of too high concentrations of free trypsin in solution, relative 
to the substrate(s), leads to excessive amounts of autocatalytic tryptic fragments, 
which limits detection sensitivity and/ or sequence coverage and increases the 
occurrence of false-positive peaks in a mass spectrum. To circumvent long digestion 
times, the proteolytic enzyme can alternatively be immobilised on a solid support. As 
an attractive approach, recent attention has been drawn in developing immobilised 
enzyme reactors (IMERs), which not only have high digestion efficiency, with a 
higher density (concentration) of the enzyme molecules on such surfaces, but are 
also easily coupled with separation and detection systems in order to achieve 
automated and high-throughput protein analysis [71-73]. The use of enzyme reactors 
enables the application of much higher enzyme-to-substrate ratios (with its 
subsequent advantages of faster digestion times) and significant reduction in 
autolysis products (sometimes even complete absence). In addition, the stability of 
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trypsin toward chemical denaturants and organic solvents could be enhanced when 
immobilised on the solid supports [74]. Proteolytic enzyme immobilisation 
approaches include co-polymerisation with polyacrylamide gels [75-76], binding onto 
microbeads [77-78], silica-based substrates (e.g., beads and monoliths) [79-81], 
synthetic polymers [82-83], coating of the inner walls of open capillaries or 
microchannels in microfluidics devices [84-85]. For IMERs, enzymes can be 
immobilised on different supports, however, a large range of favourable monolithic 
supports for enzyme immobilisation have attracted significant attention due to facile 
preparation, fast mass transfer and low backpressure [86-87]. Porous polymer 
monolithic supports have been recently introduced as novel materials, in which the 
diffusion resistance during mass transfer has been proved to be relatively small. In 
addition, this kind of material has the excellent ability to be applied under acid or 
basic conditions. The micrometer sized pores and large surface area of monoliths 
reduce the diffusion path length and also provide a low-pressure drop, thus leading 
to high digestion efficiency, which are advantageous for enzyme immobilisation [88]. 
Therefore, they are regarded as ideal supports for the immobilisation of enzymes 
and fast conversion of substrates [89-91]. The other main goal of enzyme 
immobilisation is to obtained rugged and efficient enzyme reactors. The sample that 
is digested may also be present in an acidic solution during multidimensional 
separations, for instance, after an immuno- affinity clean up or after sample 
fractionation using a cation-exchange column.  
 
Due to the small volume of the resulting reactors, they are compatible with micro- 
and nano-HPLC and can be operated both in buffers and in aqueous solutions 
containing a modifier.  
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Enhanced flow-through and mass transfer properties are important physical features 
of the materials containing a high density of immobilised enzymes for yielding a rapid 
and efficient proteolysis, especially in proteomics where a large number of proteins 
are processed for protein identification/ characterisation by mass spectrometry. It is 
also important to have a stable and robust enzyme reactor that can withstand 
aqueous as well as partial organic buffers.  
 
1.4 Protein Glycosylation 
Glycosylation refers to the attachment of a carbohydrate moiety to a protein. 
Glycosylation of proteins has long been recognised as a common and highly 
important post-translational modification (PTM) in the modulation of their structures 
and functions [92]. Besides their intrinsic functions in aiding cellular architecture and 
modifying protein properties (e.g. solubility and stability), glycoproteins are also 
involved in mediating and modulating cell adhesion, signalling, and trafficking [93-95]. 
Glycosylation is also important in the production of therapeutic proteins, since it can 
significantly affect the potency of a biological drug. It is well known that the changes 
in glycosylation can affect the physicochemical, pharmacokinetic, and biological 
properties of therapeutic glycoproteins. The variable composition, linkage, branching 
points, configuration of constituent monosaccharides, and the diversity in the degree 
of glycosylation at different sites in glycoproteins are the main reasons resulting in 
the complexity of the current analytical approaches to their characterisation. Glycan 
mapping can be carried out with glycans released from the protein or with 
glycopeptides generated by enzymatic digestion. Carbohydrate moieties are typically 
linked to asparagine (N-linked) or serine/ threonine (O-linked) units within the 
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polypeptide backbone. The N-linked glycosylation at the carboxamide side-chain of a 
particular asparagine (Asn) residue or O-linked glycosylation at the alcohol side 
chain of a particular serine (Ser) or threonine (Thr) residue is only partly determined 
by the gene DNA sequence and corresponding protein amino acid sequence. 
Various glycosidases can be used to cleave the glycan moiety from the peptide 
backbone and/ or sequentially remove and identify monosaccharide units from the 
oligosaccharide non-reducing termini [96-97]. The analysis of deglycosylated 
peptides requires the removal of glycan attachments from glycopeptides. For N-
linked glycopeptides, the N-glycosidic bond can be specifically cleaved using the 
enzyme Peptide-N-glycosidase F (PNGase F), providing deglycosylated peptides. 
The PNGase F catalysed deglycosylation results in the conversion of asparagine to 
aspartic acid in the glycopeptide sequence. This enzyme releases asparagines 
(Asn)-linked glycans from glycoproteins and glycopeptides by hydrolysing the amide 
bond at the Asn side chain [98]. The released oligosaccharides that can be of high 
mannose, hybrid or complex type, remain intact and therefore suitable for detailed 
analysis by mass spectrometry. Although the deglycosylation is usually performed in 
solution or in a gel using soluble PNGase F, immobilisation of this glycolytic enzyme 
can significantly improve the glycan release and identification of protein glycosylation 
[99].  
 
To determine N-linked glycosylation sites by MS, an efficient deglycosylation process 
is essential. Peptide-N-glycosidase F (PNGase F) is one of the most widely used 
glycosidase for liberating N-linked glycans, leading to the deamination of asparagine 
residues to aspartic acid simultaneously as shown in Figure 1.7. PNGase F is able to 
remove most N-glycans, while the enzymes in the Protein Deglycosylation Mix 
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(PNGase F, O-Glycosidase (Endo-α-N-Acetylgalactosaminidase) and other enzymes) 
remove N-glycans, short O-glycans, and certain long chain O-glycan.  
 
EPO is a protein-based drug used for the treatment of anaemia. It is the major 
glycoprotein regulator for erythropoiesis, the process that controls the production of 
red blood cells in mammals. Erythropoietin contains three N-glycans at Asn 24, 38, 
and 83, and one O-glycan at Ser-126. This glycoprotein has two disulphide bonds. 
There are various pathways for protein modification with sugars (glycans), the most 
common of which are the addition of glycans to an asparagine (N-linked) or to a 
serine or threonine (O-linked) in the secretory compartment. Therefore, due to the 
relatively large molecular weights of glycosylated peptides and the complex 
fragmentation that originates from both peptide and glycan cleavages, in order to 
overcome some of these issues in proteomic analysis, the labile sugar groups are 
often removed by deglycosylation prior to MS analysis.  
 
 
Figure 1.7 Schematic diagram shows cleavage products from PNGase F treatment 
of N-glycans [100] 
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The administration of these substances is prohibited under the rules governing 
Thoroughbred racing and to monitor compliance the doping control samples that we 
collect from racehorses are extracted and screened for the presence of the tryptic 
peptides common to these two epogens. However, when a positive result is obtained, 
it is necessary to differentiate rhEPO from DPO by targeting the analysis towards the 
peptides T5 (21-45) and T9 (77-97), as the amino acid sequence from this region is 
specific to each protein. Unfortunately, rhEPO and/or DPO T5 and T9 are 
glycopeptides with highly variable sialic acid containing glycan motifs and this 
severely hinders detection under ESI-MS conditions. This necessitates the inclusion 
of a deglycosylation step and for this study the glycosidase mixture (PNGase F, O-
Glycosidase and Neuraminidase) that was used previously [3] was replaced by the 
Promega Deglycosylation Mix™ that also contains the β1-4-galactosidase and β-N-
acetylglucosaminidase enzymes.  
 
However, traditional deglycosylation protocol by PNGase F is usually performed in 
solution, which suffers from drawbacks, such as long incubation time, low 
deglycosylation yields, manual manipulation, and probably spontaneous 
nonenzymatic deamination of the asparagine residue, caused by high temperature 
and pH, which would significantly affect the accuracy of N-linked glycosylation site 
determination [101]. As a promising alternative, on-column deglycosylation with 
immobilised enzymatic reactors has drawn much attention. Novotny et al. [92] 
prepared a monolithic reactor with immobilized PNGase F to remove N-glycans from 
small and medium-sized glycoproteins. Svec et al. [99] fabricated another two kinds 
of monolith based PNGase F-immobilised enzymatic reactors (IMERs), enabling the 
effective deglycosylation of even large glycoproteins. Later, an on-chip silica 
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PNGase F-IMER was developed and integrated with other functional chips to 
perform glycoprotein deglycosylation, protein removal, glycan capture, and 
identification [102].   
 
Immobilised enzyme reactors have recently gained in popularity, as they can be 
reusable and can be connected on-line to other analytical techniques, such as LC 
and MS, while such a process can also be automated. PNGase F enzymes are 
commercially available only in small quantities and at a relatively high cost. Such 
enzymes are more challenging to immobilise with high yield, since either the 
concentration and/ or volume can be a limiting factor for an efficient immobilised 
enzyme reactor. Through the approach shown herein, the volume is less of a limiting 
factor, while the concentration has to be relatively high for optimal enzyme 
incorporation.  Enzyme reactors can thus increase the throughput of analytical 
assays and enhance productivity. In contrast to the free-solution use of glycosidases 
at comparable sample consumption, the enzyme microreactors are reusable in 
repetitive analyses. The immobilized PNGase F reactor rapidly releases N-linked 
glycans from glycoproteins and is suitable for their fast and robust analysis.  
 
1.5 Identifying N-Terminal Aspartic Residues by Asp-N 
Asp-N is an endoproteinase that hydrolyses peptide bonds on the N-terminal side of 
aspartic and cysteic acid residues: Asp and Cys. Asp-N activity is optimal in the pH 
range of 4-9. Endoproteinase Asp-N, a metalloprotease from a mutant strain of 
Pseudomonas fragi, has been reported to specifically cleave on the N-terminal side 
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of aspartyl and cysteic acid residues. A metalloprotease from Pseudomonas fragi 
was first purified in 1975 and demonstrated substrate specificity toward the N-
terminal side of small or hydrophilic residues [103]. Enzymes with altered substrate 
specificities were later found in two mutant strains, including one enzyme, Protease 
V, which demonstrated specificity for cleavage on the N-terminal side of cysteic acid 
residues [104]. This enzyme was later found to recognise both cysteic acid and 
aspartic acid residues [105]. Asp-N efficiently cuts at the N-terminal side of Asp 
residues [106].  In these experiment, the Asp-N enzyme was utilised to differentiate 
the deamination of rhEPO and DPO, since after deglycosylation, both rhEPO and 
DPO which contained asparagine fragments, give a peptide fragment with aspartic 
acid each. Both the aspartic acid fragments give different peptide sequence, when 
cleaved at the Asp site. Hence, providing more sensitivity and confirmative result for 
the mass spectrometry screening to determine which erythropoietin analogues is 
being used for the doping. 
 
1.6 HILIC monolith as a separation column 
1.6.1 Monoliths 
Monoliths have been identified as a suitable choice for the separation of complex 
biological samples, such as proteolytic digests in proteomics by providing better 
stability, resolution and sensitivity, compared to the regular separation medium. 
Monolithic columns have been extensively studied for use in micro-HPLC [107-109] 
since first introduced for capillary liquid chromatography in 1989 by Hjertén and Liao 
[110]. Monolithic capillary columns have been an attractive alternative high-
performance separation medium because of their higher permeability at a similar 
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column efficiency and higher mechanical stability than particle-packed columns. It 
also offers a wide selection of monomers with different functional groups. Monolithic 
capillaries are used at micro- or nano-flow rates instead of normal flows and these 
small flow rates are ideal when coupling to a mass spectrometer (MS). With the 
small flow, there is an advantage of using less mobile phase. A smaller internal 
diameter (i.d.) can be used for monolithic capillaries, and as the column i.d. reduces, 
the sensitivity increases. The other great advantage for monoliths, due to their low 
backpressure, is that it allows the flow to be greatly increased even when using small 
i.d. column. By reducing the size (diameter) of the packing material particle size to 
make the pores as shallow as possible, these can minimise the band broadening 
effect. The effect of mass transfer is also lower at lower linear velocity of the mobile 
phase. The contribution of the mobile phase mass transfer for a monolith column is 
greater than that of a traditional particle-packed column. A greater flow allows a 
greater mass transfer. Monolithic columns have been successfully used with fast 
gradients and high flow rates [111-113]. 
 
The monolithic separation medium is made up of a continuous, rigid polymeric rod 
with a porous structure. The lack of intraparticular void volume improves mass 
transfer and separation efficiency, which allows for the very fast separation of 
biopolymers. The capability of coupling these columns to ESI-MS results in very fast 
and sensitive LC-MS analysis, making these columns ideally suited for high-
throughput LC-MS proteomics [114]. The mass transfer process for monoliths is 
significantly higher than conventional particle-based stationary phases, as the van 
Deemter plots (as shown in Figure 1.13) of plate height versus mobile phase linear 
velocity are shown to be very shallow which means that fast separations can be 
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performed without compromising efficiency. Even at high velocities, the mass 
transfer contribution in monolithic materials is low. This is due to the lack of 
interparticular voids in the column which results in all of the mobile phase flowing 
through the separation medium rather than around it as in the case of particle 
packed capillaries. In addition, these monoliths also show high permeability, which 
allows them to be used at high flow rates [115]. Thus, monoliths can be described as 
the integrated continuous porous separation media without the interparticular voids 
and thus circumventing the preparation of end frits for microscale separation 
columns. Mobile phases are forced through the porous monolithic media, which 
results in convective flow and consequently enhances the mass transfer rate [116].  
 
Monolithic supports can be described as a continuous rod of polymeric- organic or 
inorganic- material consisting of macro- and mesopores that are distributed uniformly 
across the entire structure [117–120]. Macropores (flow channels; flow through pores) 
enable mobile phase flow through the monolithic bed, whereas mesopores provide 
most of the surface area that is necessary for analyte retention. Since monoliths 
possess no interstitial void volume, all the mobile phase has to flow through the pore 
channels of the support. The generated convective flow enhances the mass transfer 
of analytes and accordingly has a positive effect towards chromatographic efficiency 
[121-122]. 
 
Since the pore dimensions control the specific surface area and the hydrodynamic 
properties of the stationary phase, optimising the pore size distribution represents 
one of the main challenges to obtaining high separation efficiency. It has been 
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shown that the type and amount of porogens, the amount of crosslinker and initiator 
as well as the polymerisation temperature are the key parameters to optimise the 
porous properties of monolithic stationary phases [123-124].  
 
1.6.2 Conditions affecting monolith morphology  
Monolithic columns are easy to produce, have a wide variety of chemistries and it 
does not require retaining frits. The polymerisation process is initiated either 
thermally or by photo induction of a mixture consisting of monomers and porogenic 
solvents. However, the compositions of the monomers and porogen have a profound 
effect on the overall morphology of the resulting monolith. The porous structures of 
these monoliths result from a phase separation of the solid polymer from the 
porogen mixture during polymerisation, and the pore characteristics depend heavily 
on the solvency of porogens and their content in the polymerisation mixture.  
 
1.6.2.1 Porogens 
Porogens create pores and flow through channels as the growing polymer becomes 
insoluble and precipitates out during phase separation. As the polymerisation 
progresses and the polymeric chains grow into a network of insoluble nuclei, two 
kinds of void volumes are formed. Those resulting from the repulsion between the 
insoluble polymeric macromolecules become the continuous flow through channels 
(macropores) while those produced from coalescence of smaller polymeric nuclei 
become the rough ridges or the meso or micropores. Solvents that have good 
solvency for the forming polymer will result in the formation of small pores whereas 
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macroporogenic solvents, which show poor solvency for the forming polymer, will 
result in the formation of macro-sized pores [114]. The porogenic solvents 
dominantly selected for the preparation of monolith-type media are usually poor 
solvents of the monomers utilized to form macro-through pores required for liquid 
flow. In the case of the porogenic poor solvents, the growing polymer chains tend to 
aggregate with each other because van der Waals attraction surmounts the steric 
hindrance mutually expelling the polymer chains [122]. In order to balance the effect 
favourably, both the good and poor solvents are employed by adjusting their ratio to 
give the best results. The poor porogens (macroporogens) are usually polar solvents 
e.g. alcohols such as 1-propanol, methanol or dodecanol. The good porogens 
(microporogens) are usually non-polar solvents e.g. tetrahydrofuran, and toluene.  
 
1.6.2.2 Crosslinkers 
The degree of crosslinking affects the rigidity and homogeneity of monolith. A 
change in percentage of crosslinkers in the monomer mixture affects both porous 
properties and the chemical composition of the monolith. An increase in the 
percentage of crosslinker leads to a decrease in the average pore size due to the 
formation of highly crosslinked microglobules [125]. Crosslinkers are bi-functional 
chemicals responsible for creating a network between the polymeric chains. The 
higher the amount of the crosslinker, the more rigid the three dimensional structure 
of the polymer becomes. This same rigidity limits the swelling propensity of the 
nuclei. High amount of crosslinking also triggers an earlier phase separation, as a 
function of the two reactive sites present in single crosslinking molecule.  
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1.6.2.3 Initiators and polymerisation temperature 
In order to obtain reproducible and uniform porous structures for monoliths, the 
temperature of the polymerisation process has to be controlled carefully because of 
the significant effect of heating on the rate of growth of nuclei. At a higher 
temperature, both initiator decomposition and rate of propagation are faster, the 
number of growing nuclei becomes larger and therefore, the final pore size becomes 
smaller. A faster polymerisation may result in less uniform porous structure. As the 
polymer chains continue to grow, their sizes will reach a certain limit of insolubility in 
the solvent which, will result in phase separation when the insoluble polymeric nuclei 
are formed. The higher the temperature, the earlier is the onset of phase separation. 
This translates into an increased number of small diameter nuclei, and thus smaller 
pores. An increase in initiator content results in faster nucleation than growth, which 
leads to smaller size microglobule.  
 
1.6.3 Hydrophilic monoliths 
The separation of polar and hydrophilic compounds can be significant challenging 
when using reversed-phase HPLC, which is by far the most popular HPLC mode. In 
order to achieve adequate retention of polar analytes, highly aqueous mobile phases 
are often required, which can cause a number of issues such as stationary phase 
collapse [126] and decreased sensitivity in ESI-MS [127]. Normal-phase HPLC is a 
useful separation technique for providing effective retention for polar molecules, but 
the poor solubility of polar analytes in non-aqueous mobile phases, together with 
lower peak efficiency, reduced selection of stationary phases, and decreased 
reproducibility, has great limitations [128]. Hydrophilic interaction chromatography 
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(HILIC), which was first introduced in the 1970s by Alpert [129], is a useful 
alternative and rival technique to RPLC for separating polar compounds.  
 
Hydrophilic interaction chromatography (HILIC) is a technique, where analyte 
retention is believed to be caused by partitioning of the analyte between a water-
enriched layer of stagnant eluent on the surface of a hydrophilic stationary phase 
and a relatively hydrophobic bulk eluent as shown in Figure 1.8. HILIC separations 
are carried out using polar stationary phases and a high-organic, low-aqueous 
mobile phase in order to achieve retention of very polar compounds that are difficult 
to retain using reversed-phase methods. Such mobile phase properties largely 
solved the solubility problem of polar compounds when using normal-phase HPLC. 
Additionally, the organic-rich mobile phases used with HILIC can assist spray 
formation, improve ionisation efficiencies and thus enhance the detection sensitivity 
in detectors relying on vaporisation of the eluent. Therefore, HILIC is an excellent 
technique in combination with ESI-MS detectors [130-133]. 
 
The complexity of peptide mixtures that are analysed in proteomics necessitates 
fractionation by multidimensional separation approaches prior to mass spectrometric 
analysis. In this work, hydrophilic interaction liquid chromatography based strategies 
for the separation of complex peptide mixtures were introduced and evaluated. HILIC 
has one of the highest degrees of orthogonality to RPLC [134]. The retention time in 
HILIC increases with increasing polarity or hydrophilicity, opposite to the trend 
observed in RP, HILIC is not a variation of NPLC as the HILIC technique employs 
water-miscible solvents compatible with mass spectrometry, and the elution is 
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achieved by running an aqueous gradient [129, 135-137]. Samples are loaded at 
high organic solvent concentration and eluted by increasing the polarity of the mobile 
phase. Most importantly, HILIC has been found to allow enrichment and the targeted 
analysis of post-translational modifications (PTMs) such as glycosylation [136], N-
acetylation [137] and phosphorylation [138] in proteomics applications. HILIC has 
been proposed as another means of enriching N-acetylated tryptic peptides [138]. 
When it contains a neutralised N-terminus, the hydrophilicity of an N-acetylated 
peptide is decreased. This reduction in polarity is even more pronounced at pH 3, 
where only basic peptide residues are charged and acidic residues are protonated. 
Boersema et al. has shown that this subgroup of trypsinized peptides that are N-
terminally blocked, could be enriched due to their shorter retention compared with  
‘’normal’’ trypsinized peptides.  
	  
	  
Figure 1.8 HILIC separation mechanisms [139] 
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The use of water as the strongly eluting solvent gives HILIC a number of advantages 
over conventional normal phase chromatography (NPLC). Interfacing with 
electrospray MS is often a problem with NP, since ionisation is not easily achieved in 
totally organic, non-polar eluents. Therefore, HILIC can be seen as a form of normal-
phase (NP) chromatography. NP is typically performed with non-aqueous, non-
water-miscible solvents, while HILIC is performed with water-miscible solvents and 
elution is achieved using an aqueous gradient [129, 134, 140-142]. Using a HILIC 
stationary phase, the higher the organic concentration of the mobile phase, the 
greater the retention of the more polar compounds [143]. 
 
The hydrophilic stationary phase entraps water from the mobile phase and thus 
generates an aqueous layer [129]. Elution is obtained through increasing the 
hydrophilicity of the mobile phase which is obtained by increasing the water content. 
The final separation mechanism of elution is most likely a combination of partitioning 
and electrostatic interactions or hydrogen bonding to the stationary phase [140]. The 
various types of interactions with a HILIC stationary phase are shown in Figure 1.9. 
 




Figure 1.9 Various types of interactions with HILIC stationary phase [144] 
 
The extent to which each mechanism dominates is dependent on the actual type of 
stationary phase used and the mobile phase conditions, including the level and type 
of organic content, the type and concentration of salts and the pH [145].  
 
In reversed-phase separation, the digested peptides from EPO protein are eluted in 
order of increasing hydrophobicity, but with hydrophilic interaction chromatography 
the least hydrophobic peptides (hydrophilic) will be retained most strongly by the 
column. Thus, the elution order is reversed. The use of HILIC columns for the 
analysis of the peptides obtained from an enzymatic digest of a protein would 
therefore be expected to provide increased retention and resolution of the hydrophilic 
peptides, including glycopeptides, compared with RP columns. Hence, digested 
peptides can be identified by HILIC that may not have been retained and resolved by 
RP. In general, under RP conditions, the least hydrophobic peptides (hydrophilic) will 
elute early, making their quantitation by MS analysis more difficult. Moreover, some 
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very hydrophobic peptides are difficult to dissolve in aqueous conditions, which are 
usually used as solvents for RPLC-MS analysis. This also leads to lower sensitivity. 
Therefore, with high organic solvent mobile phase, and the sample mixed with a high 
percentage organic solvent, some highly hydrophobic peptides will be dissolved and 
separated better with the HILIC column.  Another benefit of the HILIC separation 
mode is the enhanced signal in MS due to more efficient desolvation of highly 
organic mobile phases, as they have a lower density and surface tension than water, 
which results in more efficient desolvation [146]. 
 
1.7 An Orthogonal set-up of RP-WCX-HILIC 
High-resolution separations prior to MS minimise ion suppression and under 
sampling challenges associated with the analysis of highly complex proteomes, 
which often span several orders of dynamic range in protein abundance. The 
complexity of a sample can be further reduced prior to mass spectrometric analysis 
by the addition of extra dimensions of separation. Thus, the developments and 
applications of multidimensional LC (MDLC) have facilitated advances in proteomics. 
Multidimensional protein identification technology (MudPIT) has become prominent 
with directly coupled-column MDLC for proteomic research [147]. In MudPIT, a 
sample fractionated in the first dimension via strong cation exchange 
chromatography is further separated in the second dimension using RPLC. This 
configuration is relatively simple, but the first dimension can only be run in a 
stepwise mode, which limits resolution. In addition, possible combinations of 
separation modes are restricted by the limited combinations of mobile phases that 
could be used for effective orthogonal separation. It is possible to utilize MudPIT-like 
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strategies with a continuous gradient through some additional considerations in 
methodology [148]. In column-switching MDLC, fractions from the first dimension are 
transferred online, or stored in a series of loops, for the second dimension where the 
separation is accomplished using two or more columns. This setup allows greater 
flexibility in terms of combinations of separation modes. Online hyphenation 
possesses certain advantages, such as minimal loss of sample, no vial 
contamination, and no sample dilution [133, 149]. 
 
Over the years, a number of alternative configurations have been developed. In 
recent years, HILIC was introduced as a dimension for 2D-LC-MS and was shown to 
remove some of the disadvantages of existing techniques [137-150]. RPLC cannot 
separate many of the post-translationally modified isoforms (e.g. methylated, 
acetylated, and phosphorylated) from the unmodified proteins and from each other 
[151]. Weak cation exchange-hydrophilic interaction LC (WCX-HILIC) has proven to 
be an excellent complementary orthogonal mode to RPLC and has been 
successfully used to separate acetylated isoforms of histone H4 [152], methylated 
isoforms of histone H4 [153], phosphylated isoforms of histone H1 [154], as well as 
sequence variants of histone H1 [155]. 
 
WCX-HILIC, a mixed-mode chromatography introduced by Alpert in 1990 [128], 
features the simultaneous presence of dominant hydrophilic interaction (due to the 
use of a higher percentage of organic solvent in the mobile phase than traditional 
WCX) and electrostatic interaction (due to an ionic stationary phase) [155] between 
the stationary phase and the analyte.  
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Weak cation exchangers possess charged functional groups over a limited pH range. 
While mobile phase pH has a negligible effect on the ionization of functional groups 
of strong cation exchangers, it affects the ionization of functional groups of weak 
cation exchangers significantly. Weak cation exchange (WCX) was used because of 
the high polarity of the carboxylic acid functionality. A gradient of decreasing pH 
protonates the functional groups of a weak cation exchange stationary phase, 
leading to elution of retained peptides. WCX was employed before HILIC due to its 
compatibility with the solvents. Both can accommodate high concentrations of 
organic solvent. WCX traps at a higher pH and releases analytes at a lower pH, 
while the HILIC phase is also running at a high organic content with the aqueous 
component at low pH. Hence, it has a compatibility of the orthogonality of WCX-
HILIC. Reversed-phase chromatography (RPC) is the most commonly used general-
purpose method for peptide HPLC. However, RPC fails in some cases, some 
peptides are not retained whilst others co-elute. A good alternative is cation 
exchange HPLC. At pH < 4, the carboxyl- groups on the peptides lose their (-) 
charge, and peptides have a net (+) charge. They are retained by a strong cation 
exchange (SCX) material and can be eluted by an increasing salt gradient, in order 
of increasing absolute number of basic residues. This is displacement 
chromatography; the ions of the salt out compete the peptides for the binding sites of 
the stationary phase. The capacity is approx. 4x greater than with RPC. However, 
the peptides were eluted with a gradient to 15 % acetic acid (HOAc). Acetic acid is a 
weak acid and is only 1 % dissociated in aqueous solution. This suggests that it 
could uncharge the stationary phase of a weak cation exchange material. The 
volatility of the solvent made this method appealing.  
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In this experiment, the EPO samples are prepared and digested in ammonium 
bicarbonate buffer, in the aqueous form. Hence it is not suitable to be directly 
injected onto the HILIC column, which requires high amounts of organic solvent. 
Thus a multi-dimensional LC set-up is designed in order to trap and enhance the 
detection of the digested glycosylated and non-glycosylated peptides on the HILIC 
column. A reversed-phase captrap was used to trap and de-salt the digested 
peptides. Samples were loaded with high aqueous content at pH 5.5, with a small 
amount of organic from the low flow pump onto the captrap. Samples were trapped 
and de-salted on the captrap. After a while, it was released at high organic content 
and with a small amount of aqueous at a pH of 5.5 onto the WCX. Peptides were 
released and trapped onto the WCX column at high organic and high pH. After 
sometime, the valve is switched, and another pump with high organic and a small 
amount of aqueous with a low pH of 2.7 will transfer the peptides from WCX to HILIC. 
The mobile phase is compatible, as HILIC has been conditioned at this mobile phase 
of high organic and aqueous at low pH. Thus, this multi-dimensional set-up will help 
to trap, de-salt and enhanced the peak resolution. 
 
1.8 LC/MS Quantification 
1.8.1 Brief History of Chromatography 
The evolution of chromatography began in the early 1900s when Tswett produced a 
colourful separation of plant pigments through a column of calcium carbonate and 
alumina [156]. He had created an analytical separation of these compounds based 
on the differing strength of each compound’s chemical attraction to the particles. 
Compounds that were attracted more strongly to the particles slowed down, while 
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the other compounds attracted more strongly to the solvent moved faster. This 
causes each compound to move at a different speed, thus creating a separation of 
the compounds. In Tswett’s opinion, a scientist always must consider the whole 
sample and separate all the substances present [157].  
 
Chromatography methods did not make much progress after Tswett’s work until the 
mid-20th century research in new techniques emerged. Martin and Synge developed 
partition chromatography to separate chemicals [158]. There were some difficulties 
found in the initial partition chromatography due to the lack of reproducibility in the 
properties of the silica gel and not homogeneous in the packing of columns. 
Consequently, they then developed another method that was the paper 
chromatography. In 1949, Martin collaborated with Anthony T. James on developing 
gas chromatography. In 1952, Martin won the Nobel Prize in Chemistry and shared 
with Synge, for their earlier chromatographic work. Chromatography has since 
developed into an invaluable laboratory tool for separation and identification of 
compounds.  
 
Chromatography is the process where analytes are separated due to their varying 
distribution between two phases, a stationary phase and a mobile phase. 
Compounds travel in the mobile phase interacts with stationary phase. Those that 
are strongly retained by the stationary phase move slowly, while those that interact 
only weakly move rapidly. Compounds that move rapidly are thereby separated from 
the compounds that move slowly. 
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Horváth’s group [158-159] demonstrated a novel stationary phase based on the 
modification of an ion-exchange column for fast LC with a pressure-driven solvent 
delivery set-up to separate nucleosides, nucleotides and bases. Horváth named High 
Pressure Liquid Chromatography (HPLC) in his 1970 Pittcon paper, which originally 
indicated the fact that high pressure was used to generate the flow required for liquid 
chromatography in packed columns. Earlier, pumps only had a pressure capability of 
500 psi (35 bar). This was called high-pressure liquid chromatography, or HPLC. 
Then later, these new HPLC instruments could accommodate up to 6000 psi (400 
bar) of pressure, and incorporated improved injectors, detectors and columns. HPLC 
began to be more popular in the late 1970s, with the continuous advancement made 
in performance, the acronym HPLC remained, however, it was re-named as high 
performance liquid chromatography. 
 
1.8.1.1 Overview of modern Liquid Chromatography 
High performance liquid chromatography is now one of the most powerful tools in 
analytical chemistry. It has the ability to separate, identify, and quantitate the 
compounds that are present in any sample that can be dissolved in a liquid. In the 
modern HPLC, compounds in trace concentrations as low as parts per trillion (ppt) 
can be easily detected. In 2004, Ultra Performance Liquid Chromatography (UPLC) 
™ technology emerged, with further advances in instrumentation and column 
technology. These advances achieved very significant increases in resolution, speed, 
and sensitivity in liquid chromatography. Columns with smaller particles, 1.7 µm and 
instrumentation with specialised capabilities designed to deliver mobile phase at 
15,000 psi (1,000 bar) were able to achieve a new level of performance. Importantly, 
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there was at least 10-fold decrease in analysis time with at least 2-fold increase in 
peak resolution and sensitivity [160]. Today, scientists are conducting research using 
columns containing particles even smaller than 1µm in diameter particles and 
instrumentation capable of performing at 100,000 psi (6,800 bar) [160].  
 
HPLC has become an indispensible analytical tool for analytical scientist in the 
analysis of complex sample mixtures. It has gained the leadership for separation, 
purification, identification and quantification as a powerful analytical tool. Facing the 
challenge for faster and more robust analytical and separation, concurrently with the 
increasing number of complexity of sample types and stricter monitoring regulations, 
researchers continue to focus on the innovations for new column technologies and 
optimisations on instrumentation.  
 
1.8.1.2 LC Theory 
The components of a basic HPLC set-up are shown in a simple diagram in Figure 
1.10. The mobile phase is delivered to the column by a high-pressure pump that is 
used to generate a specified flow rate of mobile phase. Sample is injected into the 
injector, where the mobile phase flow from the pump to the injector, carrying the 
sample to the column where separation of the sample takes place. The column 
contains the chromatographic packing material needed to effect the separation. This 
packing material is called the stationary phase. Analytes in the sample will exhibit 
competitive affinities towards the eluent and the stationary phase. The higher the 
affinity of the analyte towards the stationary phase, the longer is its retention in the 
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column. The analytes are eluted into the detector, where the detector is necessary to 
see the separated compound bands as they elute from the HPLC column. The 










Figure 1.10 A schematic diagram of HPLC set-up 
 
HPLC is an extremely versatile technique where analytes are separated through a 
column packed with micrometer-sized particles. There are various types of LC 
techniques: normal-phase, reversed-phase, ion exchange and size exclusion 
chromatography. Reversed-phase chromatography is the most commonly used 
separation technique. Reversed-phase has a broad application range that can 
handle compounds of diverse polarity and molecular mass. The retention of an 
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stationary phase. Reversed-phase columns consist of silica or polymeric carrier and 
a coating of long chain saturated hydrocarbons or other non-polar functional groups. 
The most popular packing material is octadecylsilane with an 18-carbon aliphatic 
chain. The partitioning of an analyte between the mobile and stationary phase 
depends upon hydrophobic interactions between the sample and the mobile phase. 
Small polar molecules elute more rapidly than large apolar ones [161-162]. In normal 
phase, the stationary phase is a polar silica material while the mobile phase is a non-
polar organic solvent, typically involving high concentrations of hexane. Highly polar 
solutes therefore retain very strongly in normal phase. In recent years, HILIC has 
become the alternative technique of choice for the analysis of hydrophilic and ionic 
solutes. HILIC is considered a variation of normal phase because both techniques 
have polar stationary phases in common. The mobile phase differs for HILIC, like 
reversed-phase, it uses a water miscible organic solvent. A water-acetonitrile mixture 
with the addition of buffer salts is used, and elution takes place by the increasing of 
water content in the mobile phase. Therefore, for HILIC the initial condition is high 
organic solvent. The retention in HILIC is described as a mixed-mode mechanism, in 
which partitioning of the analyte between the organic-rich mobile phase and the 
water-enriched layer is regarded as the main retention mechanism.  
 
1.8.1.3 Definition of chromatographic terms and relevant equations 
Chromatography is the ability to separate molecules through partitioning 
characteristics of molecule to remain in a stationary phase versus a mobile phase. 
Chromatography is the process of separation, as shown in Figure 1.11.  
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Figure 1.11 Schematic diagram showing the process of chromatographic separation 
 
Retention time, tR, is the time for each component takes to travel from the injector to 
the detector, with a fixed flow rate, a longer retention time indicates stronger 
interaction between the analyte and the stationary phase.  
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Void time, t0, or dead time, is the time of migration of the unretained analytes or 
mobile phase travels through the column. In LC separations, the solvent used for the 
samples is also the mobile phase; hence void volume is sometimes represented as 
tm. 
 
Adjusted retention time, for a solute is the additional time required for solute to 
travel the length of the column beyond the time required by unretained solvent:  
tr’ = tr - tm 
 
Retention factor/ Capacity factor, k’, describes the time spent by an individual 
analyte in each of the two phases, based on the ratio of time that an analyte spends 
on the column, relative to those unretained, at a given flow rate. It is defined as 
follows: 
k’ = tr – t0 
        t0 
 
k’ = time solute spends in stationary phase 
time solute spends in mobile phase 
 
Selectivity factor, α, is an indication of how well the compounds separate. It is 
defined as the ratio between the k values of two compounds,  
α = kB 
    kA 
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Where kB is the retention factor for the more strongly retained compound and kA is 
the retention factor for the less strongly held compound. The selectivity factor is 
always greater than one. 
 
Efficiency, N, is used to describe column performance based on the number of 
theoretical plates. The value N is related to the column length (L) and the size or 
height (H) of an individual plate by the following equation:  
 
N = L/H 
 
Chromatography columns with high numbers of theoretical plates produce very 
sharp narrow peak resulting in better peak separation. From the above equation, 
increasing the length of the column or decreasing the plate height can increase N. 
The higher the N value, the better is the column efficiency. 
 
Height Equivalent to a Theoretical Plate (H), the shorter each theoretical plate, the 
more plates are ‘’contained’’ in any length of column, hence, this will have more 
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The value of N is also related to the width of a peak by the following formula: 
 
N = 5.54 (tr/ W0.5)2  or N = 16 (tr/ W)2 
 
Resolution, RS, the separation or distance between two peaks is known as their 
resolution and is a function of the 3 factors discussed above: retention (time taken 
for analytes to elute, which relates to k), selectivity (the difference between the 
analytes from each other, which relates to α), and efficiency (how good the column 
is, which relates to N). Therefore, these factors formed the equation:  
 
RS = ¼ ((α – 1)/α) (k/k+1) N1/2 
 
There is another equation that commonly used to calculate RS, from actual 
measurements of peak retention times and measured peak widths. It is defined as: 
 
RS = 2 (tR B – tR A)/ (Wb A + Wb B) 
 
Where A and B are the two peaks, tR = retention time and Wb = peak width at the 
base of each peak (Figure 1.12).  
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Another equation similar can be used, when baseline is not established, peak width 
at half height can be used to calculate as follow: 
 
RS = 1.18 (tR B – tR A)/ (W0.5 A + W0.5 B) 
 
Figure 1.12 Chromatogram showing the resolution of the two peaks 
 
1.8.1.4 Band broadening and Van Deemter plots 
Band broadening is a phenomenon that reduces the efficiency of the separation and 
leading to poor resolution and chromatographic performance. To obtain optimal 
separations, sharp, symmetrical chromatographic peaks must be obtained. This 
means that band broadening must be limited. It is also beneficial to measure the 
efficiency of the column. 
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As previously stated, column efficiency is related to the ‘’number of theoretical plates’’ 
or N. Plate theory developed by Martin and Synge, view column as divided into a 
number (N) of adjacent imaginary segments called theoretical plates. Separate 
equilibrations of the sample between the stationary and mobile phase occur in these 
‘’plates’’. The analyte moves down the column by transfer of equilibrated mobile 
phase from one plate to the next. The ‘’plates’’ serve as a way of measuring column 
efficiency, either by the number of theoretical plates in a column, N (the more plates 
the better), or by the Height Equivalent to a Theoretical Plate HETP, (the smaller the 
better). 
 
N = L/ H or HETP = L/ N 
 
The rate theory of chromatography is a more realistic description of the processes at 
work inside a column that takes account of the time taken for the solute to equilibrate 
between the stationary and mobile phase. Unlike the plate model, which assumes 
that equilibration, is fast. The rate theory takes into account the mechanism of band 
broadening, the effect of rate of elution on band shape, the availability of different 
paths for different solute molecules to follow and the diffusion of solute along length.  
 
In 1956, J.J. Van Deemter derived an equation that included the main factors 
contributing to column band broadening. He described the individual terms (A, B & C) 
and derived the Van Deemter equation and also shows a graphical representation of 
the contribution terms (figure 1.13). 




HETP = A + B/µ + Cµ 
 
Where µ = the average linear mobile phase velocity. A defines as eddy diffusion 
(multi-path effect); the mobile phase moves through the column which is packed with 
stationary phase, where solute molecules will take different paths through the 
stationary phase at random. Hence, these multiple paths arise due to 
inhomogeneities in column packing and small variations in the particle size of the 
packing material. This multiple path effect tends to make the band of analytes 
broader as it moves through the column. B defines as random molecular diffusion is 
a constant expressing the longitudinal diffusion coefficient in the mobile phase. The 
concentration of analyte is less at the edges of the band than at the center. Analyte 
diffuses out from the center to the edges. Hence this causes band broadening. 
However, if the velocity of the mobile phase is high then the analyte spends less time 
on the column, which decreases the effects of longitudinal diffusion. Therefore, using 
high linear velocity (high mobile phase flow with narrow columns), will reduce the 
effects of this broadening factor. C is the resistance to mass transfer within particle 
caused by mobile phase. The analyte takes a certain amount of time to equilibrate 
between the stationary and mobile phase. If the mobile phase flow rate is high, and 
the analyte has a strong affinity for the stationary phase, then the analyte in the 
mobile phase will move ahead of the analyte in the stationary phase. The band of 
analyte will be broadened. The higher the velocity of mobile phase, the worse the 
broadening will be. 




Figure 1.13 van Deemter curve [163] 
 
1.8.2 Overview of Modern Mass Spectrometry 
At the beginning of the 1990s mass spectrometry was introduced as a new sensitive 
detection technique for HPLC in the field of doping analysis [164]. Mass 
spectrometry has emerged as an invaluable technique with a wide array of 
applications ranging from clinical to biodefense. With the development of different 
ionisation techniques and mass analysers, more challenging samples can be 
analysed, thereby making mass spectrometry an important analytical tool in the field 
of biophysics. Mass spectrometry is the only technique that offers the combination of 
high sensitivity with structural information. The different ionisation techniques allow 
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1.8.2.1 Principles of MS 
Mass spectrometer generates multiple ions from the sample, it then separates them 
according to their specific mass-to-charge ratio (m/z). Therefore, mass spectrometry 
allows quantification of ions and provides structural information by the identification 
of a distinctive fragmentation patterns. Mass spectrometry also provides an 
alternative to ELISA and other antibody-based assay, by relying on the 
discriminating power of mass analysers to select a specific analyte and on ion 
current measurements to determine quantification.  
 
There are three major components of a mass spectrometer: 1. An ion source 
generates gas-phase ions from the sample, 2. A mass analyser separates ions 
based upon their mass-to-charge ratio (m/z), and 3. A detector monitors the ion 
current and converts it to a signal that is stored by a data system, which is then 
displayed as mass spectrum. The basic components of a mass spectrometer are 
illustrated in Figure 1.14. 
 
 




Figure 1.14 Basic components of a mass spectrometer 
 
1.8.2.2 Ionisation modes 
The key to using MS for solutions is the ability to transfer the analytes into the 
vacuum of the mass spectrometer as ionic species. There are a variety of ion 
sources used to generate ions for mass spectral analysis. For LC-MS, the commonly 
ionisation modes used are electrospray ionisation (ESI) and atmospheric pressure 
chemical ionisation (APCI). Electrospray ionisation (ESI) is an ionisation technique 
used to analyse polar compounds. In ESI gaseous ions are generated directly from a 
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liquid solution. In ESI, the analytes are often dissolved in a mixture of water and an 
organic solvent, such as acetonitrile or methanol. Normally, formic acid or acetic acid 
is added to the aqueous buffer to facilitate protonation of the analyte for the positive 
ion mode. Whereas, ammonia solution is added to facilitate deprotonation in the 
negative ion mode. Acidic molecules form negative ions [M - H]- in solutions with 
high pH, and basic molecules form positive ions [M + H]+ at low pH. Positive ion 
electrospray: electrospray ion sources are soft ionisation sources, they produce 
mostly protonated molecular ions, MH+. For small molecules, electrospray produces 
only one peak, the MH+ peak at mass M+1.  
 
For GC-MS, it is known as electron ionisation (EI), which is caused by a beam of 70 
eV electrons in the source. EI provides enough energy to fragment the molecular ion, 
so that many fragment ions occur in the spectrum. EI spectra are often quite 
complicated. Electrospray spectra are much easier to interpret than EI spectra.  
 
For ESI, ions in an electrospray source can be formed in the original solution. For 
example, quaternary amines, R4N+, are by their nature already are ions. Ions can be 
formed from basic compounds by protonation by added acids. The proton transfer 
can occur in the solution or in the droplets produced by the electrospray source. M + 
H+ à MH+.  
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If the compound has several basic sites, like a small peptide with several amine side 
chains, multiply charged ions may also be formed: M + 2H+ à MH22+ and M + 3H+ à 
MH33+ etc. The MS determines the m/z value that is the mass divided by the charge.  
 
Proteins can often produce very high charge states with z~ 40 or more. Small 
moleucles usually show only one predominant charge state. From this discusiion, it 
is easily seen that pH control for the sample solution can have a strong effect on the 
ionisation efficiency and the distribution of the charge states for the analyte ions. 
Consequently, sample soultions for electrospray MS usually are buffered or have 
added acids to enhance and control the formation of ions.  
 
The spray tip of the ion source must carry the electrospray current, so it acts as the 
anode of an electrochemical cell. Therefore, if the molecule can’t be easily 
protonated, ions may still be formed by electrochemical processes in the spray tip. 
Through direct protonation or electrochemical oxidation, most types of compounds 
can be analysed. Only nonreactive hydrocarbons are not detectable by electrospray 
ionisation. 
 
Electrospray is a soft ionisation technique. EI produces fragment rich spectra. The 
fragment ions are useful to help determine the structure of the compound. On the 
other hand, in EI some classes of compounds don’t produce intense parent peaks, 
so the molecular weight is difficult to determine. While the ease of molecular weight 
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determination is strength for electrospray, the lack of structural information from 
fragment ions can be a draw back. Hence, MSMS techniques can solve this problem. 
 
In MSMS analysis, the MH+ ions formed from the electrospray source are 
fragmented by adding extra collisional energy. MSMS is based on an ion trap 
analyser. In ion traps, ions can be held for long period of time, giving an easy 
opportunity to fragment the parent MH+ ions. The trap is always filled with about 1 
Torr of helium gas. A small radio frequency field can be applied to the trap to cause 
the ions to move faster. The parent ions collide with the helium background gas 
causing fragementation. After adding this collisional energy, the resultant ions are 
scanned in the normal way to determine their m/z. This process is called collision-
induced dissociation, CID. CID MSMS spectra are very similar to EI spectra and can 
be interpreted similarly.  
 
MSMS spectra can be acquired manually by selecting the mass of the parent ion to 
be fragmented and the amount of collisional energy. MSMS can also be done 
automatically. In Auto MSMS mode, the computer determines the mass of the most 
intense parent ions and subjects those ions to MSMS.  
 
MSMS analysis is particularly useful for biopolymers. Proteins, peptides, and 
oligonucleotides can be sequenced using MSMS. The auto MSMS analysis of 
proteolytic digests of proteins is one of the two MS techniques that have spawned 
the new field of proteomics. The other MS technique is MALDI.  
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The major processes (shown in Figure 1.15) involved during ion formation in ESI are: 
1) the solution containing the analyte, eluting from the analytical column, passes 
through a needle (the electrospray needle) that has a high potential applied to it (2 to 
5 kV). This forces the spraying of charged droplets from the needle with a surface 
charge of the same polarity to the charge on the needle. 2) the droplets are repelled 
from the needle towards the MS sampling cone on the counter electrode, as the 
droplets traverse the space between the needle tip and the cone, solvent 
evaporation occurs and shrinkage of the charged droplets, and repeated droplet 
disintegration resulting in small highly charged droplets, and 3) this produce smaller 
droplets and the process of further reduction of droplet size is repeated and naked 
charged analyte molecules are generated. These charged analyte molecules can be 
single or multiple charged [165]. There are two major theories that explain the final 
production of gas-phase ions: the ion evaporation model (IEM) and the charge 
residue model (CRM). The IEM theory explained as the droplet reaches a certain 
radius the field strength at the surface of the droplet becomes large enough to assist 
the field desorption of solvated ions [166, 167]. The CRM theory explained that 
electrospray droplets undergo evaporation and fission cycles, eventually leading 
progeny droplets that contain on average one analyte ion or less [168]. The gas-
phase ions form after the remaining solvent molecules evaporates, leaving the 
analyte with the charges that the droplet carried. 
 




Figure 1.15 Schematic diagram of ESI ionisation process on Applied Biosystem, 
Thermo and Waters Mass spectrometer. [165] 
 
Nebuliser settings: Flows of nitrogen gas are used to nebulise the analyte solution 
and dry the droplets. There are several gas flow rates that need to be set for proper 
operation of the source (shown in Figure 1.16). Nitrogen gas is used because it is 
relatively cheap and very pure. The nebuliser pressure determines the nebulisation 
efficiency. When the nebuliser is working properly, a fine and even mist will be seen 
at the tip of the spray needle. The spray cone should be stable and not showing 
fluctuations in size.  
 
The dry gas has two purposes. This gas is heated to provide for efficient evaporation 
of the solvent. The dry gas also acts a barrier that helps keep the transfer capillary 
clean. If the dry gas flow is not sufficient, droplets and contaminants can clog or 
contaminate the transfer capillary. The vacuum system must be turned off to clean 
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the capillary. Therefore, the dry gas flow must be ensured 5-9 L/s before beginning 
the spray from ESI needle.  
 
 
Figure 1.16 Electrospray Ionisation (ESI) 
 
Nano-electrospray ionisation- The advent of nano-electrospray ionisation (nano-ESI) 
has considerably extended the usability of ESI in the analytical mass spectrometric 
laboratory. One of the remarkable features of nano-ESI is its extremely low sample 
consumption. Only a few microliters of analyte solution are sufficient for molecular 
weight determination and structural investigations by MS/MS. But nano-ESI is more 
than just a minimized-flow ESI; the low solvent flow rate also affects the mechanism 
of ion formation [169]. This can be attributed to the different initial droplet sizes which 
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are in the µm range for ionspray, while in nanospray they are about one order of 
magnitude smaller (as shown in Figure 1.17).  
 
 
Figure 1.17 Comparison of ESI and Nano-ESI- ionisation efficiency  
 
1.8.2.3 MS analyzers used in Bioanalysis 
A mass analyser is the component of the mass spectrometer that takes ionised 
masses and separates them based on mass to charge ratios and outputs them to the 
detector where they are detected and converted to a digital output. There are several 
types of mass analysers used for the separation of ions; they are quadrupole, time of 
flight (TOF), magnetic sector, electrostatic sector, quadrupole ion trap and ion 
Chapter 1 Introduction 
90	  
	  
cyclotron resonance mass analysers. Among these analysers, quadrupole and ion 
trap mass spectrometers are the most commonly used.  
 
The quadrupole mass analyse is a ‘’mass filter’’, it consists of four parallel rods. Each 
opposing rod pair is connected together electrically, and a radio frequency (RF) 
voltage is applied between one pair of rods and the other. Combined DC and RF 
potentials on the quadrupole rods can be set to pass only a selected mass-to-charge 
ratio. Ions travel down the quadrupole between the rods. Only ions of a certain 
mass-to-charge ratio will reach the detector for a given ratio of voltages, other 
unstable ions will collide with the rods. Thus, this allows selection of an ion with a 
particular m/z or allows the analyst to scan for a range of m/z values by continuously 
varying the applied voltage [170].  
 
Ion trap mass analyser employs similar principles as the quadrupole analyser 
mentioned above; it uses an electric field for the separation of the ions by mass to 
charge ratios. The analyser is made with a ring electrode of a specific voltage and 
grounded end cap electrodes. The ions enter the area between the electrodes 
through one of the end caps. After entry, the electric field in the cavity due to the 
electrodes causes the ions of certain m/z values to orbit in the space. As the radio 
frequency voltage increases, heavier mass ion orbits become more stabilised and 
the light mass ions become less stabilised, causing them to collidew with the wall, 
and eliminating the possibility of traveling to and being detected by the detector.  
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The quadrupole ion trap usually runs a mass selective ejection, where selectively it 
ejects the trapped ions in order of increasing mass by gradually increasing the 
applied radio frequency voltage.  
 
Liquid chromatography-tandem mass spectrometry (LC-MSMS) is the preferred 
method used for bioanalysis as it is fast and sensitive.  
 
Triple quadrupole mass spectrometers are ideal for quantitative work, as they allow 
for linear, highly sensitive, simultaneous multi-component analysis. A triple 
quadrupole mass spectrometer is a tandem mass spectrometer consisting of two 
quadrupole mass spectrometers in series, with a (non mass-resolving) radio 
frequency RF-only quadrupole between them to act as a cell for collision-induced 
dissociation (CID). The first analyser (Q1) selects the ions of interest, the ions are 
then fragmented in the collision cell (Q2), and the fragments are analysed in the third 
quadrupole (Q3), which act as a mass filter. This collision cell is an RF-only 
quadrupole (non-mass filtering) usually using Ar gas for collision induced 
dissociation of selected precursor ion from Q1. Subsequent fragments are passed 
through to Q3 where they may be filtered or fully scanned. This process is illustrated 
in Figure 1.18. In MS/MS operation, different scan modes can be used to get 
complementary, qualitative information.  
 




Figure 1.18 Schematic of tandem mass spectrometry 
 
Selected reaction monitoring (SRM), also known as multiple reaction monitoring 
(MRM) is one of the scan method used in tandem mass spectrometry. SRM/ MRM is 
a highly sensitive and selective method for the targeted quantitation of protein/ 
peptide abundances in complex biological samples, allowing scientists to fine tune 
an instrument to specifically look for the peptides, or proteins fragments, of interest. 
SRM/ MRM allow scientists to select peptides of interest while all other peptides are 
filtered out. Peptides are detected by mass spectrometry analysis and the exact 
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Figure 1.19 Schematic diagram of SRM/ MRM experiment 
 
The first mass analyser (Q1) is set to only transmit the precursor m/z of a protein, the 
collision energy is optimised to produce a diagnostic charged fragment of a protein 
fragment (peptide) in the second mass analyser (Q2), and the third mass analyser 
(Q3) is set to transmit this diagnostic peptide fragment only. Therefore, only the 
exact m/z transition is detected.  
 
In SRM experiment, a predefined precursor ion and one of its fragments are selected 
by the two mass filters of a triple quadrupole instrument and monitored over time for 
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precise quantification. A series of transitions (precursor/ fragment ion pairs) in 
combination with the retention time of the targeted peptide can constitute a definitive 
assay. Hence, this approach allows for greater specificity, sensitivity, speed and 
quantitation of an analyte of interest.  
 
1.9 Research aims 
The objectives of this research project are to have a fast and sensitive detection of 
glycoproteins from recombinant human erythropoietin and darbepoetin in equine 
plasma by LC-MSMS, and this will be achieved by the following various techniques:  
1) To understand the art of fabricating monoliths with various factors affecting 
the morphology of monoliths, and demonstrating that fabricated HILIC 
monolith separation performance can be compared to commercially available 
columns 
 
2) To learn the technique of immobilizing trypsin enzyme and deglycosylation on 
monolithic capillary to make an enzyme reactor 
 
3) To learn the technique of immunoaffinity extraction 
 
4) To set-up an on-line detection technique for rhEPO and DPO with a trypsin 
enzyme reactor and deglycosylation reactor coupled to MS as shown in 
Figure 1.20. 
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5) To set-up an on-line LCMS, orthogonal reversed-phase trap-WCX-HILIC to 
de-salt, trap and enhance peak resolution as shown in Figure 1.20. 
 
 









Chapter 2 Fast and sensitive detection 
of rhEPO using capillary flow LC-MSMS 
Methodology and the fabrication of an 










Recombinant human erythropoietin (rhEPO), as well as the synthetic analogs 
darbepoetin-α (DPO) and methoxy-polyethyleneglycol-epoetin-ß (CERA), are 
protein-based drugs used for the treatment of anemia by stimulating red blood cell 
production. Therefore, in a healthy mammal, this could also boost stamina and, not 
too surprisingly, it had been reported to be widely abused by both human and equine 
athletes [43,171]. Recombinant human EPO, DPO and CERA are foreign proteins in 
a horse and therefore horses treated with these epoetins may produce anti-rhEPO 
antibodies that can cause severe inhibition of erythropoieses, leading to anemia and 
occasionally even death [25-26, 38]. Thus, there is a need to create an efficient 
screening method to detect rhEPO, DPO & CERA in plasma at the low 
concentrations found after administration.  
 
To deter the abuse of rhEPO, DPO & CERA in the racehorse, for both welfare and 
performance enhancement reasons, it is crucial to have an efficient screening 
method that can detect these epoetins in plasma at the very low concentrations (~0.1 
to 1 ng per ml) that are present after administration [38]. Mass spectrometry is the 
technique of choice for specific identification of prohibited substances in equine 
doping control analyses [172] and, when used in combination with LC, this is also the 
preferred technique for identification of protein-based drugs such as rhEPO. 
Selected reaction monitoring (SRM) is well known for its sensitivity and generally 
methods using this approach are both reproducible and robust.  
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Early attempts at screening for these drugs [3, 39-40, 173] by LC-MS were hindered 
by a lack of sensitivity and, as a result, were unable to detect the protein in post-
administration plasma obtained from racehorses. Then in 2008 Guan and his co-
workers published a method [38, 44, 171] that could successfully detect low 
concentrations of rhEPO and DPO in equine plasma.  However, their instrument 
configuration utilised a LC column with a diameter of 1 mm and my view was that 
even better sensitivity from this analysis could be achieved by using a smaller 
column diameter and a lower flow rate (down-sizing effect). Whilst nano LC could 
give the best response, it can be a challenge to set-up the system properly. For 
example, care must be taken to minimise any dead volume in the flow path or the 
anticipated gain in sensitivity can be destroyed by poor chromatography. 
Furthermore, the nano flow rate used generally equates to a longer analysis time for 
each sample and I was aiming for a solution which optimised both sensitivity and 
sample throughput.  In order to address this need, I opted to use a capillary LC-MS 
utilising a 300 µm i.d. column with a 4 µl per minute flow rate. I have evaluated the 
performance of this capillary flow system and these results were compared with 
those obtained using the higher flow rate LC approach used in Guan’s publication. 
 
In this chapter, I describe a capillary flow LC system using an Eksigent Tempo® LC 
system coupled to a 4000 QTRAP® LC/MS/MS instrument. The rhEPO tryptic 
peptides were separated at a flow rate of 4 µl/min on a 300 µm i.d. column and the 
limit of detection was around 0.2 ng per ml of immunoaffinity extracted equine 
plasma when screening for the T17 peptide obtained from the digest of the EPO 
protein. Peak width at half-height (PWHH), calculated from the extracted ion 
Chapter 2 Fast and sensitive detection of rhEPO 
99	  
	  
chromatograms from the SRM transitions for the target analytes, was less than 0.1 
min in all cases and resolution was satisfactory when using a 30 min solvent gradient.  
 
This methodology was successfully applied to the identification of the peptides 
obtained from digestion of the rhEPO protein and the shorter analysis time improved 
the efficiency of the operation resulting in a reduction in the amount of solvent 
consumed. 
 
In this chapter, I also explored my experiment with using the nano-spray source. I 
had also reported on the fabrication of fused silica capillaries with internal tapered 
tips filled with reversed-phase silica packing to act as an analytical column and 
emitter to the nano-electrospray MS.  
 
The tip was prepared by slowly heating the fused silica capillary end in the Oxy 
acetylene flame. The part of the coated capillary which was burnt was stripped off 
after heating, which left the glass exposed. This exposed part of the glass capillary 
end was heated at the hottest part of the flame, and was observed under the 
microscope, where we can see that the inner channel of the capillary was shrinking. 
The internal diameter of the heated end was reduced to approximately 7-10 µm. 
After the formation of this tapered tip in the internal capillary, I can also see molten 
silica form at the outside of the glass capillary which eventually sealed the capillary. 
Following this, it was required to attach the other end of the capillary to an HPLC 
pump using water as solvent. The capillary tip was then gently brushed from side to 
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side across some fine abrasive paper until there was a stream of solvent out from 
the tip, but not breaking the tip. The microscope can be used to investigate that the 
tip is still in good condition. If the flow is in droplet form, this could mean that the tip 
has broken. Hence, it requires a skill to make this internal tip successfully.  
 
There are advantages in using internal tapered tips over the commercially available 
external tapered tip and that is that external tapered tips were fragile, have poor 
durability, and are easily broken. Hence, this is successfully overcome by using an 
internal tapered tip. One publication [174] showed a comparison between external 
versus internal tapered tips, with the latter showing enhanced electrospray stability, 
resulting in significantly lower short-term noise. In this work, I explored this novel 
procedure to fabricate an internal tapered capillary tip with the aim to enhance 
stability, sensitivity, and robustness for the nano-electrospray MS.  
 
2.2 Materials and Instrumentation 
2.2.1 Materials.  
DL-dithiothreitol (DTT) and ammonium formate were all purchased from Sigma 
Aldrich (Singapore). HPLC-grade methanol and acetonitrile (ACN) were obtained 
from Fisher Scientific (Singapore). Ammonium bicarbonate and ammonium acetate 
were purchased from Merck (Singapore). Sequencing grade modified Trypsin (P/N 
No. V5111) was purchased from Promega (Singapore). The water used throughout 
all experiments was produced by a Milli-Q Gradient A10 from Millipore (Singapore). 
Epoetin alfa, Eprex® the recombinant human erythropoietin, 10,000 IU/ ml was 
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purchased from Jassen-Cilag AG, (Schaffhausen, Switzerland). Human EPO 1 mg/ 
ml protein was purchased from Genway Biotech, Inc. (San Diego, CA, USA). 
Nanosep 30 KDa OMEGA was obtained from PALL Corporation (USA). Polyclonal 
anti-rhEPO antibody (purified rabbit IgG) was purchased from R&D Systems 
(Minneapolis, MN). Magnetic beads, Dynabeads M-280 Tosylactivated, 
(concentration: 2 x 109 beads/ml, approximately 30 mg/ml) were purchased from 
Invitrogen (Singapore). Igepal CA-630 (molecular biology grade), polyethylene glycol 
6000 was purchased from Sigma Singapore. Magnetic particle concentrator was 
purchased from Invitrogen. Ultrafree-CL centrifugal filter devices (2 ml capacity) with 
0.22 µm membrane pore size and Centricon centrifugal filter devices (2 ml capacity) 
with molecular weight cut-off of 30 KDa were purchased from Millipore (Singapore).  
5 ml plastic vial (Argos Technologies. Elgin, Illinois). 75 µm i.d. fused silica capillary 
was purchased from Polymicro (U.S.A). The 2.5 µm Kinetex silica packing was 
removed from a Phenomenex column packing material. ‘’The Little Torch’’ with 
Sapphires from Smith Equipment (U.S.A), attached to a tank of acetylene and a tank 
of oxygen, was used as the burner to make the internal tapered tips. 
 
Buffers used for linking anti-rhEPO antibody to the magnetic beads and subsequent 
immunoaffinity separation of rhEPO were prepared according to Invitrogen’s manual; 
phosphate buffered saline (PBS, pH 7.4); borate buffer, 0.1 M, pH 9.5 (Buffer B); 
PBS (pH 7.4) plus 0.1 % (w/v) bovine serum albumin (BSA), 2 mM EDTA, and 0.02 % 
(w/v) sodium azide (Buffer C); Tris buffer (0.2 M, pH 8.5) plus 0.1 % (w/v) BSA 
(Buffer D); washing buffer, 1 % (w/v) Igepal CA-630 in PBS (pH 7.4); elution buffer, 
0.1 % PEG 6000 in PBS (adjusted to pH 2.0 with concentrated HCl). All the buffers 
were stored at 4 ºC. 




2.2.2.1 Capillary Flow Set-up: A Tempo® nano MDLC by Eksigent was coupled to AB 
Sciex 4000 QTRAP® LC/MS/MS with Eksigent AS1 Autosampler. The analytical 
column used with this set-up was a 2.7 µm C18-HALO® column with a dimension of 
0.3 x 150 mm. A trap column (Captrap® from Michrom) was installed on the 1/32’’ 6-
port VICI switching valve. Flow rate 4 µl/min. A custom-made turbo ion spray probe 
was fabricated by inserting a 15 µm i.d. fused silica capillary into the probe to reduce 
the dead volume when using a lower flow rate. 
 
2.2.2.2 High Flow Set-up: An Agilent 1100® LC Binary pump was coupled to an AB 
Sciex 4000 QTRAP® LC-MSMS with Eksigent AS1 Autosampler. The analytical 
column used with this set-up was a 3.5 µm XTerra® C18 (1 mm i.d. x 50 mm). A trap 
column (Captrap® from Michrom) was installed on the 1/16’’ 6-port VICI switching 
valve. Flow rate 100 µl/min.  
 
The LC gradient for both capillary and high flow set-up: Mobile phase A- 0.15 % 
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TIME (MIN) MOBILE PHASE A 
(%) 
MOBILE PHASE B 
(%) 
0 96 4 
1 96 4 
30 38 62 
31 20 80 
34 20 80 
35 96 4 
45 96 4 
 
Table 2.1 LC gradient for both capillary and high flow 
 
2.2.2.3 Nano-flow Set-up: The autosampler and LC pump set-up was similar to the 
capillary flow above, except instead of using a Turbo-ion source, a NanoSpray® III 
Source and Heated Interface was used. The fabricated internal tapered fused silica 
capillary tip was installed on the nano-spray mounting bracket and arm.  
 
The mobile phase used in both CH 1 and CH 2 are Mobile phase A- 0.15 % FA in 
water, Mobile phase B- 100 % ACN. The CH 1 pump with a high flow rate of 20 
µl/min was used as loading pump, loading the sample at 50 % A and 50 % B 
isocratic. The CH 2 pump with a low flow rate of 500 nl/min was used as gradient 
pump. The gradient starts at high aqueous, 95 % A and 5 % B for 2 min, then a 5 
min gradient, reaches 100 % B at 7 min, which is then held for 3 min. At 11 min, it 
was returned to its initial condition and re-equilibrated till 25 min.  
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2.2.2.4 MS condition for turbo ionspray (TIS). The curtain gas flow was set at 10; the 
collision gas flow (CAD) was set high, with an Ionspray voltage set at 5500 V. The 
ion source gas, GS 1 was set at 20 psi, and GS 2 was set at 0 psi. The interface 
temperature was set at 0 ºC. The collision energy (CE) was set at 20 and the 
declustering potential was set at 100 V. 
 
2.2.2.5. MS condition for nano-electrospray. The curtain gas flow was set at 25 psi; 
the collision gas flow (CAD) was set high, with an Ionspray voltage set at 3800 V. GS 
1 was set at 14 psi, and GS 2 was set at 0 psi. The interface temperature was set at 
150 ºC. The collision energy (CE) was set at 20 and the declustering potential was 
set at 100 V. 
 
2.2.3 Preparation of samples 
2.2.3.1 Procedure for linkage of anti-rhEPO antibody to magnetic beads.  
A brief summary of the procedure for immunoaffinity separation of rhEPO from 
equine plasma and LC-MSMS confirmation is described in Figure 2.1. Linkage of the 
anti-rhEPO antibody to magnetic beads was carried out as previously reported [33, 
38].  
(a) The magnetic beads, Dynabeads M-280 tosylactivated in the original vial were re-
suspended by brief shaking. 1 ml of the re-suspended beads was transferred into a 5 
ml plastic vial.  
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(b) The vial was placed in the magnetic particle concentrator (MPC-S) for 2 min, and 
the supernatant was transferred to waste using a disposable plastic pipette.  
(c) The vial was removed from the MPC-S, and 1 ml of borate buffer (0.1 M, pH 9.5) 
(Buffer B) was added to wash the beads. Steps (b) and (c) were repeated discarding 
the wash buffer and re-suspending the beads in 1 ml of the borate buffer.  
(d) Polyclonal anti-rhEPO antibody (0.5 mg) was dissolved in 0.5 ml of the borate 
buffer, and added to the magnetic beads suspended in 1 ml of the borate buffer.  
(e) The mixture from step (d) was incubated at 37 °C for 24 hr.  
(f) Step (b) above was repeated to remove the supernatant.  
(g) Coated magnetic beads were washed twice with 1 ml of PBS (pH 7.4) plus 0.1 % 
BSA, 2 mM EDTA and 0.02 % sodium azide (Buffer C) for 5 min each at ambient 
temperature.  
(h) Coated magnetic beads were incubated with 1 ml of Tris buffer (0.2 M, pH 8.5) 
plus 0.1 % BSA (Buffer D) for 4 hr at 37 ºC, to block residual tosyl groups.  
(i) Coated magnetic beads were washed with 1 ml of Buffer C for 5 min at ambient 
temperature, and re-supended in 1 ml of Buffer C. Magnetic beads coated with anti-
rhEPO antibody were now ready for use.  
 
2.2.3.2 Procedure for immunoaffinity separation of rhEPO and DPO from 
equine plasma.  
RhEPO and DPO were extracted from equine plasma by anti-rhEPO antibody linked 
to magnetic beads, using  the reported procedure [33, 38].  
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(a) An aliquot of 400 µl of magnetic beads coated with anti-rhEPO antibody was 
washed with 2 ml of Buffer C in a 5 ml plastic vial and then re-suspended in 400 µl of 
Buffer C.  
(b) 2 ml of equine plasma spiked with rhEPO (0.2 ng in 5 µl of water) was added and 
mixed to the washed magnetic beads. The mixture was incubated in the oven at 
37 °C for 24 h. During the entire incubation period, the mixture was gently shaken 
using the Stuart Rotator SB3; this is to prevent precipitation of magnetic beads.  
(c) After the incubation, the vial was centrifuged at 100 x g rcf for 1 min at 20 °C, and 
then placed in the magnetic particle concentrator (MPC-S) for 2 min, after which the 
supernatant was discarded. The magnetic beads were washed with 2 ml of 1 % 
Igepal CA-630 in PBS (pH 7.4) in the vial that was continually rotated by the rotator 
for 5 min at ambient temperature. The vial was placed in the MPC-S for 2 min, and 
the supernatant was discarded. The beads were then washed three times.  
(d) After the supernatant was discarded, 1 ml of 0.1 % PEG 6000 in PBS (pH 2) was 
added to the magnetic beads in order to elute rhEPO from the antibody. The 
magnetic beads and the elution buffer were incubated in the vial that was gently 
shaken as described in step (b) for 30 min at ambient temperature.  
(e) After the incubation, the vial was centrifuged at 100 x g rcf for 1 min and then 
placed in the MPC-S for 2 min, and the supernatant containing rhEPO was collected 
into the 0.22 µm membrane pore size filter device with, using a disposable plastic 
pipette. 
 (f) The magnetic beads with anti-rhEPO antibody were washed with 2 ml of Buffer C 
for 5 min at ambient temperature, and then separated using the MPC-S, and the 
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supernatant was discarded. The magnetic beads with anti-rhEPO antibody were 
stored in Buffer C (2 ml) at 4 °C for future use.  
 
2.2.3.3 Procedure for buffer exchange of rhEPO eluate in preparation for tryptic 
digestion.  
The eluates from the immunoaffinity separation, containing phosphate buffer (pH 2) 
and PEG 6000, were not suitable for subsequent tryptic digestion of rhEPO, 
therefore this required buffer exchange to ammonium bicarbonate (50 mM, pH 7.8) 
which was suitable for tryptic digestion. This was achieved by using a Centricon 
centrifugal filter device with molecular weight cut-off of 30 KDa. The molecular 
weight of rhEPO is 30.4 KDa and thus, it can be retained by the filter.  
(a) The eluate from the immunoaffinity separation of rhEPO from equine plasma was 
collected into an Ultrafree-CL centrifugal filter device with a 0.22 µm membrane pore 
size, and filtered by centrifugation at 2500 x g rcf for 5 min.  
(b) The filtrate was transferred into the filter device with molecular weight cut-off of 
30 KDa, and the latter was centrifuged at 3500 x g rcf for 35 min at 20 °C, resulting 
in 50 - 100 µl of the solution remaining on the filter membrane. The resulting filtrate 
was discarded.  
(c) 400 µl of ammonium bicarbonate (50 mM, pH 7.8) was added to the filter 
membrane and centrifuged at 3500 x g rcf for 15 min at 20 °C, and the filtrate was 
discarded.  
(d) The process in (c) was repeated for four times.  
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(e) The final bicarbonate buffer (50 - 100 µl) containing rhEPO on the filter 
membrane was recovered by inverting the filter device (with its cap on) and 
centrifuging at 500 x g rcf for 2 min. The bicarbonate buffer containing rhEPO was 
now in the tube, ready for trypsin digestion. The sample was reduced before trypsin 
digestion by adding 5 µl of 100 mM DTT to the sample for 10 min at room 
temperature. After the sample was reduced, it was ready for trypsin digestion. 
  
2.2.3.4 Tryptic digestion of rhEPO.  
10 µl of trypsin (20 µg in 100 µl ammonium bicarbonate) was added to each rhEPO 
extract in ammonium bicarbonate buffer (50 mM, pH 7.8). The mixture was vortexed 
and incubated in a water bath at 37 °C for 3 h. The digestion was terminated by 
adding 4 µl of 10 % formic acid in water. The digested protein was subsequently 
analysed by LC-MSMS.  
 




Figure 2.1 Flow chart showing the steps in immunoaffinity separation of rhEPO and 
DPO from equine plasma and LC-MSMS confirmation. 
 
2.2.3.5 Fabricating internal tapered tip.  
A 75 µm i.d. fused silica capillary was cut into a length of 10 cm. The front end about 
0.5 cm was inserted into the torch with Oxy acetylene flame. For a couple of seconds, 
it could be seen that the capillary coating was being stripped off which left the plain 
glass surface exposed. The fused silica capillary was removed from the flame and 
cleaned with methanol. It was viewed using a microscope. From the microscope, I 
could see the front end is clear glass, and the inner diameter could be seen clearly 
from the microscope (Figure 2.2a). The fused silica capillary was placed into the 
middle part (blue) of the flame to further burn it until it could be seen from the 
microscope (Figures 2.2b & c) that the inner channel had shrunk to a diameter of 
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approximately 17 - 40 µm Figures 2.2d & 2.3 show the formation of a tapered tip in 
the inner layer, although sometimes, the internal and diameter was sealed. In this 
case, it was required to attach the other end of the capillary to a HPLC pump to set a 
gentle flow, while the glass end was brushed gently onto an abrasive paper, until a 
stream of flow was flushed out. If droplets were seen dripping from the glass end, the 
tips are most likely broken; hence this was examined under the microscope to see if 
the tip was broken.  
 
 
Figure 2.2 Various microscopic views of the steps of fabricating an internal tapered 
fused silica capillary column [174] 
 




Figure 2.3 Microscopic view of a fabricated internal tapered fused silica capillary tip 
 
2.2.3.6 Packing the fabricated internal tapered tip with silica.  
A small piece of Teflon sleeve was inserted over the capillary with the internal taper 
end to protect the glass tip from breaking. The other end of the capillary was 
attached to the column packer, which was attached to a tank of argon gas. The 
column packer was placed on top of a magnetic stirrer plate. The column packer was 
filled with the 2.5 µm Kinetex silica (removed from a commercial Phenomenex 
Kinetex silica column) made into slurry with acetonitrile. A magnetic stirrer was 
placed inside to stir the slurry (Figure 2.4). When the argon tank was turned on, the 
homogeneous slurry was forced by the gas pressure, into the fused silica capillary, 
after which we could see solvent flowing out from the tapered tip. The packed silica 
tip was ready to use on the nano-electrospray source. A packed internal tapered 
fused silica capillary is shown in Figure 2.2e. 





Figure 2.4 Column packer sitting on the magnetic stirrer plate, attached to an argon 
gas supply 
 
2.3 Results and Discussion 
The complexity of a plasma proteome presents a great challenge in the study of low 
abundance proteins. In equine plasma as in human and other species, there are 
many abundant proteins which make it extremely difficult to reproducibly recover low 
concentrations of rhEPO and DPO from these complex matrices. It is very common 
for abundant proteins such as albumin and immunoglobins to prevent proteins of 
interest, at a physiological concentration, from being recovered and studied. One of 
the approaches to overcome this challenge was by immunodepletion [56]. However, 
there is drawback for this approach, as it results in loss of low abundant target 
proteins or analytes [41]. According to Guan et. al [38], the use of polyclonal anti-
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rhEPO antibodies can improve the recovery of rhEPO from plasma by 2-fold. The 
specificity of this method for detecting rhEPO and DPO in equine plasma resulted 
from the approaches taken in sample preparation and the subsequent analysis. 
Specifically, the anti-body-based immunoaffinity separation used in this study 
provides the highly selective separation of the analytes from plasma proteins. The 30 
KDa filter membrane used for the buffer exchange also ensured that the analytes 
retained by the membrane is the intact rhEPO or DPO protein and not their peptide 
fragments.  
 
Hence, for a start on extracting the rhEPO from equine plasma, I followed the Guan’s 
publication method on immunoaffinity extraction for my study on the comparison of 
the capillary flow and high flow LC.  
 
I had carried out two experiments, one on the high flow LC system and the other on 
the capillary flow LC system. Extracted ion current chromatograms (EICC) Figures 
2.5a and b) show the analysis of synthetic peptide (20 ng on column) standards run 
on the high flow and capillary flow LC systems set-ups respectively. Comparing the 
two sets of data, we can see that there is an average increase of around 3 times in 
the peak intensity on the capillary flow set-up. In particular, the EICC representing 
the T17 fragment from the EPO protein, which gave the best response of any of the 
target peptides under ESI conditions, showed an increase of over 5 times in the 
intensity of the peak. The peak width at half height (PWHH) achieved for both the 
experiments were less than 0.1 min. 




Figure 2.5a) 20 ng/ml Tryptic digest EPO protein standards run on high flow  
 
	  
	  Figure 2.5b) 20 ng/ml Tryptic digest EPO protein standards run on capillary flow      
                                                                                                                                  
A total of 20 ng of rhEPO, obtained from a solution of Eprex, was digested with 
trypsin (Promega) at 37 ºC for 2 hours using a 50 mM ammonium bicarbonate buffer. 
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Here again, it can be seen (Figures 2.6a and b) that there is an increase in the signal 
response obtained from the peptides screened on the capillary flow setup of 4 µl/min. 
For example, the peptide T4 fragment from rhEPO was not detectable when using 
the high flow rate 100 µl/min screening configuration, but is evident in the capillary 
flow analysis. The other peptides also have a better response of twice or even higher 
for peptide T17 upon running at low flow rate. 
 
 
Figure 2.6a) Eprex 20 ng/ml run on high flow set-up 
XIC of +MRM (7 pairs): 539.2/249.1 Da  from Sample 1 (E... Max. 1550.0 cps.
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Figure 2.6b) Eprex 20 ng/ml run on capillary flow set-up 
 
Equine plasma was spiked with rhEPO at a concentration of 0.2 ng/ml and 10 ng/ml. 
The extraction method involved analyte enrichment using immunoaffinity isolation of 
rhEPO from 1 ml of equine plasma with an anti-rhEPO antibody linked to magnetic 
beads. This was followed by buffer exchange of the extract in preparation for tryptic 
digestion of the proteins. Analyses were carried out on the high flow and capillary 
flow LC-MSMS. At 10 ng/ml the peptides were detectable using the high flow set-up, 
however, at the lower concentration (0.2 ng/ml of spiked plasma, data not shown) 
none of the peptides were detected. In contrast, using the capillary system, we were 
able to detect three of the tryptic peptides at 0.2 ng/ml of spiked equine plasma. This 
data, which is shown in Figure 2.7b), gives an intensity of 1E3 for the highest 
sensitivity peptide fragment, T17, which approaches that seen in the 10 ng/ml of 
spiked plasma (3E3) shown in Figure 2.7a, which was run on high flow.  
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Figure 2.7a) Spiked 10 ng/ml Eprex in plasma run on high flow 
 
 
Figure 2.7b) Spiked 0.2 ng/ml Eprex in plasma on capillary flow 
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Hence, it can be seen that the low flow capillary set-up is more sensitive than the 
high flow system. The capillary flow is capable of detecting the immunoaffinity 
extracted EPO peptide T17 at 0.2 ng/ml in spiked equine plasma at the intensity of 
E3 level, whereas, the high flow is only capable of detecting the 10 ng/ml of 
immunoaffinity extracted EPO peptide from spiked equine plasma, which also gives 
an intensity of E3 level. This is due to the column particle size we are using for the 
low flow. A 2.7 µm particle size C18 HALO column was used for the low flow 
compared to the 3.5 µm  XTerra® C18 particle size. Particle size and pore size of 
silica are very important parameters of a reversed phase column when selected for 
HPLC analysis. Small particle sizes of less than 3 µm including sub- 2 µm have been 
widely used for achieving high performance and fast separation.  
 
The combination of mass spectrometry and nanoflow liquid chromatography (nano 
LC) techniques is a key element of proteomics research. The strength of using a 
nanoLC/MS is that it enables the analysis of limited amounts of biological sample 
with high sensitivity. However, the low solvent flow rates used in nanoLC make 
chromatographic optimisation more challenging than higher flow rate applications. It 
is therefore important that the nanoflow interface to the mass spectrometer be robust, 
easy to use, and flexible enough to provide optimum performance on a wide variety 
of applications. Using the commercially available emitter, which was an external 
tapered tip made of fused silica glass, was very fragile and easily broken. Another 
disadvantage is that the voltage cannot be set too high, as a voltage of more than 
2000 V can cause the glass tip to break producing a poor spray. Hence, I have 
chosen to try out the novel fabrication of an internally tapered tip within the fused 
silica capillary. For this application, I had set the voltage to 3800 V and the tapered 
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tip, which act as an emitter was in the inner layer of the capillary, and was not 
therefore so fragile.  
 
A typical nano-spray set-up is shown in the schematic diagram (Figure 2.8) below, 
and Figure 2.9 shows an electrospray was generated by applying voltage to an 
emitter via a tip. The spray tip or end of the emitter is a conical aggregate of moving 
fluid called the Taylor Cone. The Taylor Cone tapers into a fine fluid jet which 
ultimately radiates into a fan-shaped aerosol called a plume. Vacuum force from the 
mass spectrometer inlet then draws the plume into the MS for analysis.  
 
Figure 2.8 Schematic diagram of a nano-spray set-up [175] 




Figure 2.9 An emitter showing a fan-shaped aerosol called a plume. 
 
The fused silica capillary fabricated with an internal tapered tip was packed with 2.5 
µm Kinetex C18 reverse phase coated silica. It was installed on a nano-electrospray 
source to act as an emitter. I injected Eprex with concentrations of 2 ng and 0.2 ng 
on-column on the 2.5 µm Kinetex silica packed in the fused silica capillary with 
internal tapered tip. Figure 2.10 and 2.11 show 2 ng of Eprex trypsin digested on-line 
(trypsin enzyme reactor) and off-line respectively. Eprex digested on-line coupled to 
the fabricated internal tapered tip obtained a good sensitivity of E3 and E4 (Figure 
2.10) for most of the peptides digested. EPO peptide T11, T14 and T17 had an 
intensity of E4 with a sharp peak shape and a PWHH of 0.1 min. Off-line digested 
Eprex injected directly into the internal tapered capillary packed with silica, had also 
shown to have a sensitivity of E3 and E4 level. Some peptides showed better 
sensitivity than the on-line digestion, however some peptides showed poorer 
sensitivity than the on-line digestion, for example, EPO peptide T2-T20 and T4 
showed poorer sensitivity than the on-line digestion.  




Figure 2.10 Extracted ion chromatogram showing 2 ng of Eprex injected onto trypsin 
reactor coupled to a fabricated 75 µm fused silica capillary with internal tapered tip, 
packed with 2.5 µm Kinetex silica. 
 




Figure 2.11 Extracted ion chromatogram showing 2 ng of off-line trypsin digested 
Eprex injected onto a fabricated 75 µm fused silica capillary with internal tapered tip, 
packed with 2.5 µm Kinetex silica. 
 
Figures 2.12 and 2.13 below show 0.2 ng of Eprex trypsin digested on-line and off-
line respectively. A better sensitivity was obtained for the nano flow compared to the 
capillary flow shown in the above experiment. EPO peptide T17 obtained an intensity 
of 1 E3 for the 0.2 ng injected on the capillary flow, whereas, the nano flow obtained 
an intensity of 4 E3 and 6 E3 for the 0.2 ng of trypsin digested Eprex on-line and off-
line respectively. For the off-line digestion, it could be seen that the EPO peptide T6 
appearing at 7 E2, whereas, in the capillary flow, it could not be seen this peptide at 
0.2 ng digestion. Figure 2.13 showing 0.2 ng off-line trypsin digested Eprex injected 
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onto a fabricated 75 µm fused silica capillary with internal tapered tip packed with 
silica which  is able to achieve an intensity of 1.5 E4 for EPO peptide T11, comparing 
to 0.2 ng Eprex digested run at capillary and high flow with only an intensity of E3 
and E2.  
 
 
Figure 2.12 Extracted ion chromatogram showing 0.2 ng of Eprex injected onto 
trypsin reactor coupled to a fabricated 75 µm fused silica capillary with internal 
tapered tip, packed with 2.5 µm Kinetex silica. 
 




Figure 2.13 Extracted ion chromatogram showing 0.2 ng of off-line trypsin digested 
Eprex injected onto a fabricated 75 µm fused silica capillary with internal tapered tip, 
packed with 2.5 µm Kinetex silica. 
 
Nano flow LC is much more sensitive than the higher flow LC, however, the 
disadvantage is more time is spent adjusting the nano spray in order to achieve a 
good sensitivity. Installing and coupling of the column should also be carried out 
carefully, or this will lead to increased dead-volume, which will result in peak tailing 
and poor peak shape. Thus, these disadvantages will result in not being able to 
achieve reproducible results.  
 
 




A sensitive and selective LC-MSMS method was developed for screening for the 
presence or absence of rhEPO or DPO in equine plasma. The methods conducted 
using a capillary flow and nano flow LC system were evaluated as a screening tool 
for detecting tryptic peptides derived from epoetins isolated from equine plasma 
using immunoaffinity chromatography. Capillary and nano flow are capable of 
achieving a much lower detection limit than the higher flow rate configuration without 
either significantly decreasing resolution or broadening the peak widths. Sensitivity 
was also superior. Thus, this chromatographic system is well suited to achieve our 
goal of detecting these low concentration analytes using a relatively high throughput 
configuration. Nano flow is much more sensitive than the higher flow and capillary 
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3.1 Introduction  
In order to isolate low abundance proteins, targeted pre-analytical purification and 
concentration of the analyte from the highly complex biological samples is required. 
This is time consuming and consequently the isolation of the EPO and DPO from 
biological matrices is a bottleneck towards achieving successful detection of the 
peptides. In plasma samples, it contains a large amount of albumin, which makes it 
difficult to prepare a sample free from other proteins for the analyses of low 
abundance proteins. In the purification step, high or low molecular weight 
substances can be removed by size exclusion filters, and highly abundant proteins 
can be removed by techniques such as immunodepletion, or low abundant proteins 
can be enriched by specific capturing tools, such as affinity extraction [46].  
 
Hence, in order to avoid interference from other proteins, an immunological detection 
step can be included in the analytical step; however, insufficient specificity might still 
result in interference as found in some EPO doping control method [64, 176-177]. In 
2000, World Anti-Doping Agency (WADA) accredited this control method which 
based on isoelectric focusing (IEF) followed by a double-blotting process, preceded 
by an ultrafiltration concentration of EPO from athletes’ urine to identify rhEPO intake 
[64, 178-179]. However, non-specific interferences from abundant urine proteins is 
claimed to result in bands that are not related to EPO or its analogues [48]. Thus, in 
2003, WADA reviewed the method and suggested some improvements, such as the 
use of an immunoaffinity method. The reason for this proposal was that EPO affinity 
purification, as sample pre-treatment, can reduce interference more significantly than 
ultrafiltration. Affinity chromatography separation, using the lectin wheat germ 
agglutinin (WGA), has also been used to distinguish hEPO forms [61]. In 2008, Guan 
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et al. identified rhEPO in equine plasma by using affinity purification with anti-hEPO 
antibody bound to magnetic particles, which is a lengthy procedure that is shown in 
Chapter 2, as a pre-analytical step for LC-MSMS detection. The magnetic particles 
were regenerated and re-used, however, this was not acceptable as it could result in 
carry-over from a positive sample and may cause a negative sample to be falsely 
reported as being positive. These different methods require skilled technicians, 
several hands-on steps, and expensive equipment and also take several days to 
complete the steps.   
 
In 2010, Lönnberg et al. presented a 6 µl column with a length of only 0.15 mm, 
which can be used for purification and concentration of EPO from biological samples. 
The column is disposable and it also simplified the pre-analytical sample treatment 
and to avoid carry-over from a positive sample. This is known as MAIIA technology 
and provided an improved method of isoform identification for the glycoproteins 
hEPO, as the extraction gives a good recovery and the technique does not 
discriminate between the minor differences between subpopulations. The technology 
is also flexible; several types of ligands can be applied to distinguish subpopulations 
through affinity chromatography [59 and 65].  
 
Detection limit challenges associated with measuring low-abundance protein can be 
addressed with hybrid immunoaffinity-mass spectrometric assays, such as 
antipeptide antibody capture followed by liquid chromatography/ tandem mass 
spectrometry. Due to the low levels that are anticipated to be present in the sample, 
EPO affinity purification is the preferred sample pre-treatment method to reduce 
interferences, as it is more effective than ultrafiltration. 
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In order to achieve confirmatory results from this glycoprotein, both sample 
preparation and LC-MSMS analysis need to be optimised. The method comprised 
analyte extraction and enrichment by immunoaffinity separation with anti-rhEPO 
antibodies, dual digestion by trypsin and followed by enzymatic released of N-linked 
glycans with peptide-N-glycosidase F (PNGase F) and analysis by LC-MSMS. The 
most important step in the sample preparation for proteomics is the conversion of 
proteins to peptides and in most cases trypsin is the preferred enzyme. Trypsin is a 
protease that specifically cleaves the proteins creating peptides both in the optimal 
mass range for MS sequencing and with a basic residue at the carboxyl terminus of 
the peptide, producing information-rich, easily peptide interpretable peptide 
fragmentation mass spectra.  
 
Recombinant human erythropoietin (rhEPO) and darbepoetin (DPO) have a number 
of identical peptide fragments after enzymic digestion with trypsin. However, there 
are still some slight differences in their amino acid sequence. In order to identify 
which of these two epogens is responsible for the detection of these common 
peptides, it is necessary to differentiate between the proteins by targeting the 
analysis towards the peptides T5 (21-45) and T9 (77-97), as the amino acid 
sequence from this region is specific to each protein. The five variant amino acids in 
DPO are located in the two regions that relate to two tryptic peptides T5 and T9. The 
two unique deglycosylated tryptic peptides were identified as (T5) 
21EAENITTGCAEHCSLNENITVPDTK45 with a disulfide bond between 29Cys and 
33Cys and (T9) 77GQALLVNSSQVNETLQLHVDK97.  
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Unfortunately, these are glycopeptides, with highly variable sialic acid containing 
glycan motifs, and this severely hinders detection under ESI/MS conditions. Thus, 
the glycopeptides with glycosylation poorly ionise under positive electrospray 
ionisation conditions, and cannot be detected at low concentrations level. To 
overcome this problem the glycans can be removed from the glycopeptides and 
removing the micro-heterogeneity improves the ionisation and increases sensitivity. 
A side effect of deglycosylation reaction is that the T5 and T9 are deaminated to 
aspartic acid residues by the PNGase F.  
 
These deglycosylated peptides, which consist of 21 to 25 amino acids in each 
fragment, are much larger than other tryptic peptides, e.g. T17, T14 and T11 and this 
could have a negative effect on the sensitivity of detecting these peptide fragments, 
when compared to those peptide fragments that are only 7 – 8 amino acids in length. 
The longer the amino acids length, the bulky the peptides (have a greater molecular 
mass, which usually contained more than one charge), hence, the sensitivity are not 
as good compared to the shorter amino acids length, which is smaller in molecular 
mass and easier to detect.   
 
According to Guan et al. publication [43], his group had differentiated and identified 
by using the two unique deglycosylated tryptic peptides. They had also investigated 
that T5 of DPO was not observed even after deglycosylation by PNGase F, this could 
be due to the disulfide bonds not reduced and alkylated. They had identified T9 from 
DPO and T5 from rhEPO. 
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I have investigated different enrichment methods and found combining trypsin with 
Asp-N enzyme digestion after deglycosylation is a suitable way of generating specific 
peptide fragments that also ionise well under +ve ESI conditions. The Asp-N enzyme 
is utilised to cleave the N-terminal side of Asp amino acid into smaller peptides Thus, 
in order to enhance the sensitivity of these glycopeptides, I have employed 
endoproteinase Asp-N enzyme which selectively cleaves the peptide bonds N-
terminal to aspartic acid residues in the deglycosylated peptide fragments to smaller 
peptide fragments. The smaller peptide fragments could help in enhancing the 
sensitivity of detecting and differentiating the rhEPO and DPO. Hence, in this 
Chapter the use of the Asp-N enzyme will be demonstrated to identify the T9 
deaminated peptide fragment as described in Table 3.1. 
 
Thus, proteolytic enzyme digestion is an indispensable tool in proteomics; it helps to 
cleave the peptide bonds, producing information-rich and easily interpretable peptide 
fragmentation mass spectra. Mass spectrometry is a powerful analytical tool that is 
highly sensitive and enables identification of the modified position, hence; this is 
commonly used in combination with peptide mapping on reversed-phase or HILIC 
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Epogens Peptides after tryptic digestion 
 
     GQALLVNSSQPWEPLQLHVDK (EPO T9)  
   PNGase F                      Deamination 
rhEPO 
     GQALLV   DSSQPWEPLQLHV   DK (EPO T9DAM) (2360.2244) 
 Asp-N                           














    GQALLVNSSQVNETLQLHVDK (DPO T9) 




   GQALLV   DSSQV   DETLQLHV   DK (DPO T9DAM) (2295.1826)  
Asp-N                               















Table 3.1 PNGase F and Asp-N digestion of T9 Tryptic fragments (77 – 97) 
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3.2  Materials and Instrumentation 
3.2.1 Materials.  
DL-dithiothreitol (DTT) was purchased from Sigma Aldrich (Singapore). Ammonium 
bicarbonate was purchased from Merck Singapore. HPLC-grade methanol and 
acetonitrile (ACN) were obtained from Fisher Scientific (Singapore). Sequencing 
grade modified Trypsin (P/N No. V5111), protein deglycosylation mix kit and 
sequencing grade Asp-N were purchased from Promega (Singapore). The water 
used throughout all experiments was obtained from a Milli-Q Gradient A10 from 
Millipore (Singapore). Epoetin alfa, Eprex® the recombinant human erythropoietin, 
10,000 IU/ ml was purchased from Jassen-Cilag AG, (Schaffhausen, Switzerland). 
Darbepoetin alfa, Aranesp® 40 µg/ 0.4ml were obtained from Amgen Manufacturing 
Limited a subsidiary of Amgen Inc. (Thousand Oaks, CA, USA). Peptide 
DSSQPWEPLQLHV (human EPO peptide T9EPOA1), peptide GQALLV (human 
EPO peptide T9A1), peptide GQALLVNSSQPWEPLQLHVDK (human EPO peptide 
T9DAM) and peptide VYSNFFLR (human EPO peptide T17F) were synthesised by 
Auspep Pty. Ltd. (Tullamarine, Victoria, Australia). The vacuum manifold for 
processing 24 columns, QIAvac 24 Plus, and the connecting system (Qiagen, 
www.qiagen.com) was used together with a vacuum pump for passing the liquids 
through the columns. The EPO purification kit was obtained from MAIIA Diagnostics 
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3.2.2 Instrumentation.  
Experiments were undertaken on a Dionex Ultimate 3000 XRS UHPLC+ focused 
pump, with a Dionex Ultimate 3000 XRS open autosampler coupled to an ESI source 
of the TSQ Quantiva MS operated by Xcalibur software, and were all from Thermo 
Scientific. The autosampler has a 6-port injection valve with a 20 µl injection loop. 
The C18 column was coupled directly between the injection port and the ESI source.  
 
3.2.3 LC Conditions 
3.2.3.1  The column used was a Kinetex C18 50 x 2.1 mm, 2.6 µm, and 100Å 
fused core. 
3.2.3.2 The mobile phase used was (A) 0.1 % formic acid in water and (B) 
ACN at a flow rate 400 µl/ min;  
3.2.3.3 The initial conditions were 95 % A and 5 % B followed by a linear 
gradient to 5 % A and 95 % B at 5 minutes. After holding at 5 : 95 for 5 min, the 
composition was returned to initial conditions over 60 seconds. The column was re-
equilibrated in preparation for the next injection between 11 and 20 min. 
 
3.2.4 MS Conditions   
3.2.4.1  The positive ion source voltage was set at 3500 V, sheath gas at 20 
arbitrary units, AUX gas at 2 arbitrary units, sweep gas at 0 arbitrary units, Ion 
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3.2.5 Preparation of standard mix.  
EPO peptide standard mix, GQALLVNSSQPWEPLQLHVDK (EPO peptide T9DAM), 
GQALLV (EPO peptide T9A1), DSSQPWEPLQLHV (EPO peptide T9EPOA1) and 
VYSNFFLR (EPO peptide T17F) were prepared at a concentration of 10 ng/ml in 
their initial running mobile phase conditions (C18 reversed-phase- 5 % ACN, 95 % 
0.1 % FA in water).  
 
3.2.6 Preparation of calibrants.  
10 µg/ml of each standard (EPO T9DAM, T9A1, T9EPOA1, DPOT9DAM, T9DPOA1 
and T17F) was prepared individually as working stock solutions (WSS). 1 µM of each 
standard was then prepared from the 10 µg/ml of WSS and adjusted according to its 
purity. Two sets of calibrators were prepared. A contained EPO T9DAM, T9A1, 
T9EPOA1 and T17F and calibrator B contained DPO T9DAM, T9A1, T9DPOA1 and 
T17F. All calibrants prepared were diluted 10 x with buffer (95 % 0.1FA and 5 % 
ACN) before injection onto TSQ Quantiva LC-MSMS. Five calibration points were 
prepared at concentrations of 2, 4, 6, 8 and 10 nM.  
 
3.2.7 Preparation of samples.  
All samples were prepared at 0.1 µM based on the mass of each protein. 1 M of 
Eprex is 32,000 mg/ml. For 0.1 µM, 3.2 µg/ml was required. Therefore, 36 µl of 84 µg 
Eprex was put into an Eppendoff tube, with 100 µl of 1 µM internal standard 
(T16T17F), then topped up with 864 µl of 50 mM ammonium bicarbonate. 1 M of 
Aranesp is equal to 37,100 mg/ml. For 0.1 µM, 3.71 µg/ml was required. Therefore, 
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37 µl of 100 µg Aranesp was put into an Eppendorf tube, with 100 µl of 1 µM internal 
standard, and topped up with 863 µl of 50 mM ammonium bicarbonate. After 
preparing the samples at 0.1 µM, 100 µl of each sample was taken and placed in a 
vial, followed by 10 µl of 100 mM DTT and left at room temperature for 10 min. A 10 
µl of Try/ Lys C enzyme was added into the vial and incubated in the oven at 37 ºC 
for 3 hr. The tryptic digestion was followed by deglycosylation steps, where 5 µl of 
10x deglycosylation reaction buffer and 5 µl of protein deglycosylation mix were 
added respectively. This was then incubated overnight at 37 ºC. The following day, 
the sample was removed from the oven and 10 µl of 2 µg Asp-N enzyme was added 
to the sample and incubated at 37 ºC for 2 hr. The samples were diluted 10 x with 
buffer (95 % 0.1FA and 5 % ACN) before injection onto TSQ Quantiva LC-MSMS.  
 
3.2.8 Preparation of sample by IAC using MAIIA.  
Prepare the anti-EPO column using the EPO purification kit from MAIIA Diagnostics, 
by placing the 25 ml funnel on top of the vacuum manifold. 1 ml of a pH neutral 
buffer was added to the funnel with vacuum suction. 20 ml of spiked Eprex in plasma 
(20 ng/ml) was added to the funnel and vacuum was applied in order to filter the 
sample. 1 ml of washing buffer was added. After filtering, the anti-EPO column was 
placed on top of the Eppendorf tube and then centrifuged at 1500 rpm for 3 min. 
Another Eppendorf tube with 20 µl of 0.5 M ammonium bicarbonate and 2 µl of 10 
ng/ ml of internal standard added was prepared and placed next to the anti-EPO 
column in the centrifuge. When 50 µl of desorption buffer was added on top of the 
anti-EPO column it was then moved across to placed it on the other prepared 
Eppendorf tube which contained the ammonium bicarbonate and internal standard; 
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EPO peptide VYSNFFLR, T16T17F. It was centrifuged again at 1500 rpm for 3 min. 
The sample is then ready for the reduction and digestion step. 
 
3.2.9 Preparation of sample for reduction and digestion. 
The samples were reduced by adding 10 µl of 100 mM DTT and then leaving at 
room temperature for 10 min. For post-spiked plasma, it was added 20 µl of 1 ng/µl 
into the extracted plasma blank. The samples were tryptic digested by adding 10 µl 
of 20 µg/ 100µl trypsin for incubation at 37 ºC for 3 hr. Deglycosylation was carried 
out by adding 5 µl of 10 x deglycosylation reaction buffers and 5 µl of protein 
deglycosylation mix from the Promega protein deglycosylation kit. Samples were 
then gently vortexed and centrifuged at 3000 rpm to allow the sample to collect at 
the bottom of the tube. Samples were then incubated in the oven at 37 ºC for 16 hr. 
After the deglycosylation step, 10 µl of Asp-N enzyme at 2 µg/ 50µl was added to the 
samples and incubated in the oven at 37 ºC for 2 hr. This digested sample was 
injected onto the RP column. 
 
3.3 Results and Discussion 
Plasma is a complex protein containing matrix and consequently the detection of the 
presence of rhEPO or DPO, which are protein-based drugs, requires extraction and 
enrichment by immunoaffinity separation with anti-rhEPO antibodies. An efficient 
pre-analytical purification and concentration step is very important, as it contributes 
to the sensitivity of the detection of the epogens in the mass spectrometer. In this 
Chapter, I have described the use of MAIIA as the immuonaffinity extraction. Post-
spiking was carried out after the blank plasma samples went through the MAIIA 
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extraction procedure and Eprex was spiked together with the internal standard (IS), 
where the IS is added to demonstrate whether the enzyme is suitably active. When 
the non-glycosylated peptides, EPO T11 and EPO T17, in the pre- and post-
extraction spiking are compared, (Figures 3.1 and 3.2) have an area of 1 E5 for pre-
spiked and 8 E4 for post-spiked for EPO T11 and 8 E4 for pre-spiked and 6 E4 for 
post-spiked for EPO T17 respectively. Thus, this shows that there wasn’t much loss 
in the extraction. As for glycosylated peptides, EPO T9DAM peptide showed a 10 x 
lower peak area than the post-spiked product (Figure 3.3 and 3.4). This might be due 
to the Asp-N enzyme which had converted the EPO T9DAM to the smaller peptide 
fragments T9A1and T9EPOA1, which resulted in a much higher area in the pre-
spiked plasma (Figure 3.3), 4.7 E4 and 7.7 E3 respectively compared to the post-
spiked plasma (Figure 3.4) 2.8 E4 and 3.8 E3 respectively. Hence, this has shown 
that spiked plasma gave a better intensity of the smaller T9 peptide fragments than 
the post-spiked plasma. Therefore, the overall results showed that using the MAIIA 
pre-purification and concentration steps it was possible to achieve a very good 
recovery for these epogens. The EPO T9 standard mix (Figure 3.5) was prepared, 
containing T9A1, T9EPOA1 and EPO T9DAM with T17F internal standard as a 
reference of retention time to the sample injected.  
 




Figure 3.1 Pre- spiked plasma with Eprex- non-glycosylated peptides 




Figure 3.2 Post-spiked plasma with Eprex- non-glycosylated peptides 




Figure 3.3 Pre-spiked plasma with Eprex- glycosylated peptides 




Figure 3.4 Post-spiked plasma with Eprex- glycosylated peptides 




Figure 3.5 Extracted ion chromatogram of T9 stdmix and ISTD 
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Two sets of calibrants were prepared as described in section 3.2.6. For calibrant 
mixture A, only T9A1 calibration curves were plotted, because EPO T9DAM and 
T9EPOA1 were unable to be detected at all the calibration levels. For calibrant 
mixture B, T9A1 and T9DPOA1 calibration curves were plotted and, in this instance, 
only DPO T9DAM was unable to be detected at all the calibration levels. A linearity 
of > 0.99 was achieved for T9A1 in calibrant mixture A and T9A1 and T9DPOA1 in 
calibrant mixture B. The calibration curve A (Figure 3.6) was used to determine the 
concentration of T9A1 in the 10 nM Eprex sample, which shows a concentration of 
4.725 nM. Calibration curve B (Figures 3.7 and 3.8) was used to determine the 
concentration of T9A1 and T9DPOA1 respectively in the Aranesp sample. The 10 
nM Aranesp, was shown to contain 7.068 nM of T9A1 and 2.809 nM of T9DPOA1. 
Both the Eprex and Aranesp samples showed a higher intensity for peptide T9A1 for 
both the deaminated peptide EPO T9DAM and DPO T9DAM (Figures 3.9 and 3.10). 
However, peptide T9A1 is a common fragment for both the rhEPO and DPO. 
However, the T9EPOA1 and T9DPOA1 peptides could be used to differentiate 
between the two epogens. Figures 3.11 and 3.12 show that Eprex and Aranesp were 
tryptic digested and deglycosylated, this could be seen that the deaminated peptide 
T9 for both the rhEPO and DPO are low at 4.5 E4 and 2.1 E4 respectively. However, 
after the Asp-N digestion step, peptides T9A1, and T9EPOA1 could be seen as 7.4 
E5 and 7.8 E4 respectively in rhEPO while T9A1 and T9DPOA1 could be seen as 
1.7 E6 and 6.6 E6 respectively in DPO. Figure 3.9 shows that Asp-N digestion of the 
Eprex, for the uncommon peptide fragment T9EPOA1 still remains low at 7.8 E4, 
however the T9A1 peptide shows an area of 7.4 E5 but this is a common fragment 
which also contain in DPO. In this case, T9EPOA1 shows a similar area to EPO 
T9DAM, whereas for Aranesp, a significant difference could be seen in DPO T9DAM 
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and T9DPOA1. For rhEPO, it is not ideal to confirm by using the T9 peptide, as it 
gives a low sensitivity, even after the Asp-N digestion. This could be due to the 
T9EPOA1, which still contained a much longer peptide fragment compared to 
T9DPOA1. Hence, rhEPO could be confirmed by using the other glycopeptide EPO 
T5 which was further discussed in Chapter 5. 
 
In Figure 3.12, it could be seen that after tryptic digestion and PNGase F digestion of 
Aranesp, the other tryptic peptides, T6, T11 and T17 could achieve an intensity of E6 
– E7 level; however, T9 DAM could only achieve 1.5 E4. From Figure 3.10, we could 
see the Asp-N digestion fragments, where the T9DPOA1 achieved at 9 E5 and T9A1 
achieved at 3 E6. However, T9A1 is a common fragment to rhEPO. Hence, we could 
differentiate which epogen was present by identifying the T9DPOA1 fragment which 
has given a much better sensitivity. Thus, this has greatly enriched the sensitivity 
with which the presence of amino acids, characteristic to each epogen, contained in 
the sequence from the deglycosylated fragment of T9 peptide can be detected. This 
provides a simpler and easier way of establishing whether rhEPO or DPO was the 
protein responsible for the common peptides (e.g. T17).  
 




Figure 3.6 Calibration curve for calibrant A- T9A1 
 
 
Figure 3.7 Calibration curve for calibrant B- T9A1 




Figure 3.8 Calibration curve for calibrant B- T9DPOA1 




Figure 3.9 EPO peptides after Asp-N digestion 




Figure 3.10 DPO peptides after Asp-N digestion 




Figure 3.11 EPO peptides after tryptic digestion and deglycosylation 




Figure 3.12 DPO peptides after tryptic digestion and deglycosylation 
 




The MAIIA EPO purification kit is able to fulfil the requirements for use as a Pre-MS 
step for human and equine EPO doping analysis for plasma samples. The recovery 
of the rhEPO spiked in plasma is comparable or better than the post-spiked 
recoveries for non-glycosylated and glycosylated peptides respectively. The 
glycosylated peptides sensitivity could be achieved by the Asp-N digestion 
converting most of the EPO T9DAM or DPO T9DAM to the smaller peptide T9A1 
and T9EPOA1 or T9DPOA1, which resulting in a higher intensity. We consider this 
pre-analytical purification step efficient, as it is able to achieve comparable or better 
intensity than the post-spiked result. The addition of Asp-N digestion helped to enrich 
the deaminated peptide T9, which gives a higher intensity for the Asp peptides, 
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4.1 Introduction  
The most important step in the sample preparation for proteomics is the conversion 
of proteins to peptides. This bottom-up approach for fragment peptides from 
enzymatic digestion of proteins, followed by LCMS was chosen in the study for 
screening and confirming of rhEPO and DPO (Figure 4.1). Trypsin is a protease that 
specifically cleaves the C-terminal proteins at the arginine, R and lysine, K position 
(Figure 4.2), creating peptides in the preferred mass range for MS sequencing and 
with a basic residue at the carboxyl terminus of the peptide, producing information-
rich, easily interpretable peptide fragmentation mass spectra.  
 
Digestion of proteins with a highly specific enzyme that produce fragments of the 
amino acid sequence which are characteristic of the intact material, and are also 
compatible with detection/identification using liquid chromatography-mass 
spectrometry, is an important step in contemporary proteomics. In-solution based 
protein digestion is the traditional way of achieving this, but this procedure has 
several drawbacks. Firstly it is a time consuming step, which requires up to 18 hours 
of incubation in order to produce a reasonable amount of the peptides [74-75, 180]. 
Secondly the by-products generated by the auto-digestion of the enzyme add 
chemical noise and, in some cases, the similarity between the autolysis fragments 
and the peptides from the protein can even complicate the interpretation of the 
results. These issues can be minimised by immobilisation of the protease onto a 
solid support [76], since the digestion time is dramatically reduced because the 
enzyme-to-substrate ratio is significantly enhanced. By doing this immobilisation the 
opportunity for enzyme autolysis by-products to be formed is significantly reduced. 
This approach enables a high-localized concentration of the enzyme and a 
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significant acceleration of the digestion without any auto digestion due to the site 
isolation effect [77-79]. Furthermore, attaching an enzyme to a solid support provides 
increased stability towards any chemical denaturants and organic solvents that may 
be present as a consequence of the preparation steps conducted prior to the 
digestion [80]. When used in an on-line configuration, this method can also reduce 
the amount of sample handling required [76] and offers a more efficient way to 
process samples where the amount of material available is limited.  
 
Enzymes can be entrapped in polyacrylamide gels [75&76] or covalently attached 
onto the surface of micro-beads [81-82], monolithic columns [83-87] and the inner 
walls of open capillaries or microchannels in microfluidics devices [88-89]. Of all of 
these available options, the use of monolithic supports has attracted the most 
attention because they are easy to fabricate and the polymeric support generally 
provides fast mass transfer and low backpressure [90-91]. Monoliths composed of 
porous solid with small-sized skeletons and relatively large through-pores, could 
offer fast mass transfer and high enzyme binding capacity, making them superior 
supports for enzyme immobilisation [71]. Their large accessible surface area 
combined with a limited diffusion path length facilitates the rapid conversion of 
substrates [72, 180-182] resulting in the limited generation of autolysis products due 
to the site isolation effect [3, 183-184]. The fused silica capillary format for containing 
the immobilised enzyme reactors provides a convenient way to combine this step 
directly with hyphenated liquid chromatography-mass spectrometry [98, 128, 136]. 
Covalent attachment has several advantages over entrapment methods [177, 185] 
such as prevention of leaching, reduced diffusional constraints and no substrate 
mass limitations. Covalent immobilisation of trypsin onto controlled pore glass (CPG) 
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particles is a classical method that is highly effective for rapid production of micro-
scale immobilised enzyme reactor systems, which can easily be fabricated. Rigid 
glass particles can withstand high pressure in fluidic systems better than agarose 
beads, but better thermal stability than crosslinked polymer beads and have a good 
solvent compatibility. The high surface-to-volume ratio of CPG particles allows high 
enzyme loading when packed as a bed compared to membranes and they provide 
almost as good mass transfer as monolithic IMERs.  
 
Diisosthiocyanate (DITC), which was employed in this work, acts as a useful spacer 
(as it increases the accessibility) between the enzyme and the aminopropylated CPG 
particle. It was evaluated that activity was slightly higher when immobilisation was 
carried out in the presence of Ca2+ whereas more enzyme could be immobilised in 
its absence [186].  
 
In this chapter, I had reported a study on immobilisation of trypsin with high apparent 
specific activity onto covalently immobilised via the 1, 4-diisothiocyanatobenzene 
(DITC) linker onto aminopropylated controlled pore glass (CPG), DITC-CPG particles 
and on the influence of calcium ions added during the immobilisation procedure. The 
immobilisation of trypsin on porous glass beads was also compared with the 
immobilisation of trypsin on microreactors.  
 
An on-line digestion (trypsin reactor) was compared with the off-line (in-solution) 
digestion, and two different types of tryptic microreactors were fabricated and 
immobilised. An evaluation of the relative efficiency of the digestion technique was 
carried out by comparing the results obtained from the off-line (in-solution trypsin 
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digestion) method versus the on-line approach with either trypsin immobilised inside 
an open tubular dextran-modified capillary or a monolithic column where the trypsin 




Figure 4.1 Workflow of bottom-up approach for protein sample preparation 




Figure 4.2 Tryptic digest for rhEPO and DPO 
 
4.2 Materials and Instrumentation 
4.2.1 Materials.  
Diisothiocyanato-CPG (80-120 mesh, 700 Å average pore size, 54 µmol 
diisothiocyanato-CPG per g of glass), tetrahydrofuran (THF) with molecular sieve, 
Aminopropyl triethoxysilane (APTES) and N-(3-dimethylaminopropyl) - 
N’ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were 
purchased from Sigma/ Aldrich Singapore. Carbonyl diimidazole (CDI) was 
purchased from Alfa Aesar Chemical Company (Singapore) while carboxyl-modified 
dextran 10 (CMD) was purchased from pK Chemicals A/S (Denmark). Amino-
modified dextran (AMD) 3000 MW was from Invitrogen, Eugene, Oregon, USA. 
Sodium carbonate, calcium chloride, sodium hydroxide, polyethylene glycol 10,000 
(PEG), sodium bicarbonate, sodium chloride, dimethoxysulfoxide (DMSO), 
ammonium persulfate (APS), dimethyl sulfoxide (DMSO), ammonium persulfate 
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(APS) were all from Merck (Singapore). Methacryloxypropyltrimethoxysilane (Bind-
silane), acrylamide, N.N’-methylenebisacrylamide, N,N,N’,N’ 
Tetramethylethylenediamine (TEMED), N-acryloxysuccinimide (NAS) and 
benzamidine were purchased from Acros Singapore. Methanol and Toluene were 
from Fisher (Singapore). Trypsin lyophilised from Bovine pancreas was purchased 
from Thermo Scientific Singapore. The fused silica capillary 50 µm i.d. was supplied 
by Polymicro U.S.A. The water used throughout all experiments was Milli-Q Gradient 
A10 from Millipore (Singapore). Epoetin alfa, Eprex® the recombinant human 
erythropoietin, 10,000 IU/ ml was purchased from Jassen-Cilag AG, (Schaffhausen, 
Switzerland). Darbepoetin alfa, Aranesp® 40 µg/ 0.4ml were obtained from Amgen 
Manufacturing Limited a subsidiary of Amgen Inc. (Thousand Oaks, CA, USA).  
 
4.2.2 Instrumentation.  
Experiments were undertaken using a TempoTM nano MDLC by Eksigent, with an 
Eksigent AS1 Autosampler coupled to the nano-electrospray III source (experiment 
for comparison of immobilisation of trypsin on CPG beads with on-line trypsin 
enzyme reactor) or TIS source (experiment for comparison of on-line enzyme reactor 
and off-line enzyme digestion) of an AB Sciex 4000 Qtrap LC-MSMS operated by 
Analyst 1.5 software. The autosampler has a 6-port injection valve with a 20 µl 
injection loop. For the nano-electrospray set-up, a 50 µm fused silica capillary was 
fitted from the injection port and coupled to the trypsin enzyme reactor (on-line 
enzyme digestion) or coupled to the HALOTM C18 0.3 x 150 mm, 2.7 µm analytical 
column (off-line digestion on CPG beads), another 50 µm fused silica capillary was 
coupled from the analytical column to the nano-electrospray head which holds a new 
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objective 50 µm tapered metal tip. For the TIS source set-up, a 50 µm fused silica 
capillary was fitted from the injection port and coupled to the trypsin enzyme reactor 
(for on-line enzyme digestion) with a microtight union, where the trypsin enzyme 
reactor is placed in the oven at 37 ºC or coupled directly to the HALOTM C18 0.3 x 
150 mm, 2.7 µm analytical column (for off-line in-solution digestion) and joint by 
another union with another 50 µm fused silica capillary connected to the 6-port 
switching valve, passing through a CAPTRAPTM, PEPTIDE (Michrom Bioresources, 
Inc.).  When this switching valve is switched, the pump running an organic solvent 
gradient, delivers the sample from the CAPTRAP to the analytical column and then 
to the TIS source (Figure 4.3).  
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4.2.3 LC Conditions 
4.2.3.1 The mobile phase used for both loading and gradient pumps were (A) 0.15 % 
FA in water and (B) ACN.  
 
4.2.3.2 Nanospray set-up the gradient pump initial conditions were 95 % A and 5 % 
B followed by a 20 min gradient to 5 % A and 95 % B, holding at 95 % B for 10 min, 
and returning to its initial condition at 26 min and re-equilibrating in preparation for 
the next injection between 26 and 35 min, at a flow rate 4 µl/ min. 
 
4.2.3.3 TIS set-up the loading pump was set at 1 µl/ min isocratic for 95 % A and 5 % 
B. The gradient pump initial conditions were 95 % A and 5 % B followed by a linear 
gradient 10 min gradient to 5 % A and 95 % B, holding at 95 % B for 5 min, and 
returning to initial conditions at 16 min and re-equilibrating in preparation for the next 
injection between 16 and 25 min.  
 
4.2.4 MS Conditions 
4.2.4.1 The nano-electrospray source voltage was set at 2800 V, Nebuliser gas GS1 
at 20 psi, curtain gas, CUR at 30 psi, Heater gas GS2 at 0 psi and TEMP was set at 
0 ̊C.  
  
4.2.4.2 The positive ion source voltage was set at 4500 V, GS 1 at 15 psi, GS 2 at 10 
psi, CUR at 30 psi and TEMP at 350 °C. 
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4.2.5 Preparation of DITC-CPG beads 
THF was dried with molecular sieves. 5 ml of dried THF was dispensed into a dried 
conical flask; 50 mg of weighed DITC was added into the conical flask. 1 g of CPG 
beads was added. The mixture in the conical flask was stirred with a magnetic stirrer, 
with the nitrogen gas blowing at room temperature for 2 hr. The mixture was then 
filtered and washed with 100 ml of toluene. (The filtrate and toluene washes can be 
concentrated to recover DITC, which is repurified by crystallisation). The beads was 
then washed with 150 ml of anhydrous MeOH and dried under vacuum. The beads 
were stored at 4 °C under N2.  
 
4.2.6 Trypsin immobilisation on DITC-CPG beads 
TPCK-treated trypsin was covalently coupled to the support (DITC-CPG) as follows: 
10 mg of washed DITC-CPG beads were reacted with 5 mg of trypsin solution (10-4 
M) in 100 mM sodium carbonate at pH 9.5 (~ 1 ml) in either the presence or absence 
of 11.5 mM calcium chloride. The mixture was allowed to react with gentle shaking at 
25 °C. The reacted support was decanted and washed with 3 volumes of 100 mM 
sodium carbonate at pH 9.5, containing 0.5 M sodium chloride and then with 3 
volumes of the same solution without sodium chloride. The reaction supernatant and 
all wash solutions were recovered for determination of unbound trypsin. The trypsin-
DITC-CPG (Figure 4.4) particles were dried on a filter paper in 37 °C oven for 30 min; 
it was then poured into the amber vial and blow dried with N2.  
 




Figure 4.4 Structure of trypsin-DITC-CPG 
 
4.2.7 Tryptic digest with trypsin-DITC-CPG beads 
2.5 mg or 5 mg of trypsin-DITC-CPG beads was weighed and added into the 
prepared 300 µl of spiked Eprex with a concentration of 2 or 20 ng on-column 
injections. It was then placed in the oven at 37 °C for oven digest. The same amount 
was repeated for the trypsin-DITC-CPG beads with calcium chloride. The same 
concentrations were also prepared for the on-line digestion. 
 
4.2.8 Preparation of dextran-coated fused silica capillaries  
Firstly, the 160 cm x 50 µm fused silica capillaries were cleaned at a flow rate of 5 
µl/min with 2 M NaOH for 30 min, 0.1 M HCl for 30 min, H2O for 5 min and finally 
with EtOH for 5 min. The dextran-coated capillaries were prepared as follows: the 
clean capillaries were incubated for 60 min with a 10 % APTES solution in EtOH. 
After this step, the capillaries were flushed at a flow rate of 5µl/min with EtOH for 5 
min and then dried overnight at 50 ºC. To modify the surface	   with dextran, the 
capillaries were incubated	   for 30 min with a solution of 5 % CMD in H2O also 
containing 200 mM EDC and 50 mM NHS. After 30 min they were flushed for 5 min 
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at 5 µl/min with H2O, then filled with a solution of 10 % AMD in H2O and incubated 
once more overnight. The resulting dextran-modified capillaries were washed at a 
flow rate of 5 µl/min with both H2O and MeOH for 5 min, after which 100 mM CDI in 
acetone was injected for 30 min. After this activation step, they were flushed with 
EtOH and H2O for 5 min. A solution containing 2.5 mg/ml trypsin in 50 mM 
ammonium bicarbonate was injected at a flow rate of 2 µl/min and the enzyme 
coupling was allowed to couple for 8 hr. The reaction was stopped by injection of 1 M 
glycin pH 3. Finally the resulting trypsin micro-reactors were flushed with H2O and 
stored in a closed box at 4 ºC or used immediately. All reactions were conducted at 
room temperature except for the drying step following APTES incubation. The 
chemistry of the surface modification and enzyme immobilisation in fused-silica 
capillaries has previously been described in ref. [4]. 
 
4.2.9 Preparation of the co-polymerised monolith column  
27 cm x 250 µm i.d. fused silica capillaries were pre-treated with 1 M NaOH for 30 
min, then flushed with 3 ml of 0.1 M HCl, and finally, rinsed with 3 ml water. 
Thereafter, a 50 % (v/v) Bind-Silane (bifunctional reagent) in acetone was introduced 
and left inside the column for 40 min at room temp. Finally, the capillary was rinsed 
with water and acetone, and then dried with N2 gas. The monolith was prepared by 
dissolving 20 mg of acrylamide, 30 mg of N, N’-methylenebisacrylamide, and 30 mg 
of PEG per ml of 0.2 M sodium bicarbonate/ 0.5M sodium chloride (pH~8) buffer. 
The mixture was vortexed for a few seconds and heated at 55 – 60 ºC for 15 min to 
completely dissolve the monomers. To 0.5 ml of this solution, 2 µl of 20 % (v/v) 
TEMED were added. The mixture was then degassed for 15 min using N2 gas 
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delivered through fused silica tubing. Next 5 µl of N-acryloxysuccinimide (NAS) (140 
mg/ml, 828 mM) dissolved in DMSO was added. Since DMSO is of a higher density 
than the buffer, the NAS was added on top of the solution, while degassing was used 
to ensure a thorough mixing of the NAS with the solution buffer. After 1 min, 2 µl of 
20 % (w/v) ammonium persulfate (APS) was added in order to initiate polymerisation. 
The APS was dispensed into the middle part of the solution while degassing, to 
ensure an efficient and rapid mixing. After 30 s, a 19 µl aliquot of this solution was 
removed and quickly mixed (so as to avoid contact with oxygen) with 1 µl of freshly 
prepared trypsin (20 mg/ml in a buffer containing 0.5 M benzamidine). This mixing 
step was performed without N2 degassing. An activated (Bind-Silane) capillary was 
then inserted into the trypsin-monomer vial, whereby the solution filled the tubing by 
capillary action. Immobilisation/ polymerisation was allowed to proceed for 30 min at 
room temperature with the capillary ends covered with parafilm.  
 
4.2.10 Preparation of samples 
10 µl of 84 ng/µl Eprex® was spiked into 100 µl of 50 mM ammonium bicarbonate 
buffer in an	  auto sampler vial. This vial was placed on the auto sampler for direct 
injection into the on-line trypsin reactor coupled to the analytical column and to the 
TIS source for detection or add 1 µl of (2.5 mg/ml trypsin prepared in 50 mM 
ammonium bicarbonate buffer) into the spiked sample for an off-line digestion in the 
37 °C oven for 3 hr digestion. 
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4.3 Results and Discussion 
The covalently immobilisation of 1,4- diisothiocyanatobenzene (DITC) linker onto 
aminopropylated controlled pore glass (CPG) particles which reaction conditions 
involving enzyme, solid support and linker are important parameters since they 
determine the biochemical, mechanical and kinetic properties of the immobilised 
enzyme. It is recognised that trypsin autolysis is inhibited by addition of calcium 
ions to the enzyme reaction solution [186].  
 
Hence, in this experiment, I had made a comparison of immobilising trypsin onto 
the DITC-CPG beads with and without calcium chloride. Figure 4.5 showing the 
Eprex digested in the DITC-CPG beads with CaCl2 and Figure 4.6 showing the 
Eprex digested in the DITC-CPG beads without CaCl2, both are digesting at the 
same concentration and injected 20 ng onto the column. Most of the peptides had 
an increased in intensity, except one of the peptides, EPO peptide T4 remained 
the same intensity. A few of the peptides achieved twice in the intensity for the 
digestion in the DITC-CPG beads with CaCl2. This had shown that the addition of 
calcium chloride does help in improving the digestion, since there is an 
improvement in the sensitivity.  




Figure 4.5 Eprex digested in trypsin immobilised onto DITC-CPG beads with CaCl2 




Figure 4.6 Eprex digested in trypsin immobilised onto DITC-CPG beads without 
CaCl2 
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I had also compared the trypsin immobilised onto DITC-CPG beads with the on-
line enzyme reactor. I had injected both digestions at 2 ng (Figure 4.7 and 4.8) and 
20 ng (Figure 4.9 and 4.10) on-column. From both the concentrations, it can be 
seen that the Eprex digested on the on-line enzyme reactor which trypsin was 
immobilised onto the dextran-modified capillary showed a higher in intensity 
compared to the Eprex digested in the 5 mg of trypsin-DITC-CPG beads.  
 
 
Figure 4.7 On-line enzyme reactor digestion for 2 ng Eprex injected on-column 




Figure 4.8 Off-line trypsin digestion in 5 mg DITC-CPG beads for 2 ng Eprex 
injected on-column 




Figure 4.9 On-line enzyme reactor digestion for 20 ng Eprex injected on-column 




Figure 4.10 Off-line trypsin digestion in 5 mg of DITC-CPG beads for 20 ng Eprex 
injected on-column 




Figure 4.11 Off-line trypsin digestion in 2.5 mg of DITC-CPG beads for 20 ng 
Eprex injected on-column 
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However, when the Eprex was digested in 2.5 mg of DITC-CPG beads with CaCl2 
(Figure 4.11), this showed a much better (~10 x) intensity compared to the 
digestion in 5 mg of DITC-CPG beads with CaCl2 and on-line enzyme digestion. It 
could be seen that when twice the trypsin-DITC-CPG beads was added, it caused 
a decrease in intensity by ~ 10 x. Hence, this could most likely be an autolysis 
which causes a decrease in the intensity. Thus, the amount of trypsin digestion 
can cause a variable in the sensitivity.  
 
From this experiment, I observed that the digestion in 2.5 mg of immobilised 
trypsin-DITC-CPG beads could achieve a much better sensitivity. However, there 
is a lot of off-line preparation work required to wash and trypsin immobilised on the 
beads and off-line digestion.  
 
I elected to use silica capillaries derivatised with a dextran hydrogel to passivate 
the silica surface as these should provide less non-specific adsorption of proteins 
and also offer a means to immobilise a larger amount of enzyme when compared 
to an unmodified surface [84 & 187]. As an alternative strategy, I coupled the 
enzyme to a monolithic polymer that had been fabricated inside a fused silica 
capillary. The digestion efficiencies of the two trypsin reactors fabricated in this 
manner were compared with the results from an in-solution digestion. Figures 4.12 
and 4.13 show the EICCs obtained from a diluted Eprex™ standard using an on-
line digestion with the dextran-modified reactor and the monolithic reactor 
respectively. The off-line (i.e. in-solution) enzyme digestion is shown in Figure 4.14. 
This data is summarised in Figure 4.15, which shows that the highest overall 
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abundance for the peptides was obtained when using the trypsin immobilised on 
dextran-modified fused silica reactor. For example, the EPO peptide T17 
(VYSNFLR) has shown a response that was approximately 4 times higher than 
that from the in-solution digest and almost twice as high as that obtained when the 
monolithic reactor was used.  It was also interesting to note that the EPO peptide 
T6 (VNFYAWK), which was below the detection limit in the in-solution digestion, 
was readily identified in the EICCs from both of the enzyme reactors. Some of the 
other peptides in these digests showed a similar result for both of the immobilised 
enzyme reactors and also the in-solution digestion. Triplicate injections onto the 
dextran-modified enzyme reactor were shown (Figure 4.16) to have a maximum 
CV of approximately 5 % for all digested peptides and therefore this reactor also 
offers better reproducibility when compared to using trypsin bound to the monolith, 
where the variation between injections was found to be much higher, ranging from 
5 to 37 % CV. Thus, both of the on-line enzyme digestion reactors were more 
robust, achieved better sensitivity and reduced the digestion time when compared 
to the off-line in-solution enzyme digestion method. Another advantage is that I 
could use these reactors for more than 50 injections without an obvious loss of 
activity and this is a cost benefit in comparison to limitation of a one-time use of 
the enzyme during in-solution digestion.  
 




Figure 4.12 Extracted ion chromatogram showing EPO peptides digested on-line on 
a trypsin immobilised dextran-coated open tubular fused silica capillary. 
 
 




Figure 4.13 Extracted ion chromatogram showing EPO peptides digested on-line on 










Figure 4.14 Extracted ion chromatogram showing EPO peptides digested off-line in-










Figure 4.15 Graph summarising the peak area intensity of the two different types of 











Figure 4.16 Graph summarising the reproducibility of the two different types of 
enzyme reactors and in-solution enzyme digestion. 
 
4.4 Conclusion 
The goal to replace an off-line (in solution) enzyme digestion with a fast and efficient 
on-line method that could be applied to detect rhEPO in equine plasma extracts has 
been achieved. I have demonstrated that immobilising trypsin on a dextran-coated 
capillary offers better sensitivity in addition to efficiency and repeatability 
performance enhancements when compared to the use of a monolithic capillary for 
this purpose. Future work will look at optimising the loading flow rate during the 
digestion/deglycosylation/trapping stage in order to reduce the cycle time between 
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5.1 Introduction  
EPO is a regulator of erythropoiesis, the process that controls the production of red 
blood cells in mammals and, therefore it is likely to be performance enhancing when 
given to racehorses [3]. Although the intact rhEPO can be detected by mass 
spectrometry [3], the most common way of screening for its presence is to digest an 
affinity extracted sample with trypsin and then conduct a target analysis for the 
characteristic peptides using LC-MSMS [184]. It is also possible to use this method 
to differentiate rhEPO from the synthetic epogen analogue Darbepoetin Alpha (DPO) 
since in addition to the presence of several peptides that are characteristic to both 
proteins, the peptides T5 (21-45) and T9 (77-97) have unique amino acid sequences 
that are specific to each protein (Figure 5.1). Unfortunately, this is not a 
straightforward process as the T5 and T9 product from both rhEPO and DPO are a 
population of glycopeptides with highly variable sialic acid containing glycan motifs 
that severely hinder detection under ESI-MS conditions. 
  
Glycopeptides consist of a peptide and a glycan part covalently bound to asparagine 
residues (N-linked) or to serine or threonine residue (O-linked). The EPO tryptic 
digest shows three groups of glycopeptides. N-linked glycans, mainly di-, tri- and 
tetra-antennary structures of the complex type, are shown to attach to N24 and N38 
in the T5 fragment of tryptic peptide 21EAENITTGCAEHCSLNENITVPDTK45 and 
N83 in T9 fragment of tryptic peptide, 77GQALLVNSSQPWEPLQLHVDK97. The O-
glycans are linked to the T13 fragment, peptide 117EAISPPDAASAAPLR131 with 
glycosylation at S126. Darbepoetin alfa (DPO) has a similar polypeptide backbone 
as rhEPO but with five amino acids differences (highlighted in red in peptide 
sequence below) and contains 5 N-linked carbohydrate at the T5 and T9 fragments. 
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The DPO tryptic digest shows the N-linked glycans at N24, N30 and N38 in the T5 
fragment of tryptic peptide   21EAENITTGCNETCSLNENITVPDTK45 and N83 and 
N88 in the T9 fragment of tryptic peptide 77GQALLVNSSQVNETLQLHVDK97. Thus, 
these are the only two unique tryptic digest peptide fragments, which can 
differentiate and identify the rhEPO from DPO.  
 
Glycosylation of proteins is one of the most common posttranslational modifications 
(PTM) in the modulation of their structure and and functions. There are various 
pathways for protein modification with sugars (glycans), one of the most common 
ways is the addition of glycans to an asparagine (N-linked) or to serine or threonine 
(O-linked).  
 
Consequently, an efficient process to remove the sugar moieties from the peptides is 
a key requirement for a successful analysis and Peptide-N-glycosidase F (PNGase 
F), which selectively releases N-linked glycans by hydrolysing the amide bond at the 
asparagine side chain [98], is frequently used for this purpose. This reaction is 
usually performed in solution using PNGase F mixed with the substrate in a small 
volume of buffer and, to keep cost under control, only a small quantity of the enzyme 
is typically used to catalyse the cleavage. As a result, the ratio of the glycolytic 
enzyme to substrate is usually lower than optimal. However, by efficiently 
immobilising the same amount of enzyme onto a solid support, this catalysis could 
be improved because only a small percentage of the sample is ever in contact with 
the enzyme at any time during the passage of the liquid through the reactor. 
Furthermore, only a small aliquot from the extract requires deglycosylation before 
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Figure 5.1 The unique tryptic fragment for differentiation of rhEPO and DPO 
 
In this chapter I report on the results obtained using serially connected trypsin and 
PNGase F reactors that were coupled in an on-line configuration with LC-ESI/MSMS. 
A monolithic PNGase F enzyme reactor was made. Coupling of the on-line trypsin 
digestion reactor and PNGase F deglycosylation reactor in series considerably 
reduced the preparation time and by linking these directly to the mass spectrometer, 
the sample losses and/or overall potential for contamination with plasticisers and 
• For screening, to differentiate equine EPO from the synthetic analogues 
(rhEPO/ DPO) 
 
	   Peptide T6- VNFYAWKR (rhEPO)    Peptide T11- SLTTLLR (rhEPO) 
      VNFYAWKR (DPO)      SLTTLLR (DPO) 
                   VNFYSWKR (eEPO)                        SLTSLLR (eEPO) 
 
 Peptide T14- TITADTFRK (rhEPO)    Peptide T17- VYSNFLR (rhEPO) 
                        TITADTFRK (DPO)                  VYSNFLR (DPO) 
                        TFAVDTLCK (eEPO)               IYSNFLR (eEPO) 
 
• For confirmation, to differentiate rhEPO and DPO 
 
 Peptide T5- EAENITTGCAEHCSLNENITVPDTK (rhEPO) 
                       EAENITTGCNETCSLNENITVPDTK (DPO) 
                       EAENVTMGCAEGCSFGENVTVPDTK (eEPO) 
 
  Peptide T9- GQALLVNSSQPWEPLQLHVDK (rhEPO) 
                       GQALLVNSSQVNETLQLHVDK (DPO) 
                       GQALLANSSQPSETLRLGVDK (eEPO) 
 
Note: EPO T5, T9 deaminated and DPO T5, T9 deaminated 
Chapter 5 PNGase F Reactor 
186	  
	  
other chemical noise could be minimised. It was demonstrated in this chapter that 
both the non-glycosylated peptides and the glycosylated tryptic peptides could be 
detected within a single analytical run.  
 
5.2 Materials and Instrumentation 
5.2.1 Materials.  
Sodium hydroxide, polyethylene glycol 10,000 (PEG), sodium bicarbonate, sodium 
chloride, dimethoxysulfoxide (DMSO), ammonium persulfate (APS), dimethyl 
sulfoxide (DMSO), ammonium persulfate (APS) were all from Merck (Singapore). 
Methacryloxypropyltrimethoxysilane (Bind-silane), acrylamide, N.N’-
methylenebisacrylamide, N,N,N’,N’ tetramethylethylenediamine (TEMED), N-
acryloxysuccinimide (NAS) and benzamidine were purchased from Acros Singapore. 
Peptide-N-glycosidase (PNGase F) 500,000 U/ml was purchased from New England 
Biolabs and the fused silica capillary 100 µm i.d. were supplied by Polymicro U.S.A. 
The water used throughout all experiments was Milli-Q Gradient A10 from Millipore 
(Singapore). Epoetin alfa, Eprex® the recombinant human erythropoietin, 10,000 IU/ 
ml was purchased from Jassen-Cilag AG, (Schaffhausen, Switzerland). Darbepoetin 
alfa, Aranesp® 40 µg/ 0.4ml were obtained from Amgen Manufacturing Limited a 
subsidiary of Amgen Inc. (Thousand Oaks, CA, USA). 
 
5.2.2 Instrumentation. Experiments were undertaken using a TempoTM nano MDLC 
by Eksigent, with an Eksigent AS1 Autosampler coupled to the TIS source of an AB 
Sciex 4000 Qtrap LC-MSMS operated by Analyst 1.5 software. The autosampler has 
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a 6-port injection valve with a 20 µl injection loop. A 50 µm fused silica capillary was 
fitted from the injection port and coupled to the trypsin enzyme reactor with a 
microtight union, where the trypsin enzyme reactor and PNGase F reactor are 
coupled with a microtight union and placed in the oven at 37 ºC and joined with 
another union with another 50 µm fused silica capillary connected to the 6-port 
switching valve, passing through a CAPTRAPTM, PEPTIDE (Michrom Bioresources, 
Inc.).  When this switching valve is switched, the pump running an organic solvent 
gradient, delivers the sample from the CAPTRAP to the 2.7 µm HALOTM C18 0.3 mm 
i.d. x 150 mm, analytical column and then to the TIS source (Figure 5.2).  
 
 
Figure 5.2 Schematic diagram of an on-line set-up with enzyme reactors coupled to 
LC-MSMS 
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5.2.3 LC Conditions 
5.2.3.1  The column used was a 2.6 µm 100 Å fused core Kinetex C18 50 mm x 
2.1 mm i.d. 
5.2.3.2 The mobile phase used was (A) 0.15 % FA in water and (B) ACN at a 
flow rate 4 µl/ min; 
5.3.3.3 The initial conditions were 95 % A and 5 % B followed by a linear 
gradient from 5 % A to 95 % B in 10 min, holding at 95 % B for 5 min, and returning 
to initial conditions at 16 min and re-equilibrating in preparation for the next injection 
between 16 and 25 min.  
 
5.2.4 MS Conditions 
5.2.4.1 The positive TIS ion source voltage was set at 4500 V, GS 1 at 15 psi, 
GS 2 at 10 psi, CUR at 30 psi and TEMP at 350 °C. 
 
5.2.5 Preparation of the co-polymerised monolith column  
27 cm x 100 µm i.d. fused silica capillaries were pre-treated with 1 M NaOH for 30 
min, then flushed with 3 ml of 0.1 M HCl, and finally rinsed with 3 ml water. 
Thereafter, a 50 % (v/v) Bind-Silane (bifunctional reagent) in acetone was introduced 
and left inside the column for 40 min at room temp. Finally, the capillary was rinsed 
with water and acetone, and then dried with N2 gas. The monolith was prepared by 
dissolving 20 mg of acrylamide, 30 mg of N, N’-methylenebisacrylamide, and 30 mg 
of PEG per ml of 0.2 M sodium bicarbonate/ 0.5 M sodium chloride (pH~8) buffer. 
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The mixture was vortexed for a few seconds and heated at 55 – 60 ºC for 15 min to 
completely dissolve the monomers. To 0.5 ml of this solution, 2 µl of 20 % (v/v) 
TEMED were added. The mixture was then degassed for 15 min using N2 gas 
delivered through fused silica tubing. Next 5 µl of N-acryloxysuccinimide (NAS) (140 
mg/ml, 828 mM) dissolved in DMSO was added. Since DMSO is of a higher density 
than the buffer, the NAS was added on top of the solution, while degassing was used 
to ensure a thorough mixing of the NAS with the solution buffer. After 1 min, 2 µl of 
20 % (w/v) ammonium persulfate (APS) was added in order to initiate polymerisation. 
The APS was dispensed into the middle part of the solution while degassing, to 
ensure an efficient and rapid mixing. After 30 s, a 2 µl aliquot of this solution was 
removed and quickly mixed (so as to avoid contact with oxygen) with 1 µl of PNGase 
F. This mixing step was performed without N2 degassing. An activated (Bind-Silane) 
capillary was then inserted into the PNGase F-monomer vial, whereby the solution 
filled the tubing by capillary action. Immobilisation/ polymerisation were allowed to 
proceed for 30 min at room temperature with the capillary ends covered with parafilm.  
 
5.2.6 Preparation of samples 
10 µl of 84 ng/µl Eprex® was spiked into 100 µl of 50 mM ammonium bicarbonate 
buffer in an	  auto sampler vial. This vial was placed on the auto sampler for direct 
injection into the on-line enzyme microreactors coupled to the analytical column and 
to the TIS source for detection.  
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5.3 Results and Discussion 
In order to detect the tryptic glycopeptides, a deglycosylation step using the enzyme 
PNGase F to cleave the N-glycan is necessary to make these protein fragments 
compatible with LC-MSMS detection. However, the PNGase F enzyme offered by 
vendors in relatively small quantities at a comparatively high cost and so the high-
wastage procedure for coating the dextran modified capillary was too costly to 
attempt. Thus the monolithic enzyme reactor was the only type prepared for this 
study and this provided good performance in comparison to the results that were 
achieved when it was carried out in an in-solution deglycosylation (Figure 5.3), as 
the peak abundances for deglycosylated peptides obtained in-solution were lower 
than for the on-line deglycosylation reactors. EPO perfused through the PNGase F 
reactor were shown to be effectively deglycosylated on a time scale of seconds 
using low nanogram to microgram per microliter concentration (corresponding to a 
total sample consumption of 0.1 µg of a glycoprotein).  
 
The trypsin and deglycosylation reactors (held inside an oven at 37 ºC) were coupled 
to the autosampler and a trap column as shown in Figure 5.2. The first factor that I 
evaluated was whether positioning the trypsin reactor either before or after the 
deglycosylation reactor in the flow path, produced any noticeable effect on the 
detection of the target peptides. Thereafter I tried sandwiching the trypsin reactor 
between two PNGase F reactors, but rather unexpectedly this orientation produced a 
50 % drop in the intensities for both T5DAM and T9DAM (Figure 5.4) when 
compared to the TRYPSINèPNGase F orientation. Lastly I doubled the length of the 
deglycosylation reactor that was connected after the trypsin reactor and this brought 
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about a favourable increase in the EICCs intensity for T5DAM and T9DAM (Figure 
5.5). Overall these results showed that there was a major difference in the 
abundance of the glycosylated peptides when using different on-line configurations. 
For example, T9 DAM shows an EICCs with 10 times lower abundance than when 
the PNGase F reactor followed the trypsin reactor (Figure 5.6). When two PNGase F 
reactors are placed after the trypsin reactor, the intensity of T5DAM is doubled to 
that of when only one PNGase F reactor is used. From this approach, by increasing 
the length of PNGase F reactor, we could enhance the sensitivity of the 
deglycosylated peptides. However, this approach can cause a slight decrease in the 
non-glycosylated peptides. This is still acceptable as the drop is insignificant and 
importantly, the glycopeptides have much higher sensitivity (almost 10 x) than the 
traditional in-solution digestion, which greatly helped to identify the rhEPO and DPO 
in doping.  
 
The reactor enzyme activity was shown to be reproducible (except for EPO T6) and 
all non-glycosylated and glycosylated peptides have less than 20 % coefficient 
variation (Figure 5.7). The glycosylated peptides showed a good repeatability of less 
than 10 % for the orientation when two PNGase F reactors are placed after the 
trypsin reactor. 
 
These results were promising, as even though it takes an hour (at 1 µl/min flow rate) 
to pass the sample through the reactors, this is considerably shorter than the two 
days that it normally takes to complete the off-line sample preparation and it was 
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also able to get an improvement in the sensitivity for both the non-glycosylated and 
glycosylated tryptic peptides in the Eprex™ digest.  
 
 
Figure 5.3 Extracted ion chromatogram showing the EPO peptides deglycosylated 









Figure 5.4 Extracted ion chromatogram showing the EPO peptides digested on-line 










Figure 5.5 Extracted ion chromatogram showing the EPO peptides digested on-line 
by the orientation of trypsin-deglycosylation-deglycosylation reactors 


















I have also demonstrated that the PNGase F enzyme can be successfully coupled to 
a monolithic column in order to fabricate a deglycosylation reactor and, in 
combination with the trypsin reactor, was used to detect both the digested non-
glycosylated and glycosylated peptides in an on-line digestion/LC-MSMS 
configuration with good sensitivity and acceptable repeatability. This time saving 
technique minimises the extent of manual sample handling, which reduces the 
potential sources of contamination. Future work will look at optimising the loading 
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cycle time between injections and/or multiplexing the analysis to improve the overall 



























Chapter 6: Novel monolithic HILIC 
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6.1 Introduction  
Peptide screening following a selective enzymatic (e.g. trypsin) digestion of 
susceptible amide bonds in the protein is an important technique for testing for the 
presence of bio-therapeutics. Reversed-phase (RP) chromatography is frequently 
used to separate peptides derived in this manner, but hydrophilic peptides are poorly 
retained under these conditions and consequently valuable information can be lost 
because early elution renders them highly susceptible to ion-suppression effects in 
ESI-MS. Ion suppression results from the presence of less volatile compounds that 
can change the efficiency of droplet formation or droplet evaporation, which in turn 
affects the amount of charged ion in the gas phase that ultimately reaches the 
detector. Thus, in this work, I demonstrate the suitability of using HILIC 
chromatography as a complementary approach to RP by analyzing peptides 
produced by tryptic digestion of the glycoproteins rhEPO and DPO. HILIC is an 
orthogonal approach to RP [128, 136, 141, 188] and this work demonstrates the 
benefits gained by using a low aqueous content mobile phase to increase sensitivity 
in ESI-MS [134,143]. This separation mode has also been used for the enrichment of 
PTMs such as glycosylation [135], N-acetylation [137] and phosphorylation [138] in 
proteomics applications. 
 
Hydrophilic interaction chromatographic (HILIC) has become increasingly popular in 
separation science due to its complementary selectivity to reversed-phase liquid 
chromatography (RPLC), and the fact that it also has good compatibility with LC-MS 
and 2D LC [128].  
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HILIC is characterized by the use of a hydrophilic stationary phase and a relatively 
hydrophobic mobile phase containing a high percentage of a water miscible organic 
solvent [189]. The order of elution is usually reversed relative to RP chromatography, 
with hydrophilic compounds being retained on the packing material for a longer 
period than hydrophobic compounds. This occurs because the HILIC stationary 
phase becomes enriched with water and thus polar analytes partition preferentially 
into this thin hydrophilic layer from the more hydrophobic mobile phase environment 
[128]. It makes use of polar stationary phases in combination with apolar aqueous, 
typically acetonitrile-rich eluents, and allows retention of hydrophilic solutes through 
interactions with polar functionalities and/ or partitioning into an absorbed water layer.  
 
When using gradient HILIC [128, 134, 141 and 143] the analytes retained on the 
stationary phase are eluted by lowering the hydrophobicity of the mobile phase and 
this is accomplished by simply increasing the water content. In most cases elution 
occurs before the mobile phase contains 30 % water [128]. The conditions required 
for elution of a specific compound are dependent on the type of stationary phase 
used as well as the mobile phase composition, including the percentage and type of 
organic solvent, the type and concentration of salts and also the pH [143].  
 
The polar zwitterionic monolith provides an environment that is not only capable of 
hydrophilic interaction with polar and charged analytes but also offers the opportunity 
for weak electrostatic interaction with analytes carrying either positive or negative 
charges to occur [190]. Whilst increasing the hydrophilicity of the monolith would 
enhance HILIC interactions, this type of polymers can be affected by shrinkage in 
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water and swelling in organic solvents and this is related to the lack of or the 
inhomogeneity of the crosslinking [191]. The resulting instability of the 
chromatographic support as the eluent composition changes leads to reduced 
column efficiency and a loss of resolution [192-193]. Therefore, to counteract this 
problem, a highly crosslinked polymer with good homogeneity is preferred. 
 
A previous study [194-196] described the use of the monomer BVPE, which has a 
spacer between aromatic rings that allows both vinyl groups to retain the same 
reactivity to free radical polymerisation, that yields a homogeneous highly 
crosslinked polymer in a short polymerisation time. The resulting monoliths also had 
significant proportions of both mesopores and macropores and this allowed for the 
rapid and high resolution separation of low molecular weight compounds, as well as 
larger biomolecules, on the same monolithic support. Furthermore, the high fraction 
of flow-channels provided enhanced column permeability and lower backpressure. 
 
According to Van Deemter et al. [197], column efficiency (height equivalent to a 
theoretical plate HETP) is directly proportional to the particle diameter of the 
stationary phase. Therefore, a good monolith should exhibit a good (bimodal) pore-
size-distribution of macropores (>75 µm) and mesopores (2-50 nm). By employing 
an approach introduced by Trojer et al. [198], which uses polymerisation time as a 
polymerisation parameter for tailoring the porous properties of organic monoliths 
[196], I used different polymerisation times to evaluate the effect that this would have 
on the efficiency of HILIC monolith column prepared by thermal-initiated co-
polymerisation of SPE-co-BVPE inside a 200-µm-i.d. fused silica capillary. The 
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composition of the polymerisation mixture was optimised in order to obtain 
satisfactory performance for column permeability, efficiency, and separation. The 
optimised monolithic column was evaluated for the separation of neutral, acid and 
basic analytes in a HILIC mode. The variations of organic solvent content on 
separation have been investigated. To date, only a few papers have reported on the 
fabrication of HILIC monoliths and this is the first to report the formation of such a 
product by the co-polymerisation of SPE and BVPE. 
	  
In this chapter, I have also reported on the synthesis of a monolithic co-polymer 
using DMBVBS, which is a novel organosilane cross-linker [191] synthesized using 
the Grignard Reaction. BVPE, the cross-linker used in our previous publication [199], 
is a solid that only dissolves in the porogen monomer mixture at elevated 
temperature and so pre-heating of the equipment prior to polymerisation is vital to 
avoid precipitation. However, it is difficult to distribute the heat uniformly and so the 
temperature fluctuations that inevitably occur when filling the capillary can lead to the 
production of inconsistent monolithic columns. Whereas DMBVBS is readily soluble 
in the SPE/porogen mixture at room temperature and this makes it much easier to 
handle [194, 200-201]. The DMBVBS/SPE combination was co-polymerised within 
the confines of 200 µm ID fused silica capillaries to produce a monolithic column with 
better resolution than was achieved with (BVPE cross-linked) formulation. The 
column yielded good peak shapes with narrow peak width at half height and 
satisfactory resolution of the rhEPO and DPO derived tryptic peptides that were 
targeted using ESI-MSMS in the selected reaction monitoring mode.  
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6.2 Materials and Instrumentation 
6.2.1 Materials.  
The monomer SPE was a kind gift of Raschig GmBH (Ludwigshafen, Germany). 
Magnesium ribbon, tetrahydrofuran (THF) inhibitor-free, azobisisobutyronitrile (AIBN), 
toluene, thiourea, acrylamide, acenapthalene, thymine, adenine, cytosine, uridine, 
cytidine were all purchased from Aldrich Chemical (Poole, UK). 3-(trimethoxysilyl)-
propyl methacrylate (γ-MAPS), ammonium acetate were obtained from BDH 
Laboratory Supplies (Poole, UK). p-vinylbenzyl chloride, uracil and ammonium 
formate were purchased from Fluka (UK). HPLC-grade methanol and acetonitrile 
(ACN) were obtained from Fisher Scientific (Leicestershire, UK). The water used 
throughout all experiments was from Millipore synergy UV (UK). The fused silica 
capillary with a dimension of 200 µm i.d. (350 µm o.d.) was purchased from 
Composite Metal Services Ltd. (Hallow, Worcestershire, UK).  
 
The monomer N, N’-dimethyl-N-methacryloxyethyl-N-(3-sulfopropyl) ammonium 
betaine (SPE), 3-(trimethoxysilyl)-propyl methacrylate (γ-MAPS), sodium chloride 
(brine solution), sodium bicarbonate (NaHCO3), anhydrous sodium sulfate (Na2SO4), 
diethyl ether, petroleum ether and ammonium acetate were purchased from Merck 
(Singapore). Magnesium ribbon, tetrahydrofuran (THF) inhibitor-free, 
azobisisobutyronitrile (AIBN), p-vinylbenzyl chloride, dichlorodimethylsilane 
(DCDMS), DL-dithiothreitol (DTT) and ammonium formate were all purchased from 
Sigma Aldrich (Singapore). HPLC-grade methanol, toluene and acetonitrile (ACN) 
were obtained from Fisher Scientific (Singapore). Sequencing grade modified 
Trypsin (P/N No. V5111) and protein deglycosylation mix kit were purchased from 
Chapter 6 HILIC Monolith 
204	  
	  
Promega (Singapore). The water used throughout all experiments was Milli-Q 
Gradient A10 from Millipore (Singapore). The fused silica capillary with a dimension 
of 200 µm i.d. (350 µm o.d.) was purchased from Polymicro (USA). Epoetin alfa, 
Eprex® the recombinant human erythropoietin, 10,000 IU/ ml with a concentration of 
84 µg/ ml was purchased from Jassen-Cilag AG, (Schaffhausen, Switzerland). 
Darbepoetin alfa, Aranesp® 40 µg/ 0.4ml was obtained from Amgen Manufacturing 
Limited a subsidiary of Amgen Inc. (Thousand Oaks, CA, USA). Human EPO 1 mg/ 
ml protein was purchased from Genway Biotech, Inc. (San Diego, CA, USA). Peptide 
SLTTLLR (human EPO peptide T11), peptide TITADTFR (human EPO peptide T14) 
and peptide VYSNFLR (human EPO peptide T17) were synthesised by Auspep Pty. 
Ltd. (Tullamarine, Victoria, Australia). C18 Zip-Tip® was obtained from Millipore 
Corporation (Billerica, MA, USA). Nanosep 30 KDa OMEGA was obtained from 
PALL Corporation (USA).  
 
6.2.2 Instrumentation.  
Experiments for poly (SPE-co-BVPE) were undertaken with a laboratory-built HPLC 
system that comprised an Applied Biosystems 783A programmable absorbance 
detector (Ramsey), a four-port injection valve with a 100 nl internal loop from Valco 
(Houston, TA), and a DINA binary pump with software version 1.29 (KYA 
Technologies Corporation) was used to run both isocratic and gradient conditions. 
Detection wavelength was set at 214 nm for the standard test mix 1 and 254 nm was 
set for test mix 2. A Data Apex chromatographic Clarity data station (Aston Scientific 
Ltd., Bucks, UK) was used for data acquisition and data handling. Chromatograms 
were converted to an ASCII file and exported as notepad and redrawn using 
Microsoft excel.  
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Experiments for both HILIC monoliths were undertaken using a TempoTM nano 
MDLC by Eksigent, with an Eksigent AS1 Autosampler coupled to a TIS of AB Sciex 
4000 Qtrap LC-MSMS operated by Analyst 1.5 software. The autosampler has a 6-
port injection valve with a 20 µl injection loop. The 200 µm x 30 cm capillary filled 
with the monolith was coupled directly between the injection port and the TIS using a 
short length of 50 µm deactivated silica capillary.  
 
6.2.3 LC conditions for SPE-co-BVPE 
6.2.3.1 The mobile phase used for the standard test mix and base test mix was (A) 
5mM Ammonium formate pH 3 and (B) ACN at a flow rate 4000 nl/min. It was run at 
isocratic condition 5 % A and 95 % B. 
6.2.3.2 The mobile phase used for the separation of pyrimidines and purines was (A) 
a pre-mix buffer of 95 % ACN and 5 % of 10 mM ammonium acetate at pH 8.6 and 
(B) a pre-mix buffer of 50 % ACN, 45 % water and 5 % of 10 mM ammonium acetate 
at pH 8.6, which run with a flow rate 4000 nl/min. The initial condition at 100 % A 
was held for 6 min, this was modified on a linear gradient to 100 % B at 9 min and 
hold for 3 min. At 13 min, it was returned to 100 % A and re-equilibrated till the run 
ends at 20 min.  
6.2.3.3 The mobile phase used for the separation of EPO peptides was (A) 10 mM 
ammonium acetate at pH 8.6 and (B) ACN at a flow rate 5 µl/min. The initial 
condition was 5 % A and 95 % B, it was changed on a linear gradient to 95 % A and 
5 % B at 15 min. After holding at 5:95 for 5 min., the composition was returned to 
initial conditions over 60 seconds. The column was re-equilibrated in preparation for 
the next injection between 21 and 30 min. 
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6.2.4 Reversed- Phase LC Conditions 
6.2.4.1 The column used was a HALOTM C18 0.3 x 150 mm packed with 2.7 µm 
Fused Core particles; 
6.2.4.2 The mobile phase used was (A) 0.1 % formic acid in water and (B) ACN at a 
flow rate 4 µl/min.;  
6.2.4.3 The initial conditions were 95 % A and 5 % B and this was modified on a 
linear gradient to 5 % A and 95 % B at 10 min. After holding at 5:95 for 5 min. the 
composition was returned to initial conditions over 60 seconds. The column was re-
equilibrated in preparation for the next injection between 11 and 20 min. 
 
6.2.5 Five minute HILIC gradient LC   
6.2.5.1 The mobile phase used was (A) 0.1 % formic acid in water and (B) ACN at a 
combined flow rate of 4 µl/min.;  
6.2.5.2 The composition at the start was 5 % A and 95 % B and was changed on a 
linear gradient to 95 % A and 5 % B at 5 min. These conditions were held for 5 
minutes before returning to initial conditions over 60 seconds.  The column was re-
equilibrated in preparation for the next injection between 11 and 20 min. 
 
6.2.6 Ten minute HILIC gradient LC   
6.2.6.1 The mobile phase used was (A) 0.1% formic acid in water and (B) ACN at a 
combined flow rate of 4 µl/min.;  
6.2.6.2 The composition at the start was 5 % A and 95 % B and was changed on a 
linear gradient to 95 % A and 5 % B at 10 min. These conditions were held for 5 min. 
before returning to initial conditions over 60 seconds.  The column was re-
equilibrated in preparation for the next injection between 16 and 25 min. 
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6.2.7 Preparation of 1, 2-bis (p-vinylphenyl) ethane (BVPE).  
BVPE synthesis was accomplished by a Grignard dimerisation of p-vinylbenzyl 
chloride (Figure 6.1). A detailed protocol of the preparation of BVPE is described in 
[134, 150, 184]. BVPE was re-crystallised from methanol to further increase the 
purity of the product. The purity of the product was checked and confirmed by GC-
MS.  
 
6.2.8 Preparation of poly (SPE-co-BVPE) monoliths.  
In order to provide anchoring sites for the polymer, each capillary was treated with γ
-MAPS, a bifunctional reagent, prior to polymerisation using a method described 
elsewhere [145]. 50 mg of SPE and 50 mg of BVPE were weighed into a 1.5 ml 
screw-cap vial, and then 220 µl of methanol and 180 µl of toluene were added and 
mixed in an ultrasonic bath at 40 ºC for 15-20 min. When completely dissolved 5 mg 
of AIBN was then added and completely dissolved. Nitrogen was bubbled into the 
mixture for 5 min to remove the dissolved gases. The polymerisation mixture was 
introduced into a pre-heated silanised fused silica capillary which was immersed in 
the ultrasonic bath operating at 40 ºC. Both the polymerisation mixture and capillary 
have to be kept warm at all times, as the polymerisation mixture quickly precipitates 
if it is not warm when filling the mixture, which could result in it precipitating in the 
capillary. After the capillary was completely filled with the polymerisation mixture, 
both ends of the capillary were sealed with GC septa, and the capillary was kept in a 
water bath at 75 ºC for 2 hr. (reaction as in Figure 6.2). The capillary column was 
then rinsed with methanol to remove the porogenic solvents and any other unreacted 
soluble compounds. A 2-3 mm detection window was created at a distance of 5 cm 
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from the end of the column using a thermal wire stripper. Monolithic material at this 
point was pyrolysed and then flushed out with methanol. The resulting capillary 
column has an effective length of 27.5 cm. A 0.5 cm length of the capillary containing 
monolith inside was cut for scanning electron microscopy (SEM) analysis (JEOL 
JSM-5600 LV, Tokyo, Japan). 
 
 
Figure 6.1 Schematic drawing for the synthesis of cross-linker BVPE by Grignard 
reaction of p-vinylbenzyl chloride, and the subsequent copolymerisation with SPE 
 
6.2.9 Preparation of dimethyl bis (p-vinylbenzyl)silane (DMBVBS).  
DMBVBS was synthesised by the Grignard Reaction of p-vinylbenzyl chloride and 
dichlorodimethylsilane (Figure 6.2). Magnesium ribbon (7.3 g, 0.12 mol) and 200 ml 
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THF were placed in a schlenck tube under argon.  After addition of 
dichlorodimethylsilane (12 ml; 0.04 mol) and p-vinylbenzyl chloride (28.2 ml; 0.08 
mol) the mixture was carefully stirred with a magnetic stirrer to initiate the Grignard 
reaction. Thereafter, the solution was sonicated for 2 h, and then washed 
consecutively with brine, saturated NaHCO3, brine and finally dried over anhydrous 
Na2SO4. After evaporation of the organic solvent, the resulting crude product was 
purified by flash column chromatography (petroleum ether/ diethyl ether 95: 5) to 
yield DMBVBS as a viscous colorless product. This synthesis followed exactly the 
method as published in ref. [187]. The purity of the product was checked and 
confirmed by proton and carbon NMR spectroscopy [187].  
 
6.2.10 Preparation of poly (SPE-co-DMBVBS) monoliths.  
In order to provide anchoring sites for the polymer, prior to polymerisation each 
capillary was treated with γ-MAPS, a bifunctional reagent, using a method described 
elsewhere [202]. 50 mg of SPE and 50 mg of DMBVBS were weighed into a 1.5 ml 
screw-cap vial, and then 220 µl of methanol and 160 µl of toluene were added and 
mixed by vortexing. When the mixtures are completely dissolved, 5 mg of AIBN was 
added, then vortexed to completely dissolve the mixture. Nitrogen was bubbled into 
the mixture for 5 min to remove the dissolved gases. Next, the polymerisation 
mixture was introduced into the silanised fused silica capillary. After the capillary was 
completely filled, both ends were sealed with GC septa, and the capillary placed in a 
water bath at 75 ºC for 2 hr (reaction as in Figure 6.2). The capillary column was 
then rinsed with methanol to remove the porogenic solvents and any other unreacted 
soluble compounds. The resulting capillary column has an effective length of 30 cm. 
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A 0.5 cm length of capillary containing monolith inside was cut for SEM analysis 
(JEOL JSM-5600 LV, Tokyo, Japan).  
 
 
Figure 6.2 Schematic drawing for the synthesis of cross-linker DMBVBS by Grignard 
reaction of p-vinylbenzyl chloride and dichlorodimethylsilane, and the subsequent 
copolymerisation with SPE 
 
6.2.11 Preparation of test mix and base mix samples.  
The standard test mix of toluene, thiourea and acrylamide were prepared in 1 mg/ml 
in 100 % ACN. The base mix of uracil, adenine and cytosine were prepared in 1 
mg/ml in 70 % H2O and 30 % ACN. The pyrimidines and purines were prepared in 2 
mg/ml in a separate mix, for mix 1 consisting of acenapthalene, uridine, cytidine, 
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consisting of uracil and adenine were prepared in 70 % H2O and 30 % ACN. Then 
prepare 1 mg/ml of the two mixes by taking 1 ml from each mix.  
 
6.2.12 Preparation of peptide samples.  
EPO peptide standard mix, VWQGLALLSE (EPO peptide E9), 
AISPPDAASAAPLRTITAD (EPO peptide E12), APPRLTCDSRVLERYLLEAKEAE 
(EPO peptide E10) and AEDITTGCAEHCSLNE (EPO peptide E5DAM) were 
prepared at a concentration of 100 ng, except for EPO E5DAM at a concentration of 
1000 ng each in their initial buffer condition (95 % ACN and 5 % 10 mM ammonium 
acetate). EPO peptide standard mix, SLTTLLR (EPO peptide T11), TITADTFR (EPO 
peptide T14) and VYSNFLR (EPO peptide T17) were prepared at a concentration of 
10 ng each in their initial running buffer conditions (HILIC - 95 % ACN, 5 % 0.1 % FA 
in water and for the C18 reversed-phase- 5 % ACN, 95 % 0.1 % FA in water). The 
deglycosylated and trypsin digested Epoetin alfa (Eprex®) and darbepoetin alfa 
(Aranesp®) were prepared as follows: 10 ng of Eprex® and 40 ng of Aranesp® were 
each spiked into 50 mM ammonium bicarbonate pH 7.8 buffer. The respective 
spiked samples were processed by taking 50 µl of each sample and placing them in 
eppendoff tubes, then adding 5 µl of 100 mM DTT in 50 mM ammonium bicarbonate 
as reducing agent. They were then left at room temperature for 10 min. After 10 min, 
deglycosylation steps were carried out for all samples. Deglycosylation was carried 
out by adding 5 µl of 10 x deglycosylation reaction buffers and 5 µl of Protein 
Deglycosylation Mix from the Promega protein deglycosylation kit. Samples were 
then gently vortexed and centrifuged at 3000 rpm to allow the sample to collect at 
the bottom of the tube. Samples were then incubated in the oven at 37 ºC for 16 hr. 
After the deglycosylation step, the samples were each transferred onto the 30 KDa 
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nanosep filter, then centrifuged at 3000 rpm for 10 min. 100 µl of 50 mM ammonium 
bicarbonate was added onto the 30 KDa nanosep filter and centrifuged at 3000 rpm 
for 20 min and then this step was repeated. After repeating the buffer exchange, it 
was followed by the trypsin digestion step. 5 µl of (20 µg per 100 µl) of trypsin 
enzyme was added and incubated in the oven at 37 ºC for 3 hrs. After the trypsin 
enzyme digestion step, the sample was desalted using a C18 Zip-Tip™ following the 
manufacturer’s protocol. The tip was first conditioned with 0.15 % FA in water, then 
ACN, followed by loading of the sample. After loading, the sample was washed with 
the aqueous buffer and the sample eluted with the 95 % ACN and 5 % aqueous 
buffer. 20 µl of this eluent was injected onto the synthesised monolithic HILIC column. 
	  
6.3 Results and Discussion   
According to Greiderer et al. [191], shorter polymerisation times for BVPE 
crosslinked co-polymers leads to more space within the polymer clusters (lower 
polymer density) with the flow channels that are larger and, consequently, the total 
porosity is enhanced. For this reason, a study was undertaken at different 
polymerisation times (1, 2, 4, 8 and 12 h) to determine the optimal time for producing 
this monolithic support. The results I obtained have supported Greiderer’s 
observation and, for example, the SEM photographs show that the polymer clusters 
that are formed become bigger as the polymerisation time increases. After 1, 2 and 4 
h polymerisation time, it can be seen (Figures 6.3a, b and c respectively) that the 
polymer cluster consists of smaller polymer microglobules compared to that from the 
8 and 12 h polymerisation times (Figure 6.3d and e). Since mesoporosity can be 
regarded as a function of the microglobule size, the smaller they are the higher the 
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fraction of mesopores is expected. It can be observed from the SEM images that the 
fraction of mesopores and thus specific surface area is optimised when the 
polymerisation time is reduced.  
	   	  	    
a.     b.       c. 
   
d.     e. 
   
f.     g. 
Figure 6.3 SEM images of monolithic columns prepared at different polymerisation 
times (a- 1 h, b- 2 h, c- 4 h, d- 8 h, e- 12 h) and different AIBN (f- 1 mg, g- 5 mg) 
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The five capillary columns obtained from the different polymerisation times were 
installed on the HPLC system and the pressure of each column was recorded (Table 
6.1) with the mobile phase (95 % ACN: 5 mM ammonium formate pH 3) at a flow 
rate of 5000 nl/min and it is evident from this data that the backpressure due to the 











Acrylamide 1.250 1610 580 
Toluene 1.340 1065  
Thiourea 2.733 1231  
Uracil 1.820 1206  
Adenine 2.160 931  
Cytosine 2.787 976  
2 h 
Acrylamide 1.740 7702 1885 
Toluene 1.827 7394  
Thiourea 3.943 9889  
Uracil 2.540 4759  
Adenine 3.037 3184  
Cytosine 3.843 3983  
	   	  


















Thiourea 3.837 734  
Uracil 2.407 889  
Adenine 2.80 630  






Thiourea 4.053 989  
Uracil 2.633 1186  
Adenine 3.093 784  






Thiourea 3.543 1280  
Uracil 2.220 875  
Adenine 2.703 421  
Cytosine 3.507 589  
 
Table 6.1 Comparison of the column efficiencies and back pressures for the 
different polymerisation time of the columns 
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The column efficiencies of the five capillary columns at different polymerisation times 
were measured using test mix 1 consisting of toluene, acrylamide and thiourea 
(Table 6.1). It can be seen that a 2 h polymerisation time has the best column 
efficiencies. Triplicate injections were undertaken using test mix 1 (toluene, 
acrylamide and thiourea) followed by a second test mix containing the basic 
compounds (uracil, adenine and cytosine). The columns produced by polymerisation 
times above 4 h generated poor peak shapes, decreased resolution and lower peak 
intensity. For example, toluene and acrylamide in the first test mix were merged into 
a single peak and the base test mix showed poor peak shape for the 3 bases with a 
low intensity and a resolution of < 1.5.  
 
The best results were obtained with the column produced with a 2 h polymerisation 
step. For example, the resolution between uracil and adenine and acrylamide and 
toluene is twice that for column produced with the 1 h polymerisation time (see 
Figures 6.4 and 6.5) and the efficiency, measured by theoretical plates per meter, 
was also found to be between 3.1 and 7.3 greater. The theoretical plates per meter 
obtained on testing under isocratic elution conditions (95 % ACN + 5 % 5 mM 
ammonium formate pH 3) was 35,930, 26,888 and 28,007 for thiourea, toluene and 
acrylamide respectively. Whilst a base mixture containing uracil (18,034), adenine 
(11,935) and cytosine (14,496) yielded slightly lower results. Therefore, the 2 h 
polymerisation capillary was selected as the optimal polymerisation time. 
 




a        b 





a          b 
Figure 6.5 Separation of base test mix for a) 2 h polymerisation, b) 1h polymerisation 
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The initiator was added at a constant concentration (1 % w/w with respect to the 
monomer) for producing monolithic columns for the experiment to evaluate the effect 
of the polymerisation time. After selecting the optimal time I compared the effect of 
adding 1 % and 5 % w/w. with respect to the monomer with a 2 h polymerisation time. 
The increase in initiator improved the results and the resolution obtained for 5 % w/w 
was twice that obtained when using the 1 %. For example, the column efficiency was 
between 3.7 to 4.6 times higher than for 1 mg AIBN. This column was able to resolve 
the toluene and acrylamide peaks in the test mixes and produced narrower peaks 
with a better shape (see Figures 6.6 and 6.7). Thus, the 2 h polymerisation time with 
5 mg AIBN for every 100 mg of monomers in the porogen has been shown to be the 
optimised condition for producing poly (SPE-co- BVPE) monolith columns.  
 
 
a       b 
Figure 6.6 Separation of standard test mix for a) 5 mg AIBN, b) 1 mg AIBN 
 




a       b 
Figure 6.7 Separation of base test mix for a) 5 mg AIBN, b) 1 mg AIBN 
 
Applications. Separation of bases and neutral compounds. 
The polar zwitterionic poly (SPE-co-BVPE) surface can provide a hydrophilic 
environment. A mixture of bases, neutral and acidic compounds were run using a 
mobile phase gradient starting from 95 % ACN to 50 % ACN, with 5 % buffer in both 
solvents. Pyrimidines and purines are often used for the evaluation of HILIC columns 
and a mixture of thymine, uracil, adenine, cytosine, uridine and cytidine was used for 
the evaluation of poly (SPE-co-BVPE) monolithic columns in this work. Figure 6.8 
shows good separation within 10 minutes for the 6 components of the mixture of 
pyrimidines and purines (acenaphthalene as t0 marker) and the peaks were sharp 
and symmetrical peaks.  
 




Figure 6.8 Separation of pyrimidines and purines 
 
Application. Separations of EPO peptides compounds. 
A mixture of erythropoietin (EPO) peptides, that are synthetic analogues of those 
generated by tryptic digestion of the intact protein, were separated using the 2 h (5 % 
w/w AIBN) column and MS/MS detection. The total ion current chromatograms 
showed sharper peaks with higher intensities than that obtained compared to a 
commercial C18 column. However, the resolution of peptides was not as good when 
compared to the separation obtained for small molecule (see Figure 6.9).  
 




Figure 6.9 Separation of Gluc digested EPO peptides on poly (SPE-co-BVPE) 
 
The synthesis of a HILIC monolithic column, consisting of SPE-co-BVPE, that 
provided good separation of small basic and neutral compounds. However, I was 
unable to find a set of chromatographic conditions that could satisfactorily resolve a 
mixture of synthetic EPO Gluc and tryptic digested (Figure 6.9 and 6.12) peptide 
standards using this column and I concluded that I was not going to be able achieve 
our goal without reformulating the monomer composition.  I opted to substitute the 
BVPE with DMBVBS, as the latter cross-linker is less difficult to handle than BVPE 
because it can be used without warming either the monomer/porogen mixture or the 
filling equipment prior to polymerisation. In addition to this benefit, a co-polymeric 
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monolithic column made with this cross-linker had been shown [187] to be effective 
in separating peptides.  
 
According to Greiderer et al. [191], reducing the polymerisation time for the SPE-co-
BVPE cross-linked co-polymer leads to more space within the polymer clusters 
(lower polymer density) with the formation of larger flow channels and enhanced 
porosity. My study, which used this monomer formulation with polymerisation times 
between 1 and 12 hours, confirmed that the polymer clusters become bigger as the 
polymerisation time increases. Furthermore, when I used a five times higher 
concentration of the initiator, the performance of the monolithic columns produced 
was approximately double that obtained with only 1 % AIBN. Therefore, based on 
this outcome, I elected to initiate the polymerisation of the modified monomer 
formulation using 5 % (w/w) AIBN and I selected a polymerisation time of two hours 
because this had given the best results with the previous monomer mixture. A SEI 
(Figure 6.10) of the new HILIC monolith showed that the material produced had 
relatively small microglobules, which is considered a sign of good mesoporosity, 
combined with an acceptable proportion of the macropores required for the rapid and 
high resolution separation of both low molecular weight compounds and 
biomolecules.  The typical backpressure of the 200 µm x 30 cm monolithic column at 
4 µl/min. with the HILIC mobile phase was observed to be very low (around 435 psi) 
and the high permeability of the co-polymer is consistent with the abundance of 
macropores seen in the SEI results. 
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Figure 6.10 Scanning electron image (SEI) and lower electron image (LEI) of poly 
SPE-co-DMBVBS monolithic column. 
 
Therefore, since SEI showed that the material looked to be suitable for this purposes, 
it was decided that there was probably little benefit to be obtained by undertaking a 
study to optimise the fabrication conditions and I proceeded to evaluate whether the 
novel monolithic column was capable of resolving a mixture of the synthetic rhEPO 
and DPO tryptic peptides T11 (SLTTLLR), T14 (TITADTFR) and T17 (VYSNFLR). 
The EICC of the standard mix of EPO peptides (Figure 6.11) shows relatively 
symmetrical peak shapes and it is evident from these results that this column was 
able resolve these peptides, unlike the poor results obtained on the SPE-co-BVPE 
(Figure 6.12) material. Furthermore, the elution order for the peptides on the SPE-
co-DMBVBS monolith was reversed in comparison to the results I obtained on a C18 
RP packed column (data not shown) and this confirms that the mode of separation is 
primarily HILIC. As anticipated, the calculated peak area for the analytes separated 
on this monolith was higher than the results obtained using the C18 RP column and 
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this is because the higher organic content of the HILIC mobile phase favours the ESI 
desolvation process which in turn enhances sensitivity.  
 
 








Figure 6.12 Separation of EPO peptide standard mix on poly SPE-co-BVPE HILIC 
monolith 
 
The primary reason for synthesising the SPE-co-DMBVBS monolith was to produce 
a monolithic column that could be used to enhance the sensitivity of the analytical 
method employ to identify the characteristic tryptic digestion peptides that are unique 
to either rhEPO (Eprex®) or DPO (Aranesp®). The doping control samples that were 
collected from racehorses are extracted and screened for the presence of the tryptic 
peptides common to these two epogens. However, when a positive result is obtained, 
it is necessary to differentiate rhEPO from DPO by targeting the analysis towards the 
peptides fragment T5 (21-45) and T9 (77-97), as the amino acid sequence from this 
region is specific to each protein. Unfortunately, rhEPO and/or DPO T5 and T9 are 
glycopeptides with highly variable sialic acid containing glycan motifs and this 
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severely hinders detection under ESI/MS conditions. This necessitates the inclusion 
of a deglycosylation step and for this study the glycosidase mixture (PNGase F, O-
Glycosidase and Neuraminidase) that was used previously [3] was replaced by the 
Promega Deglycosylation Mix™ that also contains the β1-4-galactosidase and β-N-
acetylglucosaminidase enzymes.  
 
I had tested the performance of this column using a reduced/deglycosylated rhEPO 
sample which had been digested before being desalted using a C18 Zip-Tip™. The 
eluate (ACN) was injected onto the HILIC monolith column without the inclusion of 
an evaporation and reconstitution step. Since removal of the N-linked glycosyl 
moieties from T5 and T9 causes deamination of asparagine (N) to aspartic acid (D), 
the SRM method used to monitor MSMS transitions for the deaminated T5 and T9 
peptide fragments EPO T5DAM (EAEDITTGCAEHCSLNEDITVPDTK) and EPO 
T9DAM (GQALLVDSSQPWEPLQLHVDK) peptides. The XIC (Figure 6.13) from the 
SRM experiment showed well separated peaks consistent with the presence non-
glycosylated tryptic peptides (e.g. T6, T14 and T17) as well as (deglycosylated) EPO 
T5DAM and EPO T9DAM peptides. These results were well correlated with the data 
observed when analysing the synthetic peptide reference materials (data not shown) 
under the same conditions. When an equivalent Zip-Tip™ purified digest (2X conc. 
reconstituted in 95 % of 0.1 %FA water plus 5 % ACN) was analysed using the C18 
RP column (Figure 6.14) the elution order was reversed and the more polar EPO 
T5DAM was not as well retained as the separation undertaken using HILIC 
conditions. Hence, for the reasons that I have already elaborated, this peptide 
exhibited a better response in the HILIC separation mode and an injection from the 5 
ng digest of Eprex® produces approximately the same response on HILIC as a 10 ng 
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digest in C18 RP mode.  Thus, it can be seen that there was a real improvement in 
sensitivity on the HILIC monolith compared to use of the C18 RP conditions.  
 
 
Figure 6.13 Extracted ion chromatogram of the separated deglycosylated and tryptic 
digested Eprex on poly SPE-co-DMBVBS HILIC monolith 
 




Figure 6.14 Extracted ion chromatogram of the separated deglycosylated and tryptic 
digested Eprex on RP column 
 
Guan et al. [43] have proposed that the detection of EPO T5DAM would be a 
suitable way of differentiating rhEPO from the structurally similar darbepoetin alfa (i.e. 
DPO) and the presence of DPO T9DAM (GQALLVDSSQVDETLQLHVDK) would be 
conclusive proof that DPO was present in the sample. However, it was found that 
using DPO T5DAM (EAEDITTGCDETCSLNEDITVPDTK) is a better way to achieve 
this goal, as under HILIC conditions the SRM peak intensity (Fig. 6.15) from this 
peptide was almost an order of magnitude better than the result from the DPO 
T9DAM in the same digest. This is a somewhat contradictory result, as Guan and co-
workers were unable to detect even a trace of the DPO T5DAM in their digests. 
However, one explanation could be that they did not reduce the protein and this 
resulted in a missed cleavage due to the intact 29-33 disulphide bridge and/or they 
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created conditions whereby cys-cys polymerisation could have led to depletion of 
this cysteine containing peptide from the digest solution. Alternatively, it is also 
possible that the RP conditions that they employed were not as well suited to the 
sensitive detection of this peptide as the HILIC analysis has been shown to be.  
 
 
Figure 6.15 Extracted ion chromatogram of the separated deglycosylated and trypsin 
digested Aranesp on poly SPE-co-DMBVBS HILIC monolith.  
 
6.4 Conclusion 
A highly hydrophilic porous monolith, poly (SPE-co-BVPE) formed within capillary 
columns of 200 µm i.d. was successfully applied for the rapid and high resolution 
separation of low molecular weight compounds, such as (pyrimidines and purines) 
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and produce symmetrical peaks for high molecular weight compounds such as 
peptides, albeit with less selectivity for the EPO tryptic peptides. Variation of the 
polymerisation time has a considerable impact on the porous properties of organic 
monoliths prepared by thermally initiated free radical polymerisation. The reduction 
of polymerisation time resulted in HPLC stationary phases that are characterised by 
the presence of a sufficiently high amount of mesopores to efficiently separate low-
molecular weight compounds. At the same time, the total porosity is enhanced due 
to decreased monomer to polymer conversion. This, in turn leads to the enlargement 
of the flow channel size and thus to increase column permeability. Their exceptional 
chromatographic performance towards a range of representative low-molecular 
weight compounds, confirms the incorporation of accessible mesopores onto the 
polymeric network surface. Further investigations are underway in order to extend 
the applicability of HILIC monoliths to include their use during the analysis of 
peptides generated by enzymatic digestion of proteins.  
 
A hydrophilic porous polymer based monolith stationary phase, poly (SPE-co-
DMBVBS) has been shown to be able to provide satisfactory resolution of peptides 
with relatively symmetrical peak shapes and the detection of the targeted peptides 
using ESI/MS was improved in comparison to the results obtained using a 
commercial RP column. As noted in the previous work [195], a 2 hour polymerisation 
step was optimal to produce a monolithic column with enhanced total porosity due to 
decreased monomer conversion and the enlargement of the flow channels which 
yields a corresponding increase in column permeability. Due to the good stability and 
low pressure drop experienced on this monolithic support, rapid separation of the 3 
deglycosylated tryptic digested peptides was accomplished using a 5 minute HILIC 
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gradient (e.g. see Figure 6.11). The monolithic columns were easier to fabricate than 
those made using BVPE cross-linker and offered far superior resolution for peptides.  
Furthermore, due to the low backpressure, if required, the 30 cm columns can 
probably be used at significantly higher flow rates or the improved separation 
















Chapter 7: An orthogonal WCX-HILIC set-
up with on-line mass spectrometry to 












Chapter 7 Orthogonal WCX-HILIC set-up 
233	  
	  
7.1 Introduction  
Reversed-phase (RP) liquid chromatography is the most frequently employed 
method for sample separation prior to mass spectrometric (MS) based proteomics 
analyses [203-207]. However, complex proteomics samples are often comprised of 
species of vastly differing hydrophobicities, including relatively polar analytes such 
as glycopeptides and phosphopeptides. These polar analytes tend to absorb weakly 
on the RP stationary phase and often elute directly with the dead volume. The poor 
retention of these compounds leads to decreased effective sensitivity in electrospray 
MS due to ion suppression and, as a consequence, potential loss of valuable 
biological information.  
 
In recent years, the use of HILIC has become more popular due to the growing need 
for the analysis of polar compounds that are not well retained under RP conditions 
and also the need to achieve better separation of these analytes in order to address 
the complexity of the samples to be analyzed [208]. Another advantage of this mode 
of chromatography is that the mobile phase conditions that are used for HILIC are 
highly compatible with MS, as the high organic content that is commonly used can 
potentially increase sensitivity in ESI-MS [134,143]. Despite its capability for 
separating relatively polar compounds, HILIC tends to be less useful for separating 
hydrophobic peptides. To overcome this obstacle, two separate injections of the 
samples on a RP and HILIC column could be performed; however, such analyses 
would require double the amount of sample.  
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Ideally, the combination of RP and HILIC in tandem would combine their 
complementary selectivity and allow for the separation of both hydrophobic and 
hydrophilic compounds in a single analytical method [209-212]. RP-HILIC is an 
attractive prospect as a hyphenated system for proteomics because both RP and 
HILIC employ the electrospray ionisation compatible aqueous buffers and water 
miscible organic solvents, such as acetonitrile. In theory, off-line coupling of RP-
HILIC can be performed by simply collecting the effluent from the RP separation and 
re-injecting this onto the HILIC phase. However, there is a disadvantage as offline 
collection is labour intensive and often results in significant sample loss. 
Consequently online coupling is the preferred option, but the primary technical 
challenge of implementing a serial RP-HILIC system is overcoming the solvent 
strength incompatibility between RP and HILIC. RP requires a low-organic solvent 
for separation, whereas HILIC separation is performed using a high-organic medium, 
therefore, the predominantly aqueous RP flow must be converted to a high-organic 
concentration prior to its diversion onto the HILIC column [213] for separation in the 
second dimension. Failure to address this problem would lead to peak broadening 
occurring on the HILIC dimension. 
 
RP cannot resolve many of the post-translationally modified isoforms (e.g. 
methylated, acetylated and phosphorylated variants) from the unmodified proteins 
and from each other [150]. Weak cation exchange-hydrophilic interaction LC (WCX-
HILIC) has proven to be an excellent complementary orthogonal mode to RP and 
has been successfully used to separate acetylated isoforms of histone H4 [151], 
methylated isoforms of histone H4 [152], phosphorylated isoforms of histone H1 
[153], as well as sequence variants of histone H1 [154]. WCX-HILIC, is a mixed-
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mode form of chromatography introduced by Alpert in 1990 [128]. It features the 
simultaneous presence of dominant hydrophilic interaction, (the mechanism for 
separation of differentially methylated isoforms) and electrostatic interaction between 
the stationary phase and the analyte due to an ionic WCX stationary phase, (the 
mechanism for separation of differentially acetylated isoforms) [155].  
 
‘’Top-down’’ and ‘’bottom-up’’ approaches are the two main analytical strategies for 
proteome separation and identification. Using the ‘’top-down’’ approach the intact 
proteins are directly separated by HPLC and identified by MS. The alternative 
‘‘bottom-up’’ approach firstly digests the proteins into peptides, then separates them 
using liquid chromatography and detects them using tandem mass spectrometry 
[214]. Two-dimensional (2D) and multidimensional chromatographic techniques 
coupled to mass spectrometric detection have been applied recently to improve the 
sensitivity and reproducibility for peptide analyses. Multidimensional 
chromatographic techniques can potentially improve selectivity and reduce matrix 
effects. To increase the resolution and peak capacity for ‘’entire-component’’ 
analysis of complex samples, the hyphenation of different chromatographic 
separation modes has proven to be a successful strategy [215]. When doing so, the 
selection of orthogonal separation conditions is of primary importance in order to 
achieve a maximum difference in selectivity between two separations. The 
separation principle of reversed-phase is based on the partitioning of the analytes 
between a hydrophobic stationary phase and a polar hydrophilic mobile phase. 
Peptides are loaded onto a RP column under low-organic-solvent conditions, which 
cause the peptides to partition onto the RP packing material. Salts and the majority 
of components used in digestion protocols tend to remain in the low organic solvent 
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and thus RP is often used to ‘desalt’ and concentrate the sample. Separation (or 
elution of the peptide) is then achieved by increasing the organic modifier content in 
the mobile phase and once the mobile phase is of sufficient hydrophobicity the 
peptide will start to partition between the two phases as it moves along the column 
[216]. However, peptides are not strongly retained under RP conditions and typically 
elution from the packing material can be achieved with less than 40 % of the organic 
modifier, which means that there is too much aqueous content in the mobile phase to 
provide retention under the HILIC mechanism and this makes online hyphenation of 
these stationary phases difficult. Therefore, in this experiment, RP was employed as 
a trap column to desalt the tryptic digest aqueous sample and thereafter the sample 
is released at high organic concentration from the RP trap column onto a WCX trap 
column. WCX and HILIC are complementary modes as both the WCX and HILIC 
mechanisms function in the presence of a high organic solvent concentration. Thus, 
a neutral or slightly basic pH 95 % ACN aqueous mobile phase can be employed to 
trap the peptides onto the WCX column and a lower pH 95 % ACN aqueous mobile 
phase can then be used to release them with onto the HILIC analytical column for 
separation. This method of online coupling of RP-HILIC using the WCX as an 
intermediate trap has the potential to resolve the incompatibility of mobile phase 
between RP and HILIC and it also provides a way of simultaneously analysing both 
the hydrophilic and hydrophobic peptides in the sample. Online hyphenation also 
possesses other advantages, such as minimal loss of sample, no vial contamination, 
and no sample dilution [148-149].  
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7.2 Materials and Instrumentation 
7.2.1 Materials.  
DL-dithiothreitol (DTT) and ammonium formate were all purchased from Sigma 
Aldrich (Singapore). HPLC-grade methanol and acetonitrile (ACN) were obtained 
from Fisher Scientific (Singapore). Ammonium bicarbonate and ammonium acetate 
were purchased from Merck (Singapore). Sequencing grade modified Trypsin (P/N 
No. V5111) and protein deglycosylation mix kit were purchased from Promega 
(Singapore). The water used throughout all experiments was obtained from a Milli-Q 
Gradient A10 from Millipore (Singapore). Epoetin alfa, Eprex® the recombinant 
human erythropoietin, 10,000 IU/ ml was purchased from Jassen-Cilag AG, 
(Schaffhausen, Switzerland). Darbepoetin alfa, Aranesp® 40 µg/ 0.4 ml was obtained 
from Amgen Manufacturing Limited a subsidiary of Amgen Inc. (Thousand Oaks, CA, 
USA). Human EPO 1 mg/ ml protein was purchased from Genway Biotech, Inc. (San 
Diego, CA, USA). Peptide SLTTLLR (human EPO peptide T11), peptide TITADTFR 
(human EPO peptide T14) and peptide VYSNFLR (human EPO peptide T17) were 
synthesised by Auspep Pty. Ltd. (Tullamarine, Victoria, Australia). Nanosep 30 KDa 
OMEGA was obtained from PALL Corporation (USA).  
 
7.2.2 Instrumentation.  
Experiments were undertaken using a TempoTM nano MDLC by Eksigent, with an 
Eksigent AS1 Autosampler coupled to a Turbo Ionspray (TIS) of AB Sciex 4000 
Qtrap LC-MSMS operated by Analyst 1.5 software. The autosampler has a 6-port 
injection valve with a 20 µl injection loop. An in-house fabricated 3 µm particle size 
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WCX trap packed into a 250 µm x 20 cm capillary, was coupled to an additional 6-
port valve. When switched to the inject position, it becomes in-line with the 200 µm x 
30 cm capillary filled with the fabricated HILIC monolith mentioned in the previous 
Chapter (Figure 7.1). A CAPTRAP™ from Michrom Bioresources, Inc. was installed 
after the injection valve, connecting the loading buffer line to the external 6-port valve 
(Figs. 7.6 a & b). 
 
7.2.3 LC Conditions 
Solvent A for the loading pump was 10 mM ammonium acetate pH 5.5, while solvent 
B was ACN at a flow rate of 1 µl/min. Solvent A for the gradient pump was 0.1 % 
Formic acid in water, and for B 100 % ACN. For Figure 7.1 the samples were loaded 
at a flow rate of 1 µl/min using 95 % A and 5 % B for 50 min. The gradient pump flow 
rate was 4 µl/min. The initial conditions of 95 % B and 5 % A were held for 10 min, 
and then a gradient was run from 95 % B to 5 % B for 20 min.  The gradient was 
then held for 5 min and then returned to the initial conditions at 36 min, followed by 
re-equilibration for 4 min. The mobile phase used for Figures 7.6 a & b are the same 
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7.2.4 MS Conditions 
The source temperature was maintained at 350 ºC with nebuliser, desolvation gas 
and curtain gas settings at 15, 10 and 30 psi respectively. Ion source voltage was 
maintained at 4500 V. Analytes were detected using multiple reaction monitoring 
(MRM) at a dwell time of 100 ms per transaction. Each peptide was optimised for Q1 
selection, fragmentation, and Q3 selection using declustering potential (DP) and 










T6 464.2 714.5 200 68 22 
T17 449.8 636.3 200 73 22 
T14 462.7 710.4 200 127 20 
EPO T9DAM 787.8 939.4 200 57 29 




1345.1 1345.1 200 85 20 
DPO T9DAM 766.7 907.7 200 89 27 
DPO T5DAM 1350.5 1350.5 200 89 27 
 
Table 7.2 rhEPO/DPO peptides MRM, DP and CE setting 
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7.2.5 Preparation of samples.  
Human EPO was spiked using 5 µl of (10 µg/µl), Aranesp® was spiked using 40 µl of 
(0.1 µg/µl), Eprex® was spiked using 10 µl of (84 µg/ml). Thirty five microliters of 50 
mM ammonium bicarbonate buffer pH 7.8 was added to each of the spiked samples, 
vortex mixed, followed by the addition of 5 µl of 100 mM DTT in 50 mM ammonium 
bicarbonate (reducing agent). They were then left at room temperature for 10 min. 
After 10 min, deglycosylation steps were undertaken for all samples. Deglycosylation 
was undertaken by adding 5 µl of 10 x deglycosylation reaction buffers and 5 µl of 
protein deglycosylation mix from a Promega protein deglycosylation kit. Samples 
were then gently vortexed and centrifuged at 3000 rpm to allow the sample to collect 
at the bottom of the tube. Samples were then incubated in the oven at 37 ºC 
overnight. After the deglycosylation step, the samples were each transferred to a 30 
KDa nanosep filter then centrifuged at 3000 rpm for 10 min. Buffer exchange was 
carried out by adding 200 µl of 50 mM ammonium bicarbonate buffer pH 7.8 onto the 
30 KDa nanosep filter and then centrifuging at 3000 rpm for 20 min. This step was 
then repeated. 100 µl of 50 mM ammonium bicarbonate pH 7.8 was added to the 
filter and transferred to a vial. 10 µl (20 µg/100 µl) of trypsin enzyme was then added 
and the mixture was incubated in the oven at 37 ºC for 3 hr. After the enzyme 
digestion, 4 µl of 10 % FA in ACN was added into the digested solution to stop 
enzyme digestion. The digested samples were then transferred into auto-sampler 
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7.3 Results and Discussion   
To use HILIC as a separation column in an on-line experiment, the issues relating to 
the incompatibility of the sample preparation buffer need to be resolved, as this could 
not be injected onto the HILIC column without significantly limiting the injection 
volume or perhaps reducing the aqueous content to less than 10 % by diluting the 
sample with ACN. In the previous Chapter the analytes, which are in an aqueous 
solution, required a Zip-tip™ treatment to desalt and reconstitute the peptides in a 
high organic mobile phase before injecting the sample onto the HILIC column. As 
explained in the theory section, online 2D separation possesses advantages, such 
as minimal loss of sample, no vial contamination, and no sample dilution. Hence, I 
wanted to omit the above preparation step and use on-line hyphenation to achieve 
the desired outcome.  
 
In the first part of the experiment I analysed spiked samples, prepared as described 
in section 7.2.5, followed by analysing using the WCX-HILIC configuration. Samples 
were loaded onto the auto-sampler for direct injection via the WCX trap column by 
loading the sample using a high aqueous content 10 mM ammonium acetate at pH 
5.5 with a flow rate of 1 µl/min to load the WCX trap (hold for 50 min) followed by a 
gradient elution with an acidic aqueous buffer (0.1 % FA) mixed with ACN. This was 
programmed over 20 min from high organic to high aqueous buffer to elute the 
peptides. Under the acidic conditions used for the HILIC gradient separation, the 
WCX does not retain the peptides and so these are released from the trap when the 
valve switches into the 1è6 position. 
 




















Figure 7.1 Schematic drawing of 6-port switching valves showing the loading of 
sample and injecting of sample into the WCX and HILIC column. 
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Though this required a longer elution time than the off-line approach, both the non-
glycosylated and glycosylated peptides from the Eprex® sample were separated (as 
shown in Figure 7.2) and it was able to achieve a better peak shape. However the 
intensity of extracted ion chromatograms were similar compared to that achieved 
using the off-line preparation coupled with injection onto the HILIC column (Figure 
7.3).  The Darbepoetin (Aranesp®) results obtained showed that it could also 
distinguish both the non-glycosylated and glycosylated peptides (Figure 7.4) via this 
separation and detection approach. In this regard a better peak shape and the 
intensity were observed for some peptides, but some were slightly lower when 
compared to the off-line preparation and injection onto the same HILIC column.  




Figure 7.2 Extracted ion chromatogram showing deglycosylated and tryptic digested 
Eprex via WCX-HILIC. 




Figure 7.3 Extracted ion chromatogram showing deglycosylated and tryptic digested 
Eprex prepared off-line and injected directly onto HILIC. 
 
 




Figure 7.4 Extracted ion chromatogram showing deglycosylated and tryptic digested 
Aranesp via WCX-HILIC. 
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After evaluating WCX-HILIC, a reverse phase Captrap™ was then included into the 
flow path to desalt the sample. After the Captrap™ was added, the gradient 
programme was modified to compensate for the additional time required during the 
loading steps. The sample was loaded onto the Captrap™ at a flow rate 1 µl/min with 
95 % 10 mM ammonium acetate at pH 5.5 and 5 % ACN. During this step any 
residual material from the previous injection was flushed off of the WCX trap and the 
HILIC column was equilibrated with 95 % ACN and 5 % 0.1 FA in water using 
second LC pump at flow rate 4 µl/min. When the 6-port switching valves was 
switched to the inject position a gradient from 95 % aqueous to 5 % aqueous was 
used to elute the peptides from the Captrap™ to WCX trap column (Figure 7.5). The 
use of a gradient elution step allows for equilibration of the WCX packing material 
using the higher pH aqueous buffer and creates an environment that is suitable for 
the retention of the peptides under high organic mobile phase condition conditions. 
This is an advantage because when the 6-port switching valve is switched back to 
the loading position the high percentage of ACN in the mobile phase enhances 
refocusing of the peptides onto the stationary phase of the monolithic HILIC column. 
The WCX releases the peptides at the acidic pH and the eluting peptides were then 
resolved on the HILIC column (Figure 7.6). Whilst the HILIC gradient is running the 
WCX is re-equilibrated in order to be ready for the next injection. The chromatogram 
from the EPO standard mix, that was run using on the Captrap™-WCX-HILIC online 
system in Figure 7.6 a & b, is shown in Figure 7.7. The run time of 150 min was 
much longer than using the off-line sample preparation approach, as very 
conservative programme timing was used to be certain that the entire sample 
injection volume was able to pass through the Captrap™ and to ensure that all of the 
peptides were firstly transferred from Captrap™ to WCX and subsequently from the 
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WCX to the HILIC column. The cycle time can be reduced by optimization of the flow 
rates and utilizing trap columns that have a lower dead volume than the items that 
were used in this experiment. However, even taking into account the length of time 
taken to complete the online preparation, this is offset by the advantages of 
minimizing the sample handling, as well as reducing sample loss and contamination. 
The automation can be run unattended and therefore it can be run 24 hours/day and 
seven days a week without the need for constant operator input or monitoring.  




Figure 7.5 Extracted ion chromatogram showing deglycosylated and tryptic digested 
















Figure 7.6 a) Schematic drawing of 6-port switching valves showing the loading of 
sample on the Captrap™, and transferring the sample from Captrap™ to WCX. B) 6-
port switching valves showing the releasing of peptides from the WCX to HILIC and 
separation of peptides on HILIC. 
HILIC	  
CH	  1	  gradient	  
pump	  FR	  4µl/min	  
Waste	  
CAPTRAP	  -­‐	  RETENTION	  
WCX	  –	  NO	  RETENTION	  
(BYPASS)	  
CH2	  load	  @	  1µl/min	  
95%	  10mM	  AA	  pH	  5.5,	  
5%	  ACN	  
	  	  	  	  1	   	  	  	  	  	  	  	  	  6	  
2	   	  	  	  	  	  	  	  	  	  5	  









Figure 7.7 Extracted ion chromatogram showing the separation of EPO peptides 











The on-line coupling of RPè WCX è HILIC can resolve the lack of HILIC refocusing 
that can occur when peptides are eluted from a RP column using a high aqueous 
content mobile phase. On-line hyphenation possesses some advantages, such as 
minimal loss of sample, little or no contamination from the laboratory ware used to 
undertake the off-line processing and allows for highly efficient use of samples as 
only the quality required for the actual analytical run is consumed. It can be left to run 
24 hours a day and seven days a week without constant input from laboratory staff. 
The configuration set-up is not very complicated as a single 6-port switching valve 
and two pumps, one for loading at neutral or mildly basic conditions and a gradient 
pump for the HILIC separation, will suffice. The loading pump loads the aqueous 
sample onto Captrap™ under neutral or mildly basic pH condition and elutes the 
retained peptides from the Captrap™ to WCX where they are re-trapped on the 
WCX under conditions that are compatible with HILIC. The high organic content of 
the mobile phase helps to ensure that when the peptides are released from the WCX 
under acidic conditions they can be refocused on the HILIC column. This helps to 
maintain good peak shape for the analytes under the HILIC mode. Thus, this on-line 
configuration has solved the issue whereby the high water content encountered 
under RP elution conditions would also act as a strong eluent under HILIC conditions 
and would lead to broader peaks.  The results show that this configuration enables 
on-line concentration and desalting, which minimized the preparation steps and good 
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8.1 Overall Conclusions 
The main aim of this research project was to explore methods for the fast and 
sensitive detection of rhEPO/ DPO in equine doping. Unfortunately, EPO is a 
complex glycoprotein and plasma is a complicated biological matrix, which requires 
various sample preparation steps from immunoaffinity extraction of sample through 
to the enzyme digestion of the protein to peptides, followed by deglycosylation of the 
glycopeptides to allow for sensitive detection as low as 0.1 - 0.2 ng of Epoetin 
present in the equine plasma sample.  
 
In Chapter 2, I have shown that with capillary flow LC of 4 µl/min, detection of rhEPO 
showed a better sensitivity than when using the high flow LC of 100 µl/min. This 
method was capable of detecting 0.2 ng of immunoaffinity extracted Eprex from 
equine plasma sample, compared to the high flow LC where the limit of detection is 
10 ng of immunoaffinity extraction from equine plasma. In this chapter, a novel 
internal tapered capillary tip was fabricated and packed with commercial C18 silica 
material, which was subsequently coupled to a nano-electrospray source and run at 
a flow rate of 500 nl/min. The nanoflow LC showed a much better sensitivity than 
both the capillary and high flow LC, however, it is a great challenge to fabricate the 
internal taper tip and also to optimise the nanospray in order to achieve good 
sensitivity. It is not easy to attain a reproducible result. 
 
In Chapter 3, another immunoaffinity method was investigated using the MAIIA EPO 
purification kit, which is much faster with shorter steps (prepared within 3-4 hours) 
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compared to using the magnetic beads which required linkage of anti-rhEPO 
antibody to the magnetic beads followed by overnight incubation of the anti-rhEPO 
with rhEPO spiked plasma, rinsing of the magnetic beads and elution of rhEPO from 
the anti-rhEPO (takes 2 days). A post-spike experiment was carried out to compare 
with the spike Eprex in plasma samples going through the MAIIA IAC extraction; the 
recovery achieved was comparable or better than the post-spiked method for both 
the non-glycosylated and glycosylated peptides. In this chapter, I also explored the 
possibility of adding the Asp-N enzyme digestion in order to aid the enrichment of the 
deaminated peptide T9, which gives a higher intensity for the T9A1 and T9DPOA1 
peptides fragment, which could help to differentiate and identify the rhEPO and DPO 
in EPO doping.  
 
In Chapter 4, the immobilisation of trypsin on various supports (controlled pore glass 
beads and a micro-scale reactor (µIMER)) was compared with the in-solution 
digestion. Both immobilisations showed better results than the in-solution digestion. 
However, immobilising on the CPG required a lot of off-line effort whereas, the on-
line enzyme reactor can be re-used for about 1 month and up to about 30 – 40 
injections. Therefore, this is a fast and efficient on-line method that could be applied 
to detect rhEPO in equine plasma extract. 
 
In Chapter 5, I have also successfully demonstrated the PNGase F deglycosylation 
on-line reactor. A trypsin reactor followed by a deglycosylation reactor was coupled 
on-line in a column oven and coupled to the MS, where the sample was directly 
injected and digested on-line. This on-line set-up could detect both the digested non-
Chapter 8 Overall Conclusions & Future Work 
257	  
	  
glycosylated and glycosylated peptides with good sensitivity and acceptable 
repeatability. This time saving technique minimises the extent of manual sample 
handling, which reduces the potential sources of contamination.  
 
In Chapter 6, a novel HILIC monolith was fabricated in order to separate the EPO 
peptides. A study of different polymerisation times and an increase of initiator 
concentration were carried out. The increase in initiator concentration helps to 
reduce the polymerisation time, achieving sufficiently high amounts of the 
mesopores necessary to efficiently separate the compounds. This column was able 
to provide satisfactory resolution of peptides with relatively symmetrical peak shapes 
and sensitive detection of the peptides was improved compared to the results 
obtained using a commercial reversed-phase column. 
 
In Chapter 7, an on-line coupling of RPè WCX è HILIC was configured to 
accommodate an on-line digestion sample with high aqueous content, which is 
incompatible with the loading buffer (high organic) required for HILIC separations. 
The loading pump loads the aqueous sample onto the Captrap™ (RP) under neutral 
or mildly basic pH conditions and elutes the retained peptides from the Captrap™ 
(RP) onto the WCX phase where they are re-trapped under conditions that are 
compatible with HILIC chromatography. The high organic content of the mobile 
phase helps to ensure that when the peptides are released from the WCX trap 
column under acidic conditions they can be re-focused on the HILIC column.  The 
results show that this configuration enables on-line concentration and desalting, with 
good sensitivity and minimised preparation steps. 
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In summary, this work has shown that on-line set-up for the detection of rhEPO/ 
DPO in equine doping is achievable with fast detection and good sensitivity. It is also 
capable of confirming either rhEPO or DPO being doped. However, there is a 
potential to further develop this work to a complete on-line detection with an on-line 
immunoaffinity extraction column and further improving the sensitivity by enriching 
the glycopeptides.  
 
8.2 Recommendations for future work 
According to the results discussed in the respective chapters, the following areas are 
recommended for further development. 
 
1. As can be seen from Chapter 2, using the fabricated internal tapered 
capillary tip filled with C18 silica, gave a much better sensitivity than the high 
flow and capillary flow LC. This is the area where it can be expanded on the 
skill of setting up nanospray with a more reproducible and durable method. The 
internal tapered capillary can be packed with the HILIC monolith, however this 
requires skill and technique to polymerise the monolith in the internal tapered 
capillary. The tip needs to be properly sealed whilst not breaking it during and 
after polymerisation when removing the seal.  
 
2. In Chapter 3, it can be seen that using a MAIIA purification kit can 
achieve a good recovery for the immunoaffinity extraction. This area can be 
explored to make it an on-line immunoaffinity extraction column by immobilising 
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the antibodies on the monolith. This requires the incorporation of an on-line 
buffer exchange. This could greatly help in a total elimination of the off-line 
sample handling. As for using the Asp-N enzyme for the identification of the N-
terminal of aspartic residue, this Asp-N enzyme could also be immobilised on a 
micro-reactor and coupled directly after the deglycosylation reactor, in the 
following manner, trypsin-à deglycosylationà Asp N enzyme reactors on-line.  
 
3. Both the trypsin and PNGase F reactors described in Chapters 4 and 5, 
could be explored by making a longer immobilising column, and this could help 
in enhancing the sensitivity of the digest. Future work could also look at 
optimising the loading flow rate during the digestion/deglycosylation/trapping 
stage in order to reduce the cycle time between injections and/or multiplexing 
the analysis to improve the overall throughput of the method. 
 
4. The HILIC monolith has potential of further development as it has a low 
backpressure, so if required, the 30 cm columns can probably be used at 
significantly higher flow rates or the improved separation between 2 
compounds could be achieved by producing longer columns. As mentioned 
above, this could be fabricated in an internal tapered capillary tip for nanospray, 
and this might be able to further enhance the sensitivity.  
 
5. The orthogonal set-up could be improved by changing the loading 
pump to a micro pump, where the loading flow can be set higher at 4-5 µl/min, 
instead of the nano flow pump, where the maximum flow could only be set at 1 
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µl/min. This could shorten the time for re-equilibrating all the trap columns and 
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